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Abstract  
 
Differentiation of human endometrial stromal cells (HESCs) into decidual cells represents a 
highly coordinated process essential for embryo implantation. Following the post-ovulatory 
rise in progesterone levels HESCs undergo biochemical and morphological transformation in 
a process known as decidualization. It heralds the end of the mid-secretory phase implantation 
window, defined as the limited period during which progesterone-driven changes in the 
luminal epithelium allow apposition, attachment and invasion of a developmentally 
competent blastocyst. Failure of the endometrium to acquire a receptive phenotype is widely 
viewed as a major cause of infertility and IVF treatment failure. Conversely, recurrent 
pregnancy loss (RPL) is associated with impaired decidualization. Firstly, analysis of mid-
secretory endometrial biopsies from RPL patients demonstrated that there is a decreased 
expression of the decidual marker, Prolactin but increased levels of pro-inflammatory 
cytokine, Prokineticin-1. Secondly, HESCs were then identified to mount a highly 
coordinated but transient inflammatory response that renders the endometrium receptive, by 
rapidly releasing Interleukin-33, up-regulating its cognate transmembrane receptor-ST2L and 
other pro-inflammatory mediators before mounting an anti-inflammatory response that 
includes down-regulation of ST2L and increased secretion of the soluble decoy receptor 
sST2. In agreement, only during the transient pro-inflammatory phase of the decidual process 
did HESCs secrete factors conducive to implantation in mice. Failure of HESCs to constrain 
this pro-inflammatory response appeared to prolong the implantation window and was 
associated with RPL. Furthermore, deregulated Serum and Glucocorticoid Kinase 1 (SGK1) 
activity in the endometrium during the window of implantation either interfered with embryo 
implantation, leading to infertility, or compromised the integrity of the decidual-placental 
interface, resulting in pregnancy loss. A constitutively active SGK1 mutant was expressed in 
luminal epithelial cells of the mouse uterus; perturbing uterine fluid handling and abolished 
embryo implantation. However, implantation was not impaired in Sgk1-deficient mice, 
although there was evidence of fetal demise. RPL was also associated with lower SGK1 
induction in decidualizing HESCs and impaired expression of oxidative stress defence genes. 
In summary, impaired decidualization or unfettered endometrial receptivity carries an obvious 
risk of implantation of developmentally delayed or compromised embryos thus triggering a 
spectrum of pathological events, leading to miscarriage or predisposing for obstetrical 
complications. Together, these findings provide fundamental insights of uterine receptivity 
and describe a novel paradigm of reproductive failure with potentially far-reaching clinical 
implications.  
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1.1 The Human Endometrium   
The endometrium is the mucosal layer that lines the lumen of the uterus. The main 
function of the endometrium is to allow timely implantation of a viable embryo, and 
to provide a nurturing local environment that supports the establishment of a 
successful pregnancy (1). The endometrium consists of a basal and a functional layer 
(Fig 1.1). The functional layer is highly sensitive and responsive to ovarian steroid 
hormones. This layer exhibits a cycle of proliferation, receptivity, differentiation 
(decidualization) and is subsequently shed during menstruation if pregnancy does not 
occur (2, 3). The basal layer, adjacent to the myometrium, remains after menstruation 
and undergoes only limited changes during the menstrual cycle (4). Changes in levels 
of steroid hormones gives rise to the menstrual cycle that usually lasts 28 days in 
humans. On average a woman in a developed country undergoes around 400 cycles 
leading to menstruation and ~2 pregnancies in her reproductive life (5). Cyclical 
ovarian function is critical for the regeneration of the endometrium ensuring 
endometrial receptivity in the next cycle. Failure to acquire a receptive phenotype can 
lead to infertility whilst an impaired decidual response can lead to pregnancy 
complications such as pregnancy loss. 
 
1.2 Structure of the endometrium 
The human uterus is composed of an external serosal surface, the fibromuscular 
myometrium and an inner complex mucosal lining known as the endometrium (6). 
Embryologically, the latter is of mesodermal origin and is a heterogeneous tissue 
made up of several components (7). The endometrium is lined by a single layer of 
simple columnar luminal epithelium that is in turn supported by underlying 
connective tissue and a highly cellular stromal compartment (8). Tubular uterine 
glands also lined by columnar epithelium, invaginate from the mucosal surface deep 
into the stromal compartment (Figure 1.1). Blood supply to the uterus arises from the 
uterine arteries, which pass through the myometrium and eventually splits into two 
types of endometrial vessels (9). The characteristically shorter straight arteries pass 
directly into the endometrium and give rise to the long, coiled and thick walled spiral 
arteries, which are capable of responding to steroid hormones (9). In addition, the 
spiral arteries give rise to numerous arterioles often anastomosing with each other 
thus forming a dense a complex network embedded in the stroma. During the pre-
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pubertal and post-menopausal phases of a woman’s life, the endometrium remains 
thin. However, during the reproductive years, histological examination of this tissue 
reveals two distinct layers (Fig 1.1). The basal layer, stratum basalis, which abuts the 
myometrium and persists from cycle to cycle and serves as the seat of regeneration for 
the superficial layer, the stratum functionalis (8). The basal layer of the endometrium 
contains progenitor/stem cells that are critical for endometrial regeneration (10, 11), 
which takes place after menstrual shedding of the superficial endometrial layer.  
 
In contrast, the functional layer is overtly sensitive to steroid hormones and undergoes 
cyclical changes of proliferation, differentiation, degeneration and eventual 
desquamation (12). However, in the presence of an implanting conceptus, the stratum 
functionalis remains viable and, together with the myometrial junctional zone, it 
becomes the decidua and hence the maternal component of the haemochorial placenta 
(12, 13). 
 
1.3 Stem cells in the endometrium 
Regenerative turnover in the endometrium is equivalent to that in other highly 
regenerative organs such as bone marrow, epidermis and intestine (14). The first 
published evidence of adult stem/progenitor cells in human endometrium identified 
the existence of clonogenic epithelial and stromal cells (15, 16). Since then, several 
studies published supported the existence of stromal/mesenchymal stem-like cells 
(MSC) in the human endometrium (16). Initial studies identified a small population of 
stromal cells (1.25%) and of epithelial cells (0.22%) possessing colony-forming 
ability (15), supporting a stromal cellular hierarchy hypothesis to exist in the human 
endometrium (17, 18). A striking report carried out by Taylor, 2004 (19), revealed the 
presence of donor-derived endometrial cells in endometrial biopsy samples from four 
bone marrow recipients who received single antigen HLA-mismatched bone marrow 
transplants from female donors. All 4 women had donor HLA in their epithelial (0.2-
48%) and stromal (0.3-52%) cell populations (19). These results suggest that bone 
marrow stem cells can contribute to the composition of endometrial gland and stromal 
compartments. Another study showed that endometrial biopsy specimens obtained 
from patients who had received bone marrow transplantation from male donors had 
donor-derived Y chromosome-positive endometrial cells, which accounted for 0.6–
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8.4% of glandular epithelial cells and 8.2–9.8% of stromal cells (20). Most of the 
endometrial glands were chimeric, consisting of both donor-derived and recipient 
cells. Thus, donor-derived cells can become a constituent of the endometrium in 
recipients, even if donors are of the opposite sex. However, the functional 
significance of bone marrow-derived cells in endometrium remains to be elucidated. 
 
Stem cell markers of the endometrial progenitor cells have been identified in the 
stroma of the basalis layer, namely, c-kit/CD117 and CD34 (21). The proto-oncogene 
c-kit/CD117 encodes a 145-kd transmembrane tyrosine kinase receptor (CD117), the 
ligand of which is a stem cell factor. CD34 is coexpressed with CD117 in 
hematopoietic progenitor cells (21) in keeping with previous findings of bone marrow 
derived cells in the endometrium (19). Furthermore, human endometrial MSC have 
been identified with coexpression of CD146 and platelet-derived growth factor 
receptor beta (PDGF-Rβ) (22). The gene profile of this CD146+PDGF-Rβ+ population 
indicated that these cells expressed pericyte markers, genes associated with 
angiogenesis/vasculogenesis, steroid hormone/hypoxia responses, inflammation, 
immunomodulation, and signaling pathways associated with MSC self renewal and 
multipotency (17).  
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Figure 1.1 An illustration of the human endometrium  
The mucosal endometrial layer is divided into the superficial stratum functionalis, 
which undergoes cyclical changes, and a deeper stratum basalis, which serves as an 
area of regeneration. However, in vivo these layers are much more likely to be 
gradient in nature. 
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1.4 Cyclical changes of the human endometrium 
Throughout the reproductive years, the endometrium undergoes waves of cell 
proliferation, differentiation, recruitment of inflammatory cells, apoptosis, tissue 
breakdown and regeneration lasting 28 days (23-25) (Fig 1.2). Endometrial events are 
closely controlled by the ovarian cycle as steroid hormones implement these changes. 
Following menstruation (days 1-5), the endometrium consists of a thin layer of 
stratum basalis containing the lower portions of the glands and spiral arteries. At this 
time, low circulating steroid hormones abolish the negative feedback loop and the 
anterior pituitary resumes gonadotrophin secretion. Under the influence of these 
peptide hormones, the accelerated growth of a number of follicles occurs in the ovary 
(26). Granulosa cells within these follicles acquire aromatase activity resulting in 
oestrogen secretion. This steroid hormone stimulates growth of the remnant basal 
layer, resulting in the proliferative phase of the menstrual cycle lasting from 5-13 
days. Epithelial cells rapidly proliferate to reconstitute the glands and migrate to the 
surface to cover the denuded endometrial surface (26). At this stage, the glands are 
narrow and relatively straight. In concert, the stromal cells also undergo proliferation 
as evidenced by numerous mitotic divisions. Lastly, vascular endothelial cells 
proliferate causing the spiral arteries to lengthen and grow into the replenishing 
endometrium (27) similar to the glands, they remain relatively straight at this stage. 
During the very early proliferative phase, the endometrium is 1-2 mm and expands 5-
6 mm by the time of ovulation (days 5-13) (9). The increasing serum oestrogen levels 
trigger a luteinising hormone (LH; day 14) surge stimulating ovulation and 
progesterone production from the resultant corpus luteum (26). This secretory phase 
of the menstrual cycle occurs after the post-ovulatory rise in progesterone. The 
endometrium is considered pre-receptive following ovulation (days 15-19). The uterus 
then becomes receptive during the mid-secretory phase, which spans days 20-23 after 
ovulation. This post-ovulatory rise in progesterone inhibits endometrial proliferation 
and induces differentiation also known as decidualization (27-29) and lasts around 4 
days (days 24- 28). The secretory phase is characterised by dramatic functional and 
cytoarchiterctural changes. The glands become tortous and sacculated as epithelial 
secretory products rich in glycogen accumulate. Spiral arteries become increasingly 
coiled and there is an associated influx of specialised uterine natural killer cells (uNK) 
(CD56
bright
/CD16
-
)(27). Alongside these events, the stromal compartment becomes 
oedematous with associated extensive changes in the extracellular matrix (ECM) 
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components, while the stromal cells undergo transformation into decidual cells from 
the mid-secretory phase onwards, a process termed decidualization. Together, these 
modifications are critical in providing a favourable environment for blastocyst 
implantation and development. In the absence of a conceptus, the corpus luteum 
degenerates, precipitating a fall in progesterone levels leading to spasmodic 
constriction of the spiral arterioles and eventual ischemia of the stratum functionalis. 
This endometrial component is shed during menstruation from days 1-5. However, 
during a conception cycle the trophoblast secretes human chorionic gonadatrophin 
(hCG) that sustains the corpus luteum and thus progesterone production. Therefore, 
this endometrial structure is preserved and continues in its progressive course of 
differentiation.  
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Figure 1.2 The menstrual cycle and decidual transformation 
The menstrual cycle is a series of cyclic changes in the endometrium that occur on a 
monthly basis in response to changes in levels of ovarian hormones. These correlate 
with the ovarian cycle such that the endometrium is most receptive to implantation of 
the fertilized oocyte 7 days after ovulation. The post-ovulatory rise in progesterone 
initiates decidualization during the mid-secretory phase of the menstrual cycle (days 
23-27). Treating primary endometrial stromal cells with a progestin (MPA) and a cell 
permeable cAMP analogue (8-Br-cAMP) can be replicate decidualization in vitro. 
Adapted from (25) 
 
In vitro 
Undifferentiated Differentiated 
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1.5 Menstruation 
Menstruation is the loss of most of the functional layer of the endometrium, 
accompanied by bleeding, that occurs after withdrawal of steroid hormone support at 
the end of each menstrual cycle. Progesterone concentrations fall rapidly with corpus 
luteum degeneration in all mammals with oestrous cycles. However only women, 
some old-world primates, elephant shrew and fruit bats menstruate (3). It is interesting 
to note that decidualization of the endometrial stromal compartment in the absence of 
pregnancy only occurs in menstruating species, implying that these two phenomena 
are functionally linked (30). There are several lines of evidence that demonstrate that 
loss of progesterone support is the key trigger for menstruation (31):  
 
1. If progesterone concentrations are maintained artificially, menstruation does not 
occur. 
2. Administration of the progesterone receptor antagonist, mifepristone, during the 
proliferative and secretory phases of the cycle, results in uterine bleeding. 
3. Withdrawal of oestrogen and progesterone, as in the case of cyclical contraceptive 
use, results in uterine bleeding.  
4. In mice, menstruation can be induced experimentally if decidualization has 
occurred prior to progesterone withdrawal. 
 
The dogma regarding mechanisms of menstruation originated from the studies of 
Markee 1940 (32) who postulated that the tissue destruction occurred by necrosis 
resulting from hypoxia after constriction of the spiral arterioles (33). Furthermore, as 
the spiral arterioles are specific to the endometrium of primates that menstruate, it 
seemed that menstruation was dependent upon them. Hisaw & Hisaw 1961 (34) 
observed that menstruation still occurred in the endometrium of primates that had 
undergone atrophy and had no such coiled arteries. Besides, the occurrence of 
widespread anoxia (an extreme form of hypoxia) had not been substantiated in the 
human endometrium. Indeed, the transcription factors hypoxia-inducible factor (HIF)-
1 and HIF-2, which represent the earliest known response to hypoxia, are barely 
detectable in the human endometrium and are not widespread during the peri-
menstrual phase (35), indicating that mechanisms other than hypoxia were responsible 
for initiating menstruation. 
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Since the start of the 1990s, there has been a paradigm shift in the view of the 
mechanisms underlying menstruation, from a process that is initiated and maintained 
primarily by vascular events, to a process in which tissue destruction is a key feature 
(36, 37). The break down of the endometrium is characterized by apoptosis, loss of 
decidual features, infiltration of inflammatory cells, in particular neutrophils and mast 
cells (37) and expression and activation of matrix metalloproteinase (MMP) (38-40). 
Finn 1986, (41) postulated that menstruation could be regarded as an inflammatory 
process, characterized by tissue oedema, recruitment of inflammatory cells; cells of the 
myeloid lineage neutrophils, eosinophils, macrophages or monocytes, and associated 
release of pro-inflammatory cytokines. The total number of leukocytes, in the 
endometrium increases immediately before menstruation, sometimes comprising up to 
40% of the total cell population within the stromal compartment (42). In addition to 
this an equal balance of MMPs and tissue inhibitors of metalloproteinases (TIMP) 
provides a local and controlled degradation of the ECM of the endometrial tissue (28). 
Also local production of prostaglandin causes vasospasm of the spiral arterioles, and 
subsequent ischemia and sloughing of the endometrium (40). 
 
There is wide debate on the purpose of menstruation: Profet argued that cyclical 
shedding of the endometrium protects the uterus from pathogens (43). Strassmann (44) 
instead, proposed that it is metabolically more efficient than maintaining the 
endometrium in the active state required for implantation. Also, due to the high rate of 
chromosomal abnormalities in human embryos, the endometrium is able to recognize 
and eliminate developmentally incompetent embryos, allowing the mother to limit her 
investment in poor quality embryos through menstruation (5). It is widely viewed that 
menstruation serves no other purpose than to reinitiate the endometrial cycle in the 
absence of pregnancy. It is striking that cyclic endometrial decidualization followed by 
menstrual shedding is confined to a few species, including humans, where placenta 
formation entails deep trophoblast invasion of maternal tissues and vasculature. 
Menstruation and pregnancy are both inflammatory conditions that cause a degree of 
physiological ischemia-reperfusion tissue injury, albeit much more so in pregnancy. 
These observations led to the hypothesis that the emergence of cyclic menstruation 
may not have been an evolutionary coincidence, but rather serves to protect uterine 
tissues from the profound hyperinflammation and oxidative stress associated with deep 
placentation, a process known as preconditioning (3, 45).  
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1.6 Decidualization 
Decidualization is a process critically dependent on the integration of temporal, 
spatial and physiological cues, which together orchestrate the morphological and 
biochemical reprogramming of the endometrium in preparation for pregnancy. 
Furthermore, it is a progressive phenomenon, which initially occurs in the late mid-
secretory phase, continues in pregnancy and ultimately involves the whole 
endometrium. The decidua acts as the interface to the invading fetal trophoblast; 
therefore it is hardly surprising, that it decisively controls placentation and subsequent 
growth of the conceptus. 
 
Stromal differentiation into decidual cells only occurs in animal species where the 
blastocyst breaches the luminal epithelium (12). In humans and a small handful of 
other species, the decidual process can occur in the absence of an embryo and is 
therefore maternally driven. Furthermore, trophoblast invasion is considerable in 
humans, extending beyond the endometrium into the uterine junctional zone, defined 
as the inner third of the myometrium (46, 47). In fact, structurally, the degree of 
decidualization often corresponds with the degree of trophoblast invasion (12). 
Therefore in vivo, this differentiation process involves many cellular components 
including endometrial epithelial and stromal cells, local immune cells, spiral arteries 
as well as the junctional myocytes. Spatially, the event is initiated around the terminal 
spiral arteries of the superficial endometrial layer roughly 10 days after the luteinizing 
hormone (LH) surge (48). Importantly, the commencement of these changes heralds 
the end of the limited period of uterine receptivity or the window of implantation 
(WOI).  
 
1.7 Morphological and biochemical events of decidualization 
Morphologically, the most striking changes associated with the decidual response 
occur in the stromal cells (Fig 1.2). In their undifferentiated form, the human 
endometrial stromal cells (HESCs) adopt a spindle-shaped fibroblastic appearance. 
Upon decidualization, a characteristic transformation occurs that includes progressive 
enlargement and rounding of the nucleus, expansion of the Golgi complex and rough 
endoplasmic reticulum and cytoplasmic accumulation of lipid and glycogen droplets. 
Upon decidualization, endometrial stromal cells acquire a secretory and epithelioid-
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like phenotype. Multiple projections appear on the cell surface, which extend into the 
ECM or indent adjacent cells. In addition, decidual cells express desmin, α-smooth 
muscle actin and vimentin, signifying a myo-fibroblastic phenotype (49). The 
progressive nature of the process is evidenced by the fact that decidual cells increase 
in size, as does the percentage of cells expressing the phenotypic differentiation 
markers as pregnancy ensues. 
 
Decidual transformation of HESCs is an interesting example of mesenchymal-
epithelial transition (MET). MET is an important process that is involved in various 
developmental events like kidney organogenesis and somitogenesis (50, 51). It is the 
reverse of the epithelial-mesenchymal transition (EMT). The interconversion between 
the epithelial and mesenchymal phenotype through EMT and MET processes is 
essential for embryogenesis, organ development and most importantly for wound 
healing such as following, liver injury and for cellular remodeling during 
differentiation (52-54). Epithelial cells are adherent cells that bestow cell-to-cell 
cohesion and integrity of multicellular organs, and form barriers separating external 
from internal environments (52, 54). Mesenchymal cells, in contrast, are highly 
mobile and have invasive properties (52, 54, 55). Upon decidualization, HESCs 
express a myriad of genes that are a characteristic of epithelial cells (27). MET has 
also been implicated in the generation of induced pluripotent stem cells  i SCs) from 
mouse fibroblasts upon e ogenous e pression of octamer-binding transcription factor 
4   ct4), SRY  se  determining region Y)-bo  2  So 2), Kr ppel-like factor (Klf4) 
and myelocytomatosis oncogene (c-Myc) (56). Interestingly, microarray analysis 
revealed that OCT4, KLF and MYC are upregulated upon decidualizing HESCs (57, 
58). 
 
1.8 Decidualizing cues and pathways  
1.8.1 cAMP signaling pathway  
Historically, post-ovulatory progesterone was thought to be the only mediator of these 
events however, it is now clear that integration with other pathways is important, of 
which the most crucial is cyclic adenosine monophosphate (cAMP) signaling (Fig 
1.3). In fact, in vivo adenylate cyclase activity as well as cAMP levels are higher 
during the secretory phase of the cycle (59). This intracellular second messenger is 
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elevated in response to endocrine factors abundantly present in the luteal phase 
including relaxin (RLX), corticotrophin-releasing hormone (CRH), prostaglandin E2 
(PGE2) and pituitary gonadotrophins (60-62). It is thought that pituitary 
gonadotrophins act through cAMP to regulate progesterone production and 
metabolism by modulating aromatase and 5-α reductase (63) in the endometrium. 
These molecules are ligands to G-protein coupled receptors (GPCRs). GPCRs are a 
family of seven-transmembrane domain receptors, fundamental for cellular responses, 
which are coupled to guanine-nucleotide-binding proteins (G-proteins). When a 
ligand binds to the GPCR it causes a conformational change in the receptor, which 
allows it to act as a guanine nucleotide exchange factor (GEF). The GPCR can then 
activate an associated G-protein by exchanging its bound GDP for a GTP. The G-
protein's α subunit, together with the bound GT , can then dissociate from the β and γ 
subunits to further affect intracellular signaling proteins or target functional proteins 
directly depending on the α subunit type. The cAM  signaling pathway is among the 
principal ones regulated by GPCRs with adenylate cyclase being the effector protein. 
Adenylate cyclase, which increases during the menstrual cycle, catalyzes the 
conversion of adenosine triphosphate (ATP) into the ubiquitous second messenger 
cAMP. Interestingly, the inhibition of phosphodiesterase-4, the enzyme that degrades 
cAMP to AMP, is sufficient to stimulate expression of decidual marker genes (64). 
hCG is thought to signal through cAMP and therefore may be important in 
maintaining the decidual process during pregnancy.  Two cAMP molecules bind to 
each of the two regulatory subunits of protein kinase A (PKA), causing a 
conformational change that leads to the release of the two catalytic subunits. They 
phosphorylate cytoplasmic and nuclear target molecules, thus propagating the 
extracellular signal. Once in the nucleus of HESCs the catalytic subunit of PKA 
phosphorylates numerous target proteins. These include cAMP response element 
binding protein (CREB), cAMP response element modulating protein (CREM), 
CCAAT-enhancer binding protein (CEBP-β), STAT5 and Forkhead bo  protein  1 
(FOXO1) and induces expression of decidual specific genes such as Prolactin (PRL) 
and Insulin-like growth factor binding protein 1 (IGFBP-1). Amongst the major 
secretory products are PRL and IGFBP-1, which are widely used as markers of 
decidualization (28). However, differentiated endometrial stromal cells also produce a 
myriad of cytokines, (e.g. Interleukin -11; IL-11), growth factors, (e.g. epidermal 
growth factor; EGF, Heparin-binding Epidermal Growth Factor; HB-EGF, Lefty-A, 
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activin A), and neuropeptides, (i.e. somatostatin and ghrelin), which may serve to 
amplify and propagate the decidual process in an autocrine or paracrine fashion (28).    
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Figure 1.3 cAMP signaling in HESCs  
Elevation of cAMP upon activation of GPCRs promotes expression and nuclear 
accumulation of CREM, CREB, C/EBP, FoxO1a and activated Stat5. These factors 
initiate transcription of decidua-specific genes and sensitize the cells to progesterone.  
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1.8.2 Progesterone signaling  
Primary HESCs can be separated from other endometrial components, cultured 
independently and the process of decidualization can be recapitulated in vitro (Fig 
1.2). This is achieved by treating the cells with a combination of a cAMP analogue (8-
Bromo-cAMP;8-Br-cAMP) and synthetic progestin (medroxyprogesterone acetate; 
MPA). Progesterone acts predominantly through its nuclear receptor PR-A and PR-B 
to activate or to repress target genes. The critical role of progesterone in endometrial 
function is supported by gene knockout studies. In mice lacking both PR-A and PR-B, 
the decidual reaction is absent and implantation is impaired (65). Particularly, in PR-
A, but not PR-B knockout mice, progesterone-induced decidualization of the 
endometrial stromal cells is inhibited (66, 67). Progesterone induces abnormal uterine 
epithelial cell proliferation in PR-A knockout mice, whilst in the wild-type uterus the 
progesterone inhibits oestrogen-induced proliferation. These results indicate that PR-
A is required not only to inhibit oestrogen-induced hyperplasia but also to limit 
proliferative effects of PR-B (66). Interestingly, decidualization of human stroma in 
vivo and in vitro is associated with rapid down-regulation of PR-B, rendering PR-A 
the dominant isoform (68, 69). Furthermore, in the human endometrium, the levels of 
PR-A and PR-B are differentially regulated during the menstrual cycle (68, 70, 71). 
Maintaining the spatiotemporal and relative expression of the PR isoforms is 
essential, as aberrant ratios have been linked to endometrial neoplasia (72). Upon 
binding of ligand, PR undergoes a conformational change, which consequently leads 
to its phosphorylation and dissociation from heat shock proteins. Subsequently, PR 
dimerizes and binds to specific response elements in the promoter region of target 
genes. The latter event requires interaction with steroid receptor co-activators (SRCs) 
in order to modify the chromatin landscape to enable transcription. Post-translational 
modifications play a critical role in regulating steroid receptor activity. PR activity 
(ligand-dependent and ligand-independent) is heavily regulated by post-translational 
modifications such as phosphorylation, sumoylation, methylation, acetylation and 
ubiquitination (73, 74). These modifications have been shown to regulate PR function 
by changing hormone responsiveness, altering promoter selectivity and modulating 
receptor turnover. Sumoylation is a dynamic and reversible post-translational 
modification. Interestingly, upon decidualization, cAMP signaling attenuates PR 
sumoylation leading to increased transcriptional activity of the receptor and enhanced 
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turnover. In other words, a decrease in PR sumoylation is, at least in part, responsible 
for sensitizing HESCs to progesterone signaling (75). 
 
1.8.3 Convergence of cAMP and Progesterone signaling  
The crucial role of cAMP signaling is further illustrated by the fact that progesterone 
treatment alone induces a very slow and minimal differentiation response in HESCs, 
which can take up to 10 days to occur. Thus, treatment with the cell permeable cAMP 
analogue 8-Br-cAMP results in an almost immediate effect; however this is not 
sustained in long term cultures (76).  
 
Cyclic AMP response binding protein (CREB) and the related cAMP response 
element modulator (CREM) are two major targets of PKA signaling and belong to the 
family of basic/leucine zipper (bZIP) transcriptional regulators. Mechanistically, they 
dimerize through their leucine zipper and subsequently bind via their basic region 
DNA at cAMP response elements (CREs). However, a variety of isoforms exist which 
may be transcriptional repressors or activators depending on the absence or presence 
of the transactivation domain, respectively. One such repressor is inducible cAMP 
early repressor (ICER), named because it is highly induced by cAMP that constitutes 
a negative feedback loop, thus down regulating transcription of cAMP-induced 
promoters, including its own. This serves to actively terminate a cAMP signal (77). 
 
Interestingly, activation of the PKA pathway by means of treatment with relaxin or 
with cAMP analogues results in persistent expression of ICER in HESCs, indicating a 
permissiveness of the cells to the continuous cAMP signaling (78). It is now clear that 
the activation of PKA initiates the decidual response and sensitizes the cells to 
progesterone, which is required to maintain the phenotype (29). 
 
Multiple mechanisms appear to operate whereby cAMP signaling sensitizes HESCs to 
progesterone. First, cAMP activation of the PKA pathway has been shown to disrupt 
the interaction of PR and corepressors nuclear-receptor corepressor (N-Cor) and 
silencing mediator for retinoid and thyroid receptor (SMRT) (79), thereby facilitating 
recruitment of the co-activators SRC-1 (80). Secondly, cAMP signaling in HESCs 
induces the expression or activation of various subsidiary transcription factors, 
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including FOXO1, C/EBP-β, SV40 promoter binding protein 1 (SP1) and signal 
transducers and activators of transcription 3 and 5 (STAT3 and STAT5) (81-83). 
What links all these transcription factors is their ability to interact with PR. Therefore 
the formation of these multimeric transcription complexes allows PR to regulate 
genes without a consensus progesterone response element (PRE). Finally changes in 
post-translational modifications of PR upon decidualization may also account for its 
increased transcriptional activity (75). 
 
1.9 Implantation 
Implantation spans from the moment of hatching of the blastocyst to the formation of 
a primitive placental circulation system, and is initiated by the contact between the 
blastocyst and the endometrium. Implantation is a dynamic process, which involves 
embryo apposition, adhesion to the endometrial epithelium and encapsulation into the 
stroma (Fig 1.4) (84). The cellular events that define the various stages of 
implantation are known, but the molecules and molecular genetic pathways that are 
crucial to this process (and how they interact) are not well understood. It is ethically 
and practically impossible to study human implantation process in vivo. Animal 
models do provide important information to the process regulating implantation, but 
as the process varies across species (85), the results cannot always be extrapolated to 
humans. In vitro co-culture systems allow the study of signaling between embryo and 
endometrium, however, the current systems are relatively crude representations of the 
dynamic in vivo situation (86). 
 
1.9.1 Pre-implantation embryo development 
After fertilization, the human preimplantation embryo develops during the transport 
through the Fallopian tube into the uterus, a journey taking four days. The Fallopian 
tube provides space and the biological environment for fertilization of the oocyte, 
which is then actively transported by cilia and muscle contractions towards the 
endometrium (87). The embryo undergoes several changes including cleavage, 
embryonic genome activation, compaction and cavitation during its development to 
form a blastocyst. At the 4-cell stage, the transcription starts to change from maternal 
to embryonic genome activation, and the maternal mRNAs are gradually degraded 
(88). There are two principal transient waves of de novo transcription, where the first 
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wave peaks between the 2- and 4-cell stages and the second wave peaks at the 8-cell 
stage and precedes morula to blastocyst formation (89, 90). Within 24 hours after 
fertilization, the zygote undergoes a regulated series of mitotic cell divisions. The 
zygote will enter the blastomere stage, then becomes a morula (16 cell-stage), which 
will undergo compaction where the trophoblast cells (outer cell-layer) form a compact 
epithelial structure, connected by tight junctions and microvilli. Synchronically, the 
blastocyst cavity is created and a blastocyst is formed, which will hatch from the zona 
pellucida. The zona pellucida is a glycoprotein membrane surrounding the oocyte, 
which prevents the embryo from disassembling and prevents two genetically distinct 
conceptuses from sticking together. The blastomeres are totipotent, meaning that these 
cells have the ability to differentiate into any cell type in the developing embryo. 
Trophectoderm has a crucial role in the implantation process and establishment of 
pregnancy, as they are the first cells to reach the maternal surface, invade and 
establish the embryo–maternal dialogue (91). Trophoblasts produce a number of 
cytokines, growth factors and many other factors, including hCG, MMPs, Tumor 
Necrosis Factor-α  TNFα) and interleukins, which facilitate communication with the 
maternal tract and thereby promote implantation and ongoing embryo development 
through paracrine, juxtarine and/or autocrine actions (92, 93). When the endometrium 
reaches the receptive stage, it is able to respond to signals from the preimplantation 
embryo for implantation. The so-called crosstalk requires several different molecules 
secreted both in an autocrine and paracrine manner from both the trophoblast cells 
and the endometrium. The molecules involved include integrins, matrix-degrading 
enzymes, their inhibitors, a variety of growth factors, cytokines and their receptors 
and modulator proteins (94, 95).  
 
Poor embryo quality is considered to be the leading cause of implantation failure (96) 
and maybe due to the high incidence of chromosomal abnormalities in human 
embryos (97, 98) The frequency of embryonic genetic abnormality increases with 
maternal age (97, 99) but also appears higher among infertile couples than in the 
general population (100). These abnormalities may arise from an error during meiosis, 
resulting in an abnormality present in all cells, or from segregation errors occurring 
during the first mitotic divisions, resulting in chromosomal mosaicism. Vanneste et 
al., examined the incidence of gross chromosomal errors in cleavage-stage embryos 
from young fertile women. Surprisingly, they found that only two out of the 23 
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cleavage-stage in vitro fertilization (IVF) embryos had a normal karyotype in all 
blastomeres, approximately half of the embryos had no normal cells at all and the 
remainder were mosaic for large-scale structural chromosomal imbalances, caused 
predominantly by mitotic non-disjunction (97).  Mosaicism has been reported to affect 
up to 91% of human pre-implantation embryos at some stage (97). However, over 
time the incidence of mosaicism in the cleavage stage embryo decreases drastically 
(101) which can be explained by the developmental arrest of a significant proportion 
of mosaic day 4 embryos and cell death or reduced proliferation of aneuploid cells 
within an embryo (101). Disturbances in this two-way dialogue are believed to 
represent a major reason why over 60% of all pregnancies are lost at the end of the 
peri-implantation period (102-104). 
 
1.9.2 Implantation Process 
The 4-day old embryo arrives in the uterine cavity at the stage of morula or early 
blastocyst and implantation is believed to take place 6-7 days after fertilization (87). 
Based on mouse studies, implantation is viewed as a step-wise process, akin to rolling 
and subsequent adherence of leukocytes to vascular endothelium (105). Implantation 
first involves apposition of the embryo to the endometrial surface and binding of L-
selectin expressed by the trophectoderm of the blastocyst to oligosaccharide ligands 
present on the luminal epithelial cells and a loose connection is established (105). 
During the adhesion step, the contact between blastocyst and endometrium is 
sufficiently increased to resist dissociation by flushing. There is an active 
communication between the blastocyst and the endometrium at this stage, conveyed 
by receptor-ligand-interactions (106). When adhesion is established, trophoblast cells 
differentiate into syncytiotrophoblasts on the outside and cytotrophoblast on the 
inside. Invasion starts with lytic activity of syncytiotrophoblast cells that weaken 
endometrial structures, thus enabling the penetration of the blastocyst. Then the 
blastocyst penetrates the endometrial luminal epithelium and enters the endometrial 
stroma up to the inner third of the myometrium. A proportion of these cells, the 
endovascular extravillous trophoblast cells, invade the terminal spiral arteries, 
plugging them for several weeks before destroying most of the musculoelastic vessel 
wall, thereby establishing high-flow, low-resistance uteroplacental circulation (107). 
It is a widely held opinion that the “passive” decidua is invaded by the “aggressive” 
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trophoblast, but this is being challenged by several new studies. In co-culture models, 
hatched blastocysts placed onto a monolayer of decidualized endometrial stromal cells 
undergo expansion, a process that resembles embryo invasion (108, 109). 
Interestingly, trophoblast outgrowth was found to be dependent on the migratory 
capacity of the decidual cells, as inhibition of pathways that regulate motility, 
cytoskeleton reorganization and focal adhesion in decidual cells severely 
compromised blastocyst expansion (108, 109). In fact, these findings suggest that, 
rather than being invaded, the decidual cells actively engulf and encapsulate the 
embryo. 
 
By day 9, the embryo is completely embedded by the endometrium. The role of the 
endometrium is now the opposite of that in the initial adhesion phase; it serves to 
actively limit the invasive course of action by the embryo. The balance between 
trophoblast invasion and maternal restraint on invasion is a requirement for a 
procedure that must be beneficial for the embryo without being detrimental to the 
mother (3). Both, adequate preparation of receptive endometrium and the 
development of a viable embryo are essential for successful implantation. The limited 
window of implantation ensures coordinated embryonic and endometrial 
development, thus minimizing the risk of late implantation of compromised embryos. 
Besides its receptive role in the implantation, the endometrium appears to have a 
‘selective’ role (110) and therefore able to encapsulate and dispose of 
developmentally compromised embryos by triggering a menstruation-like event (107). 
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Figure 1.4 The process of human implantation involves interactions between 
embryo and the endometrium  
(A) The initial attachment of the blastocyst to the endometrial epithelial cells is called 
apposition and is unstable. The blastocyst then adheres to the endometrial surface and 
a firm adhesion is realized. (B) Thereafter the blastocyst penetrates the epithelial layer 
and invades the stroma and is completely embedded by the tenth day. Eventually 
cytotrophoblasts invade the entire endometrium and the inner third of the 
myometrium as well as the uterine vasculature, which establishes the uteroplacental 
circulation. 
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By the tenth day, cytotrophoblasts invade the entire endometrium and the inner third 
of the myometrium as well as the uterine vasculature that establishes the 
uteroplacental circulation. Mucin-1 (MUC1) is a candidate for selection of the 
implantation site. A MUC1 barrier at the luminal epithelium impairs interaction 
between the embryo and the endometrium by anti-adhesive properties. MUC1 must 
either be locally removed during the attachment process or it has functions to promote 
the initial steps in embryo adhesion (111). The embryo itself has been speculated to 
be involved in signaling the endometrium to modify MUC1 expression (112). Hb-
EGF expression is increased in the mid-secretory phase and is also involved in the 
process of embryo attachment. Cells expressing the transmembrane form of Hb-EGF 
adhere to blastocysts displaying cell surface ErbB4 (113). The expression of Hb-EGF 
slightly precedes the expression of V3 (114). Expression of V3 integrin and its 
ligand osteopontin coincides with the opening of the WOI, was detected by 
immunohistochemistry on the endometrial luminal epithelial surface and is the first to 
interact with the trophoblast (115). Aberrant V3 integrin expression pattern has 
been associated with unexplained infertility (116). Interaction with these 
transmembrane glycoproteins leads to a firm embryo adhesion (117). The 
encapsulation of the cytotrophoblast requires enzymatic digestion of the extracellular 
matrix, by MMP-9 and secretion of transforming growth factor (TGFβ-1), a MMP 
tissue inhibitor (118). The simultaneous increase in MMPs and the tissue inhibitors of 
these metalloproteinases appear to regulate and restrict invasion of trophoblasts to an 
appropriate depth in the uterus (119). Excessive invasion of the trophoblast can lead 
to abnormally firm attachment to (placenta accreta), into (placenta increta), or through 
(placenta percreta) the myometrium, which is associated with serious haemorrhage 
complications (120). A hallmark of implantation is increased vascular permeability 
and neoangiogenesis. Vasoactive agents, such as vascular endothelial growth factor 
(VEGF) and angiopoietin are critical for early placentation. Chemokines are small 
chemotactic cytokines, well known for their function in leukocyte recruitment and 
activation. There is evidence that chemokines may also control embryo trafficking 
The embryo has receptors for a number of chemokines, such as Monocyte 
chemotactic protein-1 (MCP-1), Eotaxin and Interferon gamma- induced protein-10 
(IP-10) (121, 122). 
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1.10 Endometrial receptivity 
Endometrial receptivity refers to the time when the luminal epithelium is favourable 
for blastocyst implantation. This limited period, also referred to as the implantation 
window, is restricted to approximately days 19 to 24 of a menstrual cycle of 28 days 
(123, 124). This corresponds to the time when the embryo hatches, 6 days after the 
LH surge, and is consequently is ready for implantation within the following 24 hours 
(4). A limited ‘implantation window’ that synchronizes implantation with embryo 
development, may serve as an important mechanism to select against developmentally 
compromised by potentially invasive embryos (110). Consistent with this concept, the 
population study of Wilcox et al., 1999 demonstrated that implantation beyond the 
normal period of endometrial receptivity is strongly associated with early pregnancy 
loss (104). The development of a receptive endometrium depends on adequate 
secretory transformation of the oestrogen-primed endometrium in response to 
progesterone. Significant developmental changes occur in luminal epithelium, 
glandular epithelium as well as in endometrial stroma.  
 
Many molecules have been identified in the involvement of this process, such as 
integrins and their ligands (e.g. osteopontin), mucins, growth factors (HB-EGF), 
cytokines (LIF, leptin, IL-1, IL-11), homeobox transcription factors (HOXA gene 
products), lipids and other molecules (94, 125, 126). The availability of new methods 
for investigating human endometrium has provided deeper knowledge in the 
molecular regulation of endometrial receptivity.  
 
Microarray analyses have been extensively used to identify the gene networks that 
underpin either the receptive or unreceptive states of the endometrium (Table1.1). The 
global gene expression analysis has been successfully applied in several endometrium 
transcriptome studies and distinct regulation of hundreds of genes in different 
menstrual cycle phases has been demonstrated (127-136). Although each study 
yielded numerous candidate genes, the number of common ‘endometrial receptivity’ 
genes is relatively small (132). This poor consistency is perhaps due to changes in the 
timing of the assay, experimental designs, methods for data analysis, and/or 
geographical location where subjects reside or the geographical location of the origin 
of subjects selected. Nevertheless, molecular and genetic evidence indicates that 
locally produced signaling molecules, including cytokines, growth factors, homeobox 
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transcription factors, lipid mediators and morphogens, together with ovarian 
hormones, serve as autocrine, paracrine and juxtacrine factors to specify uterine 
receptivity and impaired expression of endometrial receptivity genes is increasingly 
linked to common reproductive disorders.  
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Table 1.1 Genes implicated in human uterine receptivity for implantation by data from independent microarray analysis  
(Refs: 56,115-124) 
Up regulated Down regulated  
Gene Name Gene Name 
APOD  Apolipoprotein D CCNB Cyclin B proteins (cell-cycle regulator) 
CLDN4 Claudin-4/CEP-R GATA2 GATA-binding protein-2 
C1R   Complement component-1r  MSX1 Hox Msh-like protein-1 
DAF Decay accelerating factor for complement  MSX2 Hox Msh-like protein-2 
DF  Complement factor D/Adipsin    
DKK1  Dickkopf-1 (WNT antagonist)   
GADD45a  Growth arrest and DNA-damage-inducible protein 
alpha 
GBP3   Guanylate-binding protein-2 (GTP-BP) 
ID4  Inhibitor DNA binding-4 (transcription coregulator) 
IL15   Interleukin-15 (cytokine) 
MAP3K5  Mitogen activated protein kinase kinase kinase 5 
(MAPK signalling 
MT1  Metallothionein-1 family proteins (MBP) 
MAOA   Monoamine oxidase A (catechol-NT metabolizing 
enzyme) 
PAEP   Progestagen-associated endometrial protein (SecP) 
SERPING1 Ser (or Cys), clade G (C1 inhibitor), member 1 
(proteolysis inhibitor) 
SGK1 Serum and glucocorticoid 1 
SPP1 Secreted phosphoprotein-1 (StrP) 
TGFb TGF beta-super-family proteins 
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The dynamic and overlapping expression of many signaling molecules during the 
period of receptivity makes it difficult to assign the contribution of a specific 
molecule to failure to establish a receptive phenotype in the human endometrium. 
Therefore, genetic studies in mice provide an insight to assess whether these genes are 
critical to uterine receptivity in humans, since such studies are not possible in humans 
except for the identification of mutations of these genes in human populations. These 
mouse models have contributed greatly to our understanding of the physiological and 
molecular events necessary for the process of implantation (Table 1.2). Mouse models 
are instrumental in elucidating the physiological changes associated with implantation 
in conjunction with DNA microarray technology, which has begun to elucidate the 
global gene changes involved in implantation. However, it has proven difficult to 
unequivocally implicate these key implantation regulators in reproductive failure in 
women or to exploit them for therapeutic purposes (125). A case in point is leukaemia 
inhibitory factor (LIF), which was shown to be indispensable for embryo implantation 
in mice (137). Subsequently, some (but not all) studies reported that LIF is also 
deregulated in mid-secretory endometrium of women with unexplained infertility, 
thus providing a rationale for LIF-based interventions. However, a recent randomized 
placebo-controlled trial demonstrated that recombinant LIF administered to women 
with a history of unexplained implantation failures after assisted reproductive 
treatments (ART) paradoxically lowered clinical pregnancy rates (138). Beside LIF, 
the expression of a host of other, and often very disparate, endometrial genes has been 
reported to be perturbed in reproductive disorders associated with subfertility, such as 
endometriosis (125). A major hurdle is that, in the absence of an appropriate animal 
model, it is difficult to ascertain if impaired expression of an endometrial factor prior 
to conception is causal, or even relevant, to subsequent reproductive failure (126, 
137).  
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Table 1.2 Mouse Knock-out models critical to uterine biology (Ref: 56, 113, 125)  
Uterine patterning during post natal growth  
Genes Molecule Phenotype 
Hoxa10 Homeobox A10  Homeotic transformation of anterior uterus to oviduct  
Hoxa11 Homeobox A11  No uterine glands; partial homeotic transformation of uterus 
to oviduct 
Wnt5a WNT-5a protein  No morphologically defined cervix; no uterine glands  
Wnt7a WNT-7a protein  Abnormal oviduct and uterine development infertility 
 
Uterine physiology in adult life 
Genes Molecule Phenotype 
Adamts1 
 
A disintegrin-like and metalloprotease with thrombospondin-
type-1 motif-1 (Enzyme, tissue remodeling) 
Impaired follicular development and fertilization, uterine 
cysts; subfertility 
 
Bteb1 
 
Basic transcription-element-binding protein-1  
 
Uterine hypoplasia; compromised uterine P4 function, 
impaired embryo implantation; subfertility  
Cenpb 
 
Centromere protein B (Centromere assembly) 
 
Disrupted luminal and glandular uterine epithelia; 
subfertility (genetic-background-dependent) 
Cyp27b1 25-hydroxyvitamin D 1alpha–hydroxylase enzyme (Vitamin D 
metabolism) 
Uterine hypoplasia; absence of corpus luteum; infertility 
Esr1 Oestrogen receptor-alpha Ovarian cysts; uterine hypoplasia, infertility 
Igf1 Insulin-like growth factor-1  Ovulation failure; uterine myometrial hypoplasia; infertility 
Pgr Progesterone receptor  Unopposed oestrogen action; uterine hyperplasia; infertility 
Ube3a Ubiquitin-protein ligase E3A (Protein modification, proteolysis 
and peptidolysis) 
Impaired follicular development and uterine hypoplasia; 
subfertility 
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Vdr Vitamin D receptor  Uterine hypoplasia with impaired folliculogenesis; infertility 
 
Uterine preparation for initiating implantation 
Genes Molecule Phenotype 
Bsg  Basigin (Immunoglobulin) Defective fertilization; no implantation 
Esr1  
 
Oestrogen receptor-alpha 1 No uterine attachment, but uterine responsiveness to 
decidualization persists with P4 priming 
Fkbp52 FK506-binding protein-4 (Immunophilin co- chaperone for 
steroid hormone) 
Compromised P4 function; no uterine receptivity  
Gp130/Stat GP130/Signal Ttransducer and activator of transcription 
(Cytokine-receptor signalling) 
No implantation  
Hmx3   H6 homeobox-3  No implantation  
LpA3 Lysophosphatidic acid receptor-3 (LPA signalling) Deferred, on-time implantation; aberrant embryo spacing; 
postimplantation defects; small litter size  
Lif  Leukaemia inhibitory factor (Cytokine) No implantation  
Pgr  Progesterone receptor  No implantation or decidualization  
Pla2g4a Phospholipase A2, group IVA (Arachidonic-acid- releasing 
enzyme) 
Deferred on-time implantation; aberrant embryo spacing; 
postimplantation defects; small litter size  
Ppard Peroxisome proliferator-activated receptor-  Initiating embryo attachment; placental defects; subfertility 
Ptgs2 Prostaglandin-endoperoxide synthase-2 (Prostaglandin 
synthesis) 
Multiple reproductive failures, including defective 
attachment reaction; genetic-background-dependent 
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Uterine decidualization 
Genes Molecule Phenotype 
Fkbp52 FK506-binding protein-4 (Immunophilin co- chaperone for 
steroid hormone) 
Compromised P4 function; defective decidualization  
Hoxa10 Homeobox A10  Defective decidualization; reduced fertility  
Hoxa11 Homeobox A11  Defective implantation and decidualization; infertility 
Il11ra1 Interleukin-11 receptor-α1  Cytokine signaling) Impaired decidualization; infertility 
Pgr Progesterone receptor  Lack of decidual response even after P4 priming 
Ptgs2 Prostaglandin-endoperoxide synthase-2 (Prostaglandin 
synthesis) 
Defective decidualization; reduced angiogenic response 
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1.11 Initiation of the window of implantation 
Opening of the implantation window is characterised by remarkable ultrastructural 
changes in endometrial epithelial cell morphology. In several studies the time of 
implantation coincided with the presence of endometrial pinopodes (139-141). 
Pinopodes are cytoplasmic protrusions of the endometrial surface, arising from the 
apical surface of the epithelial cells and extending into the uterine cavity. Although 
some groups have questioned the correlation between pinopodes and endometrial 
receptivity (142), the timed correlation of pinopode expression, period of blastocyst 
hatching, and preference of human blastocyst to attach to pinopodes suggest 
pinopodes as structural markers of receptive endometrium (125, 143, 144). 
Furthermore, pinopode formation and maintenance is shown to be hormone 
dependent, where progesterone is crucial for their appearance, and oestrogen 
interferes with the formation or induces regression (145-147). Further, the co-
expression of pinopodes and other markers of endometrial receptivity have been 
demonstrated, such as with integrin αVβ3 (95), osteopontin (148), glycodelin (149) 
and progesterone receptors (146). The relative lack of clinical investigation of the 
endometrium is partly from the lack of objective tools for examining endometrial 
receptivity in a clinical setting. As a result, most current therapeutic interventions 
aimed to modulate endometrial receptivity are empirical, with little evidence base to 
support their use (126). Nevertheless, recent developments in understanding the 
molecular regulation of endometrial receptivity are offering novel insights into the 
role of the endometrium in determining whether or not implantation could be 
successful. Indeed, studies comparing endometrium at the pre-receptive and receptive 
phases in fertile women and women with poor reproductive success demonstrate that 
implantation failure is, at least in part, due to a failure of the endometrium to 
differentiate into a receptive state (150). The exact signal that initiates the 
implantation window remains to be defined. 
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1.12.Immunomodulation  
The fetus has a genetic makeup derived from both paternal and maternal genes and is 
therefore a semi-allograft to the maternal immune system. Intriguingly, the fetus 
escapes immune rejection and is tolerated for the duration of pregnancy. This 
phenomenon was first described in 1953 as ‘the parado  of pregnancy’ (151). The 
mechanism behind this remains a central question in reproductive immunology. 
During the decidual process, there is an influx of innate immune cells that is primarily 
populated by three leukocyte subpopulations, namely uNK cells, macrophages and T 
cells. B cells are virtually absent (152).  
 
In humans, mature NK cells constitute 5-20% of the total lymphocyte population in 
peripheral blood and can be divided into two subsets based on their expression of 
receptors CD16 and CD56 (152). The CD56
dim
CD16
+
 subset is primarily cytotoxic 
and makes up the majority of peripheral blood NK cells. CD56
bright
CD16
-
 NK cells 
have limited lytic ability and are the main source of immunoregulatory cytokines 
released by NK cells (153). Human uNK cells are terminally differentiated 
CD56
bright
CD16
-
 NK cells found in transient endometrial decidua (33). They have a 
tenfold higher expression of CD56 than blood CD56
dim
 NK cells. uNK cells also 
express killer immunoglobulin-like receptors (KIR) that interact with major 
histocompatibility complex. Their differentiation is triggered by decidualization, they 
comprise 70% of all decidual lymphocytes during early pregnancy (154). uNK cell 
numbers begin to decline around weeks 14-16 of pregnancy (153). 
 
Whether human CD56
bright
 uNK cells arise from uterine progenitors or from 
circulating CD56
bright
 or other CD34
+
 hematopoietic progenitor cells that home to 
implantation sites is not well defined. Recent reports strongly indicate that at least a 
significant proportion, if not all, mature human uNK cells arise from extra-uterine 
progenitors in secondary lymphoid tissues and in the thymus (155). 
 
A large body of literature has questioned the potential harmful effects of uNK cells 
for the conceptus. However, Croy et al., 1996 used knock-out and transgenic mouse 
models to show that although uNK cells are equipped with cytolytic killing 
machinery, they have limited killing activity (156). Since then, a number other 
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cytokines and growth factors have been found to be produced by uNK cells, providing 
support for the concept that uNK cells contribute to biological processes other than 
classical immune surveillance and cytotoxic killing. It was observed that uNK cells 
secrete a plethora of cytokines such as granulocyte macrophage colony stimulating 
factor (GMCSF), Interferon- γ (IFN γ)-, IL-2, IL-10, LIF and MMP (157), suggesting 
that uNK cells may instead have functions related to the dialogue at the maternal-
embryonic interface and subsequent development of the placenta (126, 137, 158). 
Gene microarray (159, 160) and explant studies (159) characterized uNK cells as 
highly pro-angiogenic cells that produce angiogenic factors such as members of the 
VEGF family, including placenta growth factor (PGF) (159-161). Mouse knock-out 
models devoid of uNK cells have shown that uNK cells not only participate in 
angiogenesis, but also regulate the structure of blood vessels in the uterus (162). 
During pregnancy, spiral arteries arising from branches of the maternal uterine artery 
feeding the placenta, dilate and their vascular smooth muscle is lost (120). The result 
of this change is increased blood volume flowing to the placenta, the organ where 
gases and other molecules exchange between the maternal and fetal blood (120). This 
change called spiral artery modification does not occur in mice in the absence of uNK 
cells (162). Lack of spiral artery modification and poor angiogenesis are often 
features of gestational diseases such as preeclampsia, fetal growth retardation and in 
some cases of recurrent spontaneous abortion (12, 120). Previously, the poor 
placentation observed in these diseases led investigators to address the hypothesis that 
uNK cells obstructed the proper development and support of the placenta because of 
their cytotoxic killing (163). However, more consideration is now given to the growth 
factors and cytokines that are produced by uNK cells based on results that describe 
uNK cells as key players that regulate placentation (164). 
 
1.12.1 Cytokine signaling in the endometrium 
Cytokines are regulatory peptides or glycoproteins that can be produced by virtually 
every nucleated cell type in the body, secreted by cells in response to a variety of 
stimuli. They are a diverse group of molecules that are secreted into the extra cellular 
medium and then influence the target cells in a non-antigen specific manner (165). 
Cytokines and the subfamily of IL’s belong to an ever-expanding family of active 
peptides that regulate cell growth and differentiation in several biological processes. 
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Cytokines were first discovered and studied in the immune and hematopoietic systems 
(166), but have pleiotropic regulatory effects on endocrine, neural and many other cell 
types to modulate cell function ranging from proliferation and differentiation to 
metabolic effects (165). The expression of several cytokines and their respective 
receptors in the normal endometrium resemble those associated with inflammation 
and tissue repair (167). Several lines of evidence increasingly suggest that a number 
of endometrial-derived immunoactive cytokines and growth factors play an essential 
role in early reproductive events such as pregnancy recognition, implantation, 
placental development and ultimately in the establishment of successful pregnancy 
(168). Furthermore, cytokines may influence pre-implantation embryo development 
and trophoblast growth/differentiation and migration, which are necessary for 
placental development (169). In accordance with this assumption, the establishment 
and continuation of normal pregnancy in mice is facilitated or hindered by 
administration of various cytokines (126, 137) suggesting that cytokines have a 
function in regulating the feto-maternal relationship. Among the cytokines identified, 
both in mouse and human endometrium, a few seem to play more important roles than 
others. Female mice with either an inactive or null mutation for the IL-11 receptor 
alpha chain (IL-11Rα) demonstrate implantation defects (170). Blockade of 
endometrial IL-1 R type I (IL-1RtI) by its natural antagonist IL-1 receptor antagonist 
(IL-1Ra) prevents implantation in mice (171). In humans, possible interaction of the 
cytokines at some of the early events during the process of implantation is evident 
from the higher pregnancy rate observed when the in vitro fertilized embryos were 
incubated with IL-1 prior to their transfer to the uterus (172).  
 
1.12.2 Th1/Th2 paradigm in pregnancy  
CD4
+
 T helper cells play a central role in deciding the nature of the immune response 
as they produce large amounts of cytokines and therefore regulate a variety of 
immune functions. In addition to T cells and monocytes, other cells including 
epithelial, endothelial and mesenchymal cells produce overlapping as well as distinct 
sets of cytokines. The response of T-helper (Th) cells upon activation is characterized 
functionally according to the cytokines produced, which are roughly divided into two 
subsets: type 1 cells (Th1) and type 2 cells (Th2) (173-176). Inflammatory mediators 
produced by T helper type-1 cells (Th1 cytokines) include IL-2, TNF-α and IFN-γ, 
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whereas T helper type-2 cells produce cytokines such as IL-4, IL-5, IL-6, IL-10 and 
IL-13 (Th2 cytokines) (173-176). IFN-γ and IL-2 are involved in the development of 
delayed type hypersensitivity and promote the development of cytotoxic T 
lymphocytes and NK cells. Whereas, IL-4, IL-5 and IL-6 are involved in B-cell 
development and in the antibody production response. After discovery of 
heterogeneity in Th cell populations in the 1980s, for several years maternal tolerance 
towards fetal alloantigens was explored in the context of the Th1/Th2 paradigm, with 
Th2 cells and cytokines proposed to overrule the Th1 cellular immune response, 
which can lead to fetal abortion (176, 177) (Fig 1.5). 
 
Interleukin (IL)-33 is a newly described member of the IL-1 family, which binds its 
receptor ST2L to induce type 2 cytokines. A soluble variant of ST2 (sST2) acts as a 
decoy receptor to regulate the activity of IL-33. Aberrant signaling of either IL-33 or 
its receptor ST2 is associated with pregnancy complications such as pre-eclampisa 
(178) or miscarriage (179). ST2 (180) and IL-33 knockout mice (personal 
communication with Dr A McKenzie, University of Cambridge) are reportedly fertile. 
However, the role of IL-33/ST2 in the endometrium, or in early pregnancy events, are 
currently unknown.   
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Figure 1.5 The Th1/Th2 paradigm in pregnancy 
The exact role of cytokines in maternal-fetal interactions is still poorly understood, 
particularly in humans. The presence of numerous cytokines at the maternal-fetal 
interface and on the trophoblastic cells suggests that they play a role in the growth and 
survival of the feto-placental unit. The evidence for a dichotomous T-helper response 
in reproduction originated from murine models, which showed that pregnancy 
rejection is mediated by Th1 cytokines, whereas a Th2 cytokine response confers 
protection. 
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In vivo the murine feto-placental unit spontaneously releases IL-4, IL-5 and IL-10 
during all three trimesters of pregnancy, whereas IFN-γ, a Th1 type cytokine, is only 
secreted during the earliest phase of gestation (177). In humans, Th1 cells 
predominate in the non-pregnant endometrium, especially during the proliferative 
phase (181). However, Th2 (IL-4 and IL-6) cytokines are more dominant in the peri-
implantation endometrial tissue and in pregnancy, the majority of cytokines produced 
in the non-lymphoid tissue of placenta and decidua are Th2 derived (175, 182). 
Interestingly, in the presence of progesterone, lymphocytes from pregnant females 
produce an immunomodulatory protein, progesterone-induced blocking factor (PIBF), 
which inhibits several Th1-type responses in vitro and prevents resorptions in mice 
induced by transfer of spleen cells with high natural killer activity (183). In the 
presence of PIBF, murine splenocytes activated with mitogen, produce significantly 
higher levels of IL-10 and IL-4, bringing about a Th1 to Th2 shift (184) Additionally, 
Piccinni et al., have reported that progesterone favours Th2 cytokine production 
(185). At concentrations that are similar to those seen at the feto-maternal interface, 
progesterone drives the development of Th2 cell lines and interestingly is even 
capable of transiently inducing the production of Th2 cytokines in established Th1 
cell lines (185). Therefore, progesterone may be responsible, at least in part, for a Th1 
to Th2 switch at the maternal–fetal interface.  
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1.13 Functions of the Decidua 
High progesterone levels enable endometrial stromal cells to acquire a secretory 
phenotype and become specialized epithelioid cells that can regulate various 
biological functions such as, trophoblast invasion, immunomodulation (mentioned 
above), haemostasis, angiogenesis and oxidative stress defence mechanisms, that are 
cardinal for ensuring a successful pregnancy (Fig 1.6). In the absence of pregnancy, 
however, declining progesterone levels trigger a switch in the secretory repertoire of 
decidual stromal cells. These cells express pro-inflammatory cytokines, chemokines 
and matrix metalloproteinases, which in turn activate a sequence of events leading to 
tissue breakdown of the superficial endometrial layer, focal bleeding and menstrual 
shedding (28). 
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Figure 1.6 Functions of decidualization 
Decidual transformation of human endometrial stromal cells in vivo and in vitro. (A) 
Decidualization of the stromal compartment (arrowheads) is initiated during the mid-
secretory phase of the cycle in stromal cells that surround the terminal portion of the 
spiral arteries (left panel) and then spreads to encompass the entire superficial 
endometrial layer by the late luteal phase of the cycle (right panel). (B) Phalloidin 
staining (red staining) of filamentous actin in undifferentiated and decidualized 
primary endometrial stromal cells in culture (left and right panels, respectively) 
highlights the phenotypic reprogramming of the cells that underpins their very diverse 
functions (e.g receptivity, immunodulation, invasion etc). Decidualization is 
characterized by a dramatic increase in filamentous actin polymerization and stress 
fiber formation. The nuclei were stained with 4',6-diamidino-2-phenylindole (blue 
stain).   
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1.13.1 Tissue Haemostasis 
Decidualizing HESCs secrete several factors that promote haemostasis (halting of 
bleeding by the clotting process) before and throughout the trophoblast invasion. It 
involves remodeling of the spiral arteries, which entails endothelial swelling, 
vacuolation and disorganization of the smooth muscle media. Tissue factor (TF), a 
membrane-bound glycoprotein also known as coagulation factor III (F3), is the key 
initiator of the blood coagulation cascade. TF initiates haemostasis through binding to 
factor VII, whilst the tissue factor pathway inhibitor (TFPI) inhibits the cascade. TF 
has been proposed to have a central role in the connection of haemostatic, angiogenic 
and pro-inflammatory pathways (186), as it acts as a signaling molecule that binds 
FVIIa and cleaves protease-activated receptor 2 (PAR-2), which plays a role in 
angiogenesis, inflammation, and tumor progression (187). Ablation of TF gene 
resulted in embryo lethality in mice as a consequence of defective vascular integrity 
and neoangiogenesis of the yolk sac (188). In the presence of low levels of TF, the 
TF-null embryos were rescued (189). Endometrial TF is upregulated at the time of 
implantation and any modification in expression can lead to various pathologies of the 
endometrium including infertility and endometrial carcinogenesis (186, 190). 
 
1.13.2 Angiogenesis 
Angiogenesis is an essential component of endometrial regeneration and maturation. 
It is a process involving growth of new blood vessels from pre-existing vessels. 
Angiogenesis occurs periodically at three distinct stages in the human endometrium: 
Firstly, during menstruation for repair of the vascular bed; secondly, at the 
proliferative phase during rapid endometrial growth; and thirdly during secretory 
stage when spiral arterioles exhibit growth and coiling (191). Additionally, vascular 
development is important during implantation and early placentation (192). At the 
time of implantation, adequate uterine vascularity is needed to provide a richly 
vascularized endometrium, and following the implantation, development and 
expansion of placental villous vasculature is needed to facilitate transport of nutrients 
and oxygen to the embryo (192). It has been demonstrated, in mice, that inhibition of 
angiogenesis either before or shortly after implantation interrupts placentation and 
results in resorption of all embryos (193), thus highlighting the critical role of 
angiogenesis in normal implantation and placentation. Thus, perturbations in 
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endometrial haemostasis are believed to represent a potential source of implantation 
failure and subsequent pregnancy complications in humans (194). During the mid-
secretory phase, when endometrial stromal cells decidualize around blood vessels, 
these cells are temporally and spatially positioned to create a local haemostatic milieu. 
This can counteract the threat of haemorrhage during the implantation process, as 
blastocyst-derived trophoblasts penetrate the spiral arteries to establish the primordial 
utero-placental circulation (194). A wide range of soluble factors, some with well-
established angiogenic functions (e.g. VEGF, PIGF, FGF, TGF) (192) as well as other 
factors, could contribute to vascular development and maintenance at the maternal-
fetal interface.  
 
1.13.3 Oxidative Stress Defences 
There is no doubt that the profound vascular changes at the feto-maternal interface in 
early pregnancy exposes the decidua to considerable oxidative stress. The survival and 
growth of the developing fetus is critically dependent upon sufficient utero-placental 
blood flow (195). In early pregnancy the extravillous trophoblast invades the 
decidualized endometrial stromal compartment and its spiral arteries, replacing the 
endothelial lining and the musculo-elastic tissue within the vessel wall (195). 
Trophoblast vascularisation and digestion of the upper parts of the spiral arterioles 
completes remodelling of the maternal vasculature (196). As a result, the efficiency of 
nutrients and oxygen exchange is raised with the increase of trophoblast surface area 
(196). 
 
As a consequence of these vascular modifications, major fluctuations in oxygen 
concentration occur at the feto-maternal interface during normal pregnancy (195). The 
partial oxygen pressure measured within the placenta between 7-10 weeks gestation is 
less than 20 mm Hg but rises to more than 50 mm Hg between 11-14 weeks when the 
maternal perfusion of the placenta occurs (195). During these oxygen tension changes, 
reactive oxygen species (ROS) have been reported to be generated in the endometrium 
(197). An overproduction of ROS can lead to oxidative stress, which can modify cell 
function, endanger cell survival or both (198). 
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In fact, pregnancy is a state of oxidative stress arising from increased placental 
mitochondrial activity and production of ROS (199). The placental ROS have 
pronounced effects on placental function including trophoblast proliferation and 
differentiation and vascular reactivity (199). Excessive production of ROS may occur 
at certain windows in placental development and in pathologic pregnancies, such as 
those complicated by pre-eclampsia (200) or IUGR (201), overpowering antioxidant 
defences with deleterious outcome. In the first trimester, establishment of blood flow 
into the intervillous space is associated with a burst of oxidative stress (202). The 
inability to mount an effective antioxidant defence against this results in early 
pregnancy loss. In late gestation increased oxidative stress is seen in pregnancies 
complicated by diabetes, IUGR, and pre-eclampsia in association with increased 
trophoblast apoptosis (201). ROS generation by exogenous sources have been known 
to trigger a number of signaling pathways, downstream of growth factor receptors 
(203). ROS can trigger the activation of phosphorylation cascades leading to the 
activation of mitogen-activated protein kinases (MAPKs) and NF-B (204). Mammals 
express at least three related groups of MAPKs; namely classical MAPK (also known 
as ERK), C-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and 
p38 kinase (205, 206). MAPKs transduce extracellular signals from hormones, growth 
factors, cytokines and oxidative stress, which can cause a diverse range of 
physiological functions (206). ROS is known to activate members of the PI3K/AKT 
signaling pathway and members of the JNK/p38 stress kinase family (203), which is 
known to promote nuclear import and increase cellular protection against oxidative 
stress via transcriptional activation of SOD-2 and catalase (195). In proliferative cells, 
activation of c-AKT protects cells from apoptosis and in quiescent cells, which lack c-
AKT, FOXO3a directly increases the quantity of SOD-2 mRNA and protein (207) 
protecting the cells from oxidative stress. FOXO1 induces expression of SOD-2 upon 
HESC differentiation conferring to the notion that the decidua already possesses 
heightened defence mechanisms against oxidative stress (195). Oxidative stress also 
induces FOXO3a and apoptosis in undifferentiated HESCs but not in differentiated 
HESCs (195). Thus, silencing of FOXO3a upon decidualization disables the apoptotic 
pathway, which is activated by oxidative stress (195). 
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1.14 Clinical perspective 
Many couples worldwide are involuntarily childless due to infertility or pregnancy 
loss, which is often associated with social and psychological implications (208). In 
Europe, low birth rate is one of the distinctive population features in most countries, 
and with delayed childbearing the need for infertility treatment is increasing (209). 
Although many underlying causes of human infertility have been overcome by 
assisted reproductive techniques, the implantation process remains the rate-limiting 
step with regards to the success of treatment (126). A prerequisite for successful 
implantation is an adequate preparation of a receptive endometrium and a normally 
developed viable embryo. The success of implantation further relies upon a two-way 
communication between the embryo and the uterus. In order to increase success rates, 
there is, therefore, a continuing need to understand the molecular basis of the pre-
implantation and implantation processes. Many studies have been performed to 
improve our understanding of these mechanisms, but the majority of the knowledge 
regarding human embryo development and implantation is derived from animal 
models. Studies on human endometrium provide useful information on endometrial 
preparation for implantation. Nevertheless, there is still a lack of diagnostic and 
therapeutic tools for implantation dysfunction, and an optimal marker for defining a 
state of endometrial receptivity that is needed. 
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1.14.1 Fertility and Infertility 
Fertility is the natural capability to give life. It can be measured by the time taken to 
achieve pregnancy. Time-to-pregnancy (TTP) is expressed in the monthly fecundity 
rate, which in humans, compared to other mammalian species, is relatively low ~20% 
(208). It has been estimated that 79% of the population is fertile, 18% subfertile or 
infertile and 3% superfertile (5, 208). In addition to subfertility, the incidence of 
embryo wastage and pregnancy loss is relatively high in humans, estimated to be 30% 
prior to implantation, a further 30% of early pregnancy loss, and over 10% of clinical 
pregnancies (103, 210). In humans, the prevalence of infertility is high, affecting over 
10% of couples of fertile age (211). Infertility is defined as inability of a couple to 
become pregnant within a year without using any contraceptives (208). It is estimated 
that over 72 million women worldwide, aged 20 – 44, are currently infertile, however, 
only every second couple seeks medical care for infertility (211). Infertility in a 
couple could be caused by female (over one-third) or by male factor (over one-third) 
or by a combination of problems in both partners, or is unexplained (approximately 
20%) (103). Female fertility is regulated by a complex coordination and 
synchronization of interactions in the hypothalamic-pituitary-ovarian-axis. Thus, it is 
influenced by different diseases or dysfunctions of reproductive tract, neuroendocrine 
system, immune system or by any general disease (208). Major causes of female 
infertility are disorders in ovulation (most commonly polycystic ovary syndrome, 
PCOS), tubal factor infertility, endometriosis and unexplained infertility (212)  
(summarized in Table 1.3). In the case of male factor infertility, it is generally defined 
by the finding of an abnormal semen analysis.  
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Table 1.3 Aetiology of female infertility  
 
Primary clinical diagnosis Incidence % 
Ovulatory dysfunction 27 
Male Factor 25 
Tubo-peritoneal 22 
Unexplained 17 
Endometriosis 5 
Idiopathic 4 
(Adapted from ref 194) 
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1.14.2 Recurrent pregnancy loss 
In addition to infertility, the incidence of embryo wastage and pregnancy loss is also 
astonishingly high in humans, estimated to be 30% prior to implantation 
(preimplantation loss), a further 30% before 6 weeks gestation (early pregnancy loss 
or EPL) and 10% of clinical pregnancies, mostly prior to 12 weeks gestation (Fig 
1.7) (103, 213). A recent study has shown that this preclinical pregnancy wastage 
does not present as subfertility and is therefore an additional reproductive challenge 
in humans (5). Moreover, 1–2% of couples experience recurrent pregnancy loss 
(RPL), defined in Europe as three or more consecutive miscarriages (213, 214). 
Miscarriage, whether sporadic or recurrent, is widely viewed as a dichotomous 
disorder, attributed either to chromosomal or other developmental abnormalities in 
the embryo or due to uterine factors. Although numerous anatomical, endocrine, 
immunological, thrombophilic and genetic perturbations have been invoked to 
explain non-chromosomal miscarriages, none of these are specific or prevalent (213, 
214). It is however thought to be due to a failure in natural embryo quality control 
(215). In fact, the current paradigm of RPL and its management are firmly anchored 
in the conjecture that pre-existent disease, often much more relevant to subfertility, 
also underpins RPL. However, many women with RPL, especially those who have 
experienced many consecutive losses, report exceptionally high pregnancy rates. A 
retrospective analysis of TTP in 560 recurrent miscarriage patients revealed that 
40% could be considered as ‘superfertile’, here defined as a mean TT  of 3 months 
or less (216).  
However, even after three consecutive miscarriages, many RPL patients will 
ultimately achieve a successful pregnancy (213), suggesting that this intrinsic failure 
may relate to a modifiable programming event in endometrial cells, as suggested by 
the ‘menstrual preconditioning’ hypothesis (45). Sustained programming of cellular 
responses likely involves epigenetic changes like DNA methylation or post-
translational histone tail modifications. Interestingly, inflammatory signals are 
important epigenetic modifiers (217), which raise the possibility that the tissue trauma 
associated with menstrual events between pregnancies may provide cues that 
dynamically modulate subsequent decidual responses in the endometrium (218). 
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Figure 1.7 The embryo wastage iceberg in fertile women 
The embryo wastage iceberg gives an overview of the outcome of 100 conceptions in 
a normal fertile population. (Adapted from Ref 4). 
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Perhaps, the most compelling evidence that inflammatory signals modify 
endometrial differentiation responses comes from the baboon model. Kim et al., 
demonstrated that induction of endometriosis and chronic inflammation in this 
model resulted in a gradual decrease in endometrial HOXA10 expression, a 
homeobox transcription factor involved in endometrial development and 
differentiation (219). Importantly, this down-regulation was only significant 6–12 
months after the induction of endometriosis and corresponded to increased 
methylation of the proximal promoter of the HOXA10 gene. In fact, the ability of 
local tissue injury to modify subsequent decidual responses has been long 
recognized and increasingly exploited for clinical purposes. Karow et al., reported 
that an endometrial biopsy decreases subsequent miscarriage rates, especially in 
subfertile patients (220), a finding confirmed in several more recent observational 
studies (221, 222). In sum, menstrual preconditioning and the repeated inflammatory 
events and tissue trauma associated with each cycle may be crucial to sensitize the 
endometrium to environmental signals and coordinate a precise spatiotemporal 
decidual response (45). 
 
1.15 Molecular Basis of reproductive failure: Endometrial SGK1  
Serum and glucocorticoid kinase 1 (SGK1) encodes for a serine/threonine kinase 
involved primarily in epithelial ion transport and cell survival responses (223). SGK1 
was identified as a gene aberrantly expressed in mid-secretory endometrium of 
women with unexplained infertility (129). SGK1 expression is regulated by 
progesterone in the human endometrium in vivo as well as in explant cultures. During 
the mid-secretory phase of the cycle, SGK1 mRNA and protein expression were 
predominantly but not exclusively expressed in the luminal epithelium and its 
expression in this cellular compartment was higher in infertile women (129). In the 
stromal compartment, SGK1 expression was largely confined to decidualizing cells 
adjacent to the luminal epithelium. In vitro culture, SGK1 was induced and 
phosphorylated upon decidualization of endometrial stromal cells in response to 8-
Bromo-cAMP and progestin treatment. Moreover, overexpression of SGK1 in 
decidualizing cells enhanced phosphorylation and cytoplasmic translocation of the 
FOXO1 and inhibited the expression of PRL (129). Conversely, knockdown of 
endogenous SGK1 by small interfering RNA increased nuclear FOXO1 levels and 
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enhanced PRL expression. The role for this kinase in coordinating the molecular 
events in uterine receptivity remains to be defined. 
 
1.15.1 Characterization of SGK1 
SGKs are members of the AGC protein kinase subfamily of serine/threonine protein 
kinases. SGK1 was originally characterised as a 49 kDa protein kinase whose mRNA 
was rapidly induced by serum and dexamethasone in a rat mammary tumour cell line 
and was therefore named serum/glucocorticoid regulated kinase (SGK) (224). The 
later discovery of the SGK paralogues SGK2 and SGK3 led to the original SGK being 
renamed SGK1. SGK2 and SGK3 were discovered as products of distinct genes, but 
with 80% amino acid identity between the kinase (catalytic) domains of the three 
SGK paralogues, 50% homology in their COOH-terminal domains, but <10% 
homology in their NH2-terminal domains (225) (Fig 1.8). In humans, the SGK1 gene 
locus is on chromosome 6q23. A common (approximately 5% prevalence) SGK1 
gene variant is associated with increased blood pressure and body weight. SGK1 may 
thus contribute to metabolic syndrome (223). 
 
SGKs are broadly conserved and are present in mammals, shark, chicken, C. elegans, 
and two orthologues also exist in yeast. In mammals, SGK1 is expressed in most 
tissues including brain, heart, intestine, kidney, liver, lung, and muscle (223). SGK1 
consists of an N-terminus domain of ~100 residues; which is thought to be 
responsible for regulating localisation, the remaining ~330 residues constitute a 
kinase domain containing various putative binding sites and motifs (226). SGK1 is 
involved in regulation of many different cellular processes including proliferation, 
signaling, survival, and trafficking (227). 
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Figure 1.8 Domain comparisons of SGK1, SGK2, and SGK3 
SGK1 was originally identified as a glucocorticoid-sensitive gene and, subsequently, 
the homologous kinases SGK2 and SGK3 have been cloned. They are products of 
distinct genes, which are differentially expressed and share 80% identity in their 
kinase (Blue) domains. Upstream regions are highly conserved (Red), NH2 termini of 
SGK1 and SGK3 share sequence homology (Orange) and Tail (Black) (Adapted from 
239). 
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1.15.2 Regulation of SGK 1 
Following its characterization as a serum and glucocorticoid regulated kinase in 1993, 
SGK1 was later shown to be upregulated by aldosterone in A6 cells, rat kidney distal 
nephron, and rabbit cortical collecting duct cells (228, 229). These studies of 
aldosterone also showed that SGK1 increased activity of the epithelial Na
+
 Channel 
(ENaC), suggesting involvement in regulation of sodium reabsorption. This led to the 
investigation of the possible involvement of SGK1 in other diseases associated with 
hypertension. SGK1 was shown to be up regulated by transforming growth factor- β 
(TGF-β), increased e tracellular glucose concentration, osmotic cell shrinkage and 
thrombin, suggesting SGK1 may have a role in the pathogenesis of diabetic 
nephropathy (223, 230, 231).  
 
SGK1 is a powerful stimulator of the Na
+
 coupled glucose transporter SGLT1 (223, 
232), the SGK1 gene variant (E8CC/CT-I6CC) may further accelerate the intestinal 
glucose absorption. Enhanced SGLT1 activity accelerates intestinal glucose 
absorption leading to excessive insulin release, fat deposition, and subsequent 
decrease of plasma glucose concentration triggering repeated glucose uptake and thus 
obesity (232). 
 
The MAPK/ERK pathway is known to regulate SGK1 and mediates induction of 
SGK1 in response to cell stress allowing SGK1 to protect cells from stress-induced 
apoptosis by negatively regulating forkhead box protein O3A (FOXO3A) (233, 234). 
Transcriptional regulation of SGK1 occurs through several intracellular signaling 
pathways and as such a number of different signaling proteins have been shown to be 
involved. In addition to components of the PI3K, MAPK/ERK, SGK1 may also be 
transcriptionally regulated by changes in nitric oxide, and IL-2 (235). However, the 
transcriptional regulation of SGK1 probably involves many more potential players as 
the SGK1 promoter region has been suggested to contain various transcription factor 
binding sites such as for PR, vitamin D receptor, farsenoid X receptor (FXR), sterol 
regulatory element binding protein (SREBP), p53, Sp1 transcription factor, activating 
protein 1, activating transcription factor 6, heat shock factor (HSF), NFkB (236), 
signal transducers and activators of transcription (STAT). As well as binding sites for 
Glucocorticoid receptor, Minerocorticoid receptor, CREB (237),   ARγ, TGF-β-
dependent transcription factors SMAD3 and SMAD4, and forkhead activin signal 
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transducer (FAST) (223, 238-240). Phosphorylation of SGK1 controls its activity, 
which may occur at various phosphorylation sites with a unique substrate for each 
different activator.  
 
The most well-documented phosphorylation of SGK1 is performed by 3-
phosphoinositide-dependent protein kinase 1 (PDK1) at threonine-256 and by 
mechanistic target of rapamycin complex 2 (mTORC2) at serine 422, which promotes 
its actions in inhibiting neuronal precursor cells expressed developmentally 
downregulated (Nedd4-2) (225, 241, 242). Phosphorylation of SGK1 at threonine 256 
is first dependent on the phosphorylation of serine 422 (225). PDK1 is activated by 
the PI3K pathway and binds to PtdIns(3,4,5)P3 via its PH domain. SGK1 has also 
been shown to bind to phosphoinositides, possibly due to being localised with PDPK1 
by NHERF2 (243). The findings of these studies suggest that activation of SGK1 by 
via the PI3K pathway may occur at the plasma membrane. The activity of SGK1 has 
been shown to be dependent on its N-terminal domain, which may contain an amino-
acid sequence required for specific localisation (226, 243). Recently, it has also been 
argued that phosphorylation of SGK1 at serine-397 and serine-401 is required for 
maximum SGK1 activity, which was dependent on co-expression with active PKB 
and with no lysine kinase 1 (WNK1) (244, 245).  
 
SGK1 has a half-life of ~30 min in the cell and is degraded through being ubiquitin-
tagged at a specific six-amino-acid motif in its N-terminal domain, signaling it for 
degradation by the 26-S proteasome (246). Ubiquitination of SGK1 is performed by 
phosphorylated Nedd4-2, which itself is phosphorylated by SGK1 forming a negative 
feedback loop of regulation of SGK1 (223). 
 
1.15.3 Functions of SGK1 
To date, two modes of SGK1 action in regulating transporters and ion channels have 
been identified. It either regulates transporters by phosphorylating them at the 
putative consensus site (Arg-X-Arg-X-X-Ser/Thr)-φ  X; any amino acid and a φ; 
hydrophobic amino acid) (223) or by inhibiting the downregulating effect of protein 
ubiquitin ligase Nedd4-2. These two modes of regulation of SGK1 were observed in 
ENaC (245, 247) (Fig 1.9).  
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SGK1 also increases activity and cell-surface expression of the renal Na
+
/K
+
-ATPase, 
suggesting an additional stimulation of sodium reabsorption in the distal nephron by 
SGK1, separate to the stimulation of ENaC (248, 249). Further transporters that are 
regulated by SGK1 include the cystic fibrosis transmembrane conductance regulator 
Cl
-
 channel (CFTR) (250), various amino acid transporters (251-253) the creatinine 
transporter (SLC6A8) (254), and the peptide transporter (PEPT2) (255).  
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Figure 1.9 Schematic model showing molecular mechanisms of ENaC regulation 
by SGK1.  
Progesterone binding to the progesterone receptor (PR) can stimulate the transcription 
of SGK1 as well as ENaC. Insulin or Insulin-like growth factor (IGF-1) 
phosphorylates SGK1 at Ser422 through PI3K and PDK2 signaling cascade. 
Activated (P; phosphorylated) SGK1 enhances ENaC plasma membrane abundance 
either directly by phosphorylating the channel or indirectly by phosphorylating 
ubiquitin ligase Nedd4-2. (Adapted from 220)  
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SGK1 phosphorylation of Nedd4-2 induces binding of Nedd4-2 by members of the 
14-3-3 family of chaperone-regulatory proteins which block the tryptophan-rich WW 
domains of Nedd4-2 that are involved in PY motif interactions to inhibit ENaC (256, 
257). SGK1 also phosphorylates and inactivates the proapoptotic enzyme glycogen 
synthase kinase 3β  GSK3β), which is involved in regulation of β-Catenin (258, 259). 
SGK1 also phosphorylates members of the MAPK/ERK signaling pathway in 
regulation of cell proliferation including MEKK3 (260) and B-Raf (261). 
Microtubule-associated protein tau interacts with microtubules as part of being 
involved in cell proliferation and apoptosis and is inhibited upon phosphorylation by 
SGK1 (262). SGK1 also showed possible regulatory effects on insulin-stimulated 
glycosylation of glycoproteins involving phosphomannose mutase 2 (PMM2) (263).  
 
In sum, SGK1 is a powerful regulator of metabolism, transport, transcription and 
enzyme activity and thus participates in the regulation of a wide variety of 
physiological functions including epithelial transport, excitability, cell proliferation 
and apoptosis. The phenotype of SGK1 knockout mice is mild and the function of this 
kinase is involved in but not critically important for the maintenance of house-
keeping functions. However, following appropriate challenges the lack of SGK1 
becomes obvious and physiologically or pathophysiologically relevant. SGK1 plays a 
particularly important role in electrolyte balance, extracellular volume regulation, 
metabolic syndrome, tumor growth, inflammation, and fibrosing disease.  
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1.16 Hypothesis & Aims 
 
I postulate that impaired decidualization of the endometrium prior to conception 
predisposes for subsequent pregnancy failure, either by prolonging the implantation 
window or by disrupting the maternal responses to embryonic signals leading to 
reproductive failure.  
 
My specific aims are: 
1. To characterize the decidual phenotype in patients with and without RPL, by 
comparing key decidual markers and receptivity genes in 3 known groups of 
patients (normal, infertile and RPL) using timed endometrial biopsies.   
2. To mine an existing microarray and identify any key genes known to play a 
role in implantation and to further to assess this using HESCs using 
knockdown and functional characterization. To establish how the implantation 
window is initiated and if it is perturbed in different patient groups. To define 
how pro-inflammatory signals that control receptivity in the endometrium. To 
undertake an extensive survey of HESCs from different patient groups and the 
response to early pregnancy signals and delineate any molecular pathways. 
3. To establish an in vivo based technique to establish if different factors secreted 
from HESC from different patient groups can affect implantation rates in 
mice. 
4. To prepare a SGK1 mutant construct to flush in the uterus of mated female 
mice, in order to understand the molecular mechanism of reproductive failure, 
by further investigating its specificity and regulatory function in the 
endometrium of the mouse. 
5. To demonstrate the role of endometrial SGK1 by phenotypic and functional 
characterization and examine its contributions to implantation failure. 
6. To establish the clinical relevance of these pathways.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 2: Materials and Methods
Chapter 2: Materials and Methods 
 
 58 
 
2.1 Materials 
2.1.1 Antibodies 
Primary 
Antibody Dilution Manufacturer 
Total-SGK (Ser255/Thr256) 1:1000 Millipore 
Phospho-SGK1 (Ser255/Thr256) 1:1000 Millipore 
Catalase 1:2000 Abcam 
NEDD4-2 1:1000 Abcam 
ENaC-α 1:1000 Santa-Cruz 
Cleaved-Poly (ADP-ribose) 
polymerase (214/215) (c-PARP) 
1:1000 BioSource International 
Total-AKT (Ser473) 1:1000 Cell Signalling 
Phospho-AKT (Ser473) 1:1000 Cell Signalling 
CFTR 1:1000 Cell Signalling 
eGFP 1:500 Invitrogen 
Il1rl1 (St2) 1:1000 Abcam 
IL-33 1:1000 Abcam 
β-actin (AC-15) 1:100,000 Abcam 
 
 
Secondary 
Alexa-fluor 488 goat anti-rabbit IgG (H+L) Invitrogen  
Alexa fluor 594 goat anti-mouse IgG (H+L) Invitrogen  
Horseradish peroxidase (HRP)-conjugated goat 
anti-rabbit IgG 
Dako 
Horseradish peroxidase (HRP)-conjugated goat 
anti-mouse IgG 
Dako 
Horseradish peroxidase (HRP)-conjugated 
mouse anti-goat IgG 
Dako 
 
Normal Serum 
Goat Dako 
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2.1.2 Cells  
HESC Human endometrial Stromal cells (Primary) 
Ishikawa Epithelial Endometrial Carcinoma (Cell line) 
 
2.1.3 Plasmids 
WT SGK1 Kind gift from Prof Florian Lang 
SGK1 s422n Kind gift from Prof Florian Lang 
WT-catalase Kind gift from Prof Stephen Grimm 
 
2.1.4 siRNA  
All siRNA regents were purchased from Dharmacon. The RefSeq gene accession 
numbers are given below. 
 
On-target plus SMARTpool for human SGK1 (NM_005627) 
On-target plus SMARTpool for human IL-33 (NM_033439) 
On-target plus SMARTpool for human IL1RL1 (NM_016232) 
siCONTROL non-targeting siRNA pool 
 
2.1.5 Bacterial media and strains 
All compounds listed below were supplied by BD Biosciences or Sigma. 
 
L-agar 
1.0% (w/v) Bacto Tryptone 
0.5% (w/v) Yeast Extract 
0.5% (w/v) NaCl 
0.1% (w/v) Glucose 
1.5% (w/v) Bactoagar 
 
L-broth 
1.0% (w/v) Bacto Tryptone 
0.5% (w/v) Yeast Extract 
0.5% (w/v) NaCl 
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0.1% (w/v) Glucose 
SOC medium 
2.0% (w/v) Bacto Tryptone 
0.5% (w/v) Yeast Extract 
8.6 mM NaCl 
2.5 mM KCl 
20 mM MgSO4 
20 mM Glucose 
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2.1.6 Reagents 
Absolute Ethanol VWR 
Acetone BDH 
30% acrylamide/Bis solution (37.5:1) Bio-Rad 
Agarose powder Appleton woods 
Ammonium Persulphate (APS) Sigma 
Ampicillin  Sigma 
Bovine serum albumin (BSA) fraction V Sigma 
8- Bromoadenosine-3,5'-cyclic 
monophosphate sodium salt  
(8-Br-cAMP) 
Sigma 
Bromophenol blue Sigma 
2-Butanol BDH 
Calcium chloride BDH 
Coelenterazine Calbiochem 
Chloroform BDH 
Digitonin Sigma 
Dimethyl sulphoxyde (DMSO) Sigma 
Di-sodium hydrogen orthophosphate BDH 
Dithiothreitol (DTT) BDH 
DPX mountant for histology BDH 
Estradiol Sigma 
Ethidium bromide Sigma 
Ethylenediaminetetraacetic acid (EDTA) Sigma 
Glucose BDH 
Glycerol Sigma 
Glycine BDH 
Haematoxylin BDH 
Hydrochloric acid Sigma 
Hydrogen peroxide solution 30% Sigma 
Histo-clear National diagnostics 
Imidazole BDH 
Insulin Sigma 
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Isopropanol BDH 
Magnesium chloride BDH 
Magnesium sulphate BDH 
Methanol VWR 
MPA Sigma 
NA (Pyridine-3-carboxylic acid) Sigma 
Nonidet p-40 (np-40) BDH 
N,N,N',N'-tetramethyl- 
ethane-1,2-diamine (TEMED) 
Sigma 
(4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid ) HEPES 
Sigma 
Paraformaldehyde (PFA) Sigma 
Potassium phosphate monobasic Sigma 
Progesterone Sigma 
Puromycin Sigma 
Recombinant human epidermal growth 
factor (EGF) 
Sigma 
RU486 Sigma 
Sodium azide Sigma 
Sodium chloride BDH 
Sodium deoxycholate BDH 
Sodium dodecyl sulphate (SDS) BDH 
Sodium Fluoride VWR 
Sodium hydroxide BDH 
Sodium phosphate dibasic Sigma 
Sodium pyrophosphate Sigma 
SDS 20% solution (w/v) National diagnostics 
Tris (hydroxymethly)methylamine tris BDH 
Tris base BDH 
Tris HCl BDH 
Triton X-100 Sigma 
Tween 20 BDH 
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β-mercaptoethanol Sigma 
 
2.1.7 Cell culture media and materials 
Dulbecco’s modified eagles medium 
(DMEM)/F-12 (1:1) 1x nutrient mixture, 
with L-Glutamine, 15 mM HEPES ± 
phenol red 
Invitrogen 
Charcoal Sigma 
Collagenase type IA Sigma 
Dextran Sigma 
Deoxyribonuclease I (DNase I) Roche 
Foetal bovine serum (FBS) heat 
inactivated 
Invitrogen 
L-Glutamine, 200 mM (x100) Invitrogen 
Penicillin (10,000 U/ml)-streptomycin 
 10,000 μg/ml) solution   100) 
Invitrogen 
Trypsin-EDTA solution (x1) Invitrogen 
 
Tissue culture plasticware Orange scientific 
Falcon Nunc 
Corning 
Starlab 
VWR 
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2.1.8 Buffers and solutions 
 
All buffers and solutions were made with deionised and distilled water. Solutions 
were stored at room temperature (RT), unless otherwise stated. 
 
Phosphate buffered saline (PBS) 
140 mM NaCl 
2.5 mM KCl 
1.5 mM KH2PO4 
10 mM Na2HPO4 
 
Tris Buffered Saline (TBS) 
130 mM NaCl 
20 mM Tris, pH 7.6 
 
TBS-Tween 20 (TBS-T) 
0.1% Tween 20 in TBS 
 
Tris-Borate EDTA (TBE) Buffer (10x) 
0.9 M Tris-Borate 
2 mM EDTA, pH 8.0 
 
Hanks Balanced Salt Solution (HBSS) 
120 mM NaCl 
5.4 mM KCl 
0.8 mM MgSO4 
10 mM HEPES 
10 mM Glucose 
Adjust pH to 7.4 with NaOH 
 
HBSS with CaCl2 
1.8 mM CaCl2 in HBSS buffer 
Adjust pH to 7.4 with NaOH 
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Dextran Coated Charcoal (DCC) suspension 
1% (w/v) activated Charcoal 
0.1% (w/v) Dextran 
 
DNA Loading Buffer (10x) (Store at -20 
o
C) 
0.2% (w/v) Bromophenol blue 
40% (v/v) Glycerol 
0.25 M EDTA, pH 8.0 
 
Basic Lysis Buffer (Store at -20 
o
C) 
10 mM Tris-HCl, pH 7.5 
5 mM EDTA 
150 mM NaCl 
50 mM NaF 
30 mM Sodium Pyrophosphate 
10% (v/v) Glycerol 
0.5% (v/v) Triton X-100 
1 Complete Protease Inhibitor Cocktail Tablet per 50 ml of buffer 
 
Radio Immuno Precipitation Assay (RIPA) buffer (store at -20 
o
C) 
1% NP-40 (v/v) 
1% Triton X-100 
150 mM NaCl 
2 mM NaF 
1% Sodium Deoxycholate (w/v) 
0.1% SDS (w/v) 
10 mM Tris, pH 8.8 
1 Complete Protease Inhibitor Cocktail Tablet per 50 ml of buffer 
 
High Salt Buffer 
0.4 m KCl,  
20 mm HEPES (pH 7.4),  
1 mm dithiothreitol, 
20% glycerol 
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0.5 mM PMSF 
1 Complete Protease Inhibitor Cocktail Tablet 
 
Protein loading buffer (Laemmli buffer) (store at -20 
o
C) 
50 mM Tris-HCl, pH 6.8 
50 mM Imidazole, pH 6.8 
1% (w/v) SDS 
10% (v/v) Glycerol 
2%  v/v) β-mercaptoethanol  
0.002% (w/v) Bromophenol Blue 
 
Acid Alcohol Solution 
1% HCl (v/v) in Ethanol 
 
4% PFA solution 
4% PFA (w/v) in PBS 
Adjust to pH 7.4 with NaOH 
 
Western SDS Running Buffer (10x) 
250 mM Tris Base 
1.9 M Glycine 
1% (w/v) SDS 
 
Western Transfer Buffer 
250 mM Tris Base 
192 mM Glycine, pH 8.3 
20% (v/v) ethanol 
 
Western Blocking Buffer and Secondary Antibody Incubation Solution 
5% (w/v) non-fat milk in TBS-T 
 
Western Primary Antibody Incubation Solution 
3% (w/v) BSA in TBS-T 
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Western Stripping Buffer 
100 mM β-mercaptoethanol 
2% (w/v) SDS 
62.5 mM Tris-HCl, pH 6.7 
 
Immunofluorescence blocking solution 
3% BSA (w/v)/10% normal serum (v/v) in PBS 
 
Immunofluorescence Antibody dilution solution 
3% BSA (w/v) 0.5-10% normal serum (v/v) in PBS 
 
Immunohistochemistry Blocking Solution and Primary Antibody Dilution Solution 
3% BSA (w/v) / 10% normal serum (v/v) in PBS 
 
Immunohistochemistry Secondary Antibody Dilution Solution 
0.3% BSA (w/v) / 1% normal serum 
 
SDS Polyacrylamide Gels 
Resolving Gels 
375 mM Tris-HCl, pH 8.9  
1% (w/v) SDS 
10% (v/v) Acrylamide Bis Solution (37.5:1) 
0.03% (w/v) APS 
TEMED added at 1:1500 
 
Stacking Gel 
80 mM Tris-HCl, pH 6.8 
80 mM Imidazole 
0.06% (w/v) SDS 
5% (v/v) Acrylamide Bis Solution (37.5:1) 
0.06% (w/v) APS 
TEMED added at 1:1500 
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2.1.9 Kits 
3,3’-diaminobenzidine (DAB) substrate 
kit for peroxidase 
Vector Laboratories 
ST2, IL-33, PRL ELISA kits R & D systems 
DNAseI, Amplification grade Invitrogen 
ECL+ Western Blotting detection reagent GE Healthcare 
Maxi prep plasmid prep kit Qiagen 
Superscript First Strand synthesis kit for 
Reverse transcriptase –PCR (RT-PCR) 
Invitrogen 
Vectastain Elite ABC kit Vector laboratories 
 
2.1.10 Miscellaneous 
Bio-Rad Protein Assay Dye reagent 
concentrate 
Bio-Rad 
Chemiluminescent peroxidase substrate Sigma 
Complete Protease Inhibitor Cocktail 
Tablets 
Roche 
Coverslips Menzel-Glaser 
Culture Chamber Slides BD Falcon 
Diethylpyrocarbonate (DEPC) treated 
water 
Ambion 
ECL hyperfilm Amersham 
FuGENE 6 Transfection Reagent Roche 
Hybond PVDF membrane Amersham 
Hyperladder DNA makers Bioline 
Lipofectamine 2000 transfection reagent Invitrogen 
NuPAGE MOPS SDS running buffer 
(20x) 
Invitrogen 
4-12% NuPAGE Novex Bis-Tris Gels Invitrogen 
Optically Clear Adhesive Seal Sheets Abgene 
Protein ladders Fermentas 
Primers Invitrogen 
QPCR Human reference Total RNA Stratagene 
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Restriction enzymes New England Biolabs 
RNAlater Ambion 
RNAse free tubes Ambion 
RNaseZap Ambion 
Skimmed Milk VWR 
SYBR green PCR Master Mix Applied Biosystems 
0.22 μM syringe filters Nalgene 
Stat60 AMS Biotechnology 
Pro-GOLD Mounting media with DAPI Invitrogen 
96 well plates for RTQ-PCR Abgene 
CaPO4 Transfection kits Promega 
GenomeONE-NEO TM,  Ishihara Sangyo Kaisha Ltd, Japan 
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2.2 Methods 
2.2.1 Ethics Approval and Patient Recruitment 
The study was approved by Hammersmith and Queen Charlotte’s & Chelsea Research 
Ethics Committee (1997/5065). All women who participated in this study had read the 
patient information leaflet and written informed consent was obtained from all 
patients before endometrial sampling (See Appendix).  
 
2.2.2 Timed Endometrial Samples. 
Timed samples were collected from three different patient groups. Fertile controls 
were women who had at least 2 children, who were experiencing regular menstrual 
cycles, had not used hormonal preparations in the preceding 3 months and did not 
have a history of fertility problems (including PCO or PCOS). A regular cycle was 
defined as that of an inter-menstrual interval of not less than 25 and not more than 35 
days, with no more than a 4-day variation from one cycle to the next. Unexplained 
infertility was defined as conception delay of 24 months or more after excluding 
anovulation, tubal blockage, pelvic adhesions and endometriosis, or impaired semen 
quality; and RPL as three or more consecutive pregnancy losses before 24 weeks 
gestation. A ‘biochemical’ loss was defined as a miscarriage at 4-6 weeks gestation 
with ultrasound evidence of either an intrauterine pregnancy sac with no fetus or 
retained products of conception. A ‘fetal’ loss was defined as a pregnancy failure 
between 6-13 weeks gestation with prior ultrasound evidence of fetal development. 
All participants had regular cycles and monitored daily urinary luteinizing hormone 
(LH) levels using anovulation prediction kit (Assure Ovulation Predictor, USA). 
Endometrial biopsies were timed between 7 and 11 days after the pre-ovulatory LH 
surge (LH+7 to LH+11). For the purposes of RNA analysis, the biopsies were 
submerged at RT in approximately 5x volume of RNAlater, stored at 4
 o
C overnight 
to allow the solution to thoroughly penetrate the tissue and then archived at -20
 o
C for 
long term storage. Subsequently, the tissue was used directly for RNA extraction. For 
the purposes of immunohistochemistry, the endometrial tissues were formalin-fixed 
for 12-24h, paraffin-embedded and serially sectioned (5 μm) onto polysine glass 
slides. 
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2.2.3 Endometrial samples for primary cell culture 
Endometrial biopsies were obtained by curettage from women aged 18-40 years at the 
time of diagnostic laparoscopy, diagnostic hysteroscopy, laparoscopic sterilization or 
pippelle method at any phase of the cycle. For the establishment of these cultures, 
biopsies were collected in 10% DCC/FCS DMEM/F12 supplemented with 
antibiotic/antimycotic. 
 
2.3 Cell culture 
2.3.1 General maintenance of cell cultures 
All HESCs were managed in a standard cell culture incubation conditions using a 
NU-5500 Direct Heat AutoFlow CO2 Incubator (NuAire, Inc) which provided a 
humid atmosphere with 5% v/v CO2 maintained at 37 
o
C. A class II labguard 
Microbiological Safety Cabinet (NuAire, Inc) was used for cell culture. The working 
surface of the cabinet was swabbed down with 70% ethanol and the cabinet was left 
running 5 min before work commenced. Sterile plastic tissue culture flasks (Corning), 
plugged disposable serological pipettes (Corning) and plastic universal tubes (Sterilin) 
were used for routine culturing. Primary cell cultures and cell lines were cultured in 
separate hoods and incubators. 
 
2.3.2 Preparation of Dextran coated charcoal (DCC) stripped fetal calf serum 
(FBS) 
FBS contains endogenous steroid hormones that may mask the effect of exogenously 
added ligands. Serum used for cell culture was therefore stripped of small molecules 
by DCC treatment. A 500 ml of FBS had 1.25g of charcoal and 125 mg of dextran 
added and the solution incubated in a water bath at 56 
o
C for 2h, inverting at regular 
intervals. Following centrifugation at 4000 x g for 30 min, the supernatant was filter 
sterilized using a 0.2 μm bottle neck filter into a sterile bottle, aliquoted and stored at -
20 
o
C. For cell culture DMEM/F12 was supplemented with 10, 5, 2 and 0.5 % v/v 
DCC/FCS 
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2.3.3 Primary human endometrial stromal cell culture 
A fresh endometrial biopsy was washed in serum-free DMEM to remove mucus and 
blood then finely minced in a Petri dish using scalpels. The tissue was transferred into 
a T-25 cm
2
 flask containing 10ml of digest media which enzymatically dispersed the 
HESCs. The digestion media consisted of additive free DMEM containing 0.5 mg/ml 
collagenase type IA (Sigma) which disintergrated the extracellular matrix and 0.1 
mg/ml DNAse I (Roche) which eliminated the viscous DNA released during this break 
down process as some cells die. The endometrial sample was left to digest at 37
 o
C 
with vigorous shaking every 20 min. After 1h, 10 ml of 10% DCC/DMEM was added 
which stopped the collagenase activity, which was then centrifuged at 180 x g for 5 
min. The resultant pellet contained epithelial, glands, stromal and red blood cells, 
which was resuspended in 15 ml of 10% DCC/DMEM. The cells were transferred to a 
T-75 cm
2
 flask and left undisturbed for a 1h at 37 
o
C. The differential attachment of 
stromal and epithelial cells allowed for separation of the two cells types; stromal cells 
adhere earlier. Therefore after 1h, the media consisted of blood and the epithelial 
component, which was transferred to a second T-75 cm
2
 flask. The stromal cell flask 
was replenished with fresh 10% DCC/DMEM. The purity of this separation method 
has been assessed in our laboratory and has been well established (76). Both 
proliferating stromal and epithelial monolayers were maintained in 10% DCC/DMEM. 
Upon reaching confluence, the cells were passaged. Briefly, the medium was removed, 
the cells washed with 10 ml of pre-warmed PBS and then aspirated. Further to this 5ml 
of pre-warmed trypsin-EDTA was added for 5min at 37 
o
C, followed by gentle taping 
of the flask. Trypsin activity was terminated by the addition of 10 ml of 10% 
DCC/DMEM. Following, centrifugation at 1000 rpm for 5 min the cells were 
resuspended and cultured at a suitable dilution, typically 1:3. Experiments were carried 
out in 6-, 12-, 24- or 96-well plates in 10% DCC/DMEM. All experiments were 
carried at or before the third passage when the cells reached ~80% confluency. 
 
2.3.4 Hormone treatment of cells 
Prior to treatment, all monolayers were cultured in 2% DCC/DMEM for 24h. 
Hormone treatment of cells was carried out in 2% DCC/DMEM with the exception of 
transient transfections, which were carried out in 5% DCC/DMEM. Cells were left 
untreated, in the presence of 1 µM ethanol (vehicle), or left treated alone or with a 
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combination of 0.5 mM 8-Br-cAMP and 1 µM medroxyprogesterone acetate (MPA). 
When appropriate cells were treated with 10 UI hCG (Pregnyl; Organon UK) or rb 
IL-33 0.1 ng/ml (R&D systems, UK) 
 
2.3.5 Maintenance of cell stocks 
Ishikawa cells (well-differentiated human endometrial adenocarcinoma cell line) were 
routinely grown in monolayer 75cm
2 
tissue culture flasks at 37 
o
C in a humid 
atmosphere maintained at 5% (v/v) CO2. Cells were maintained in DMEM/F-12 
supplemented with 10% (v/v) FBS, 1% penicillin/streptomycin and 1% (v/v) L-
glutamine. Cell cultures were passaged once or twice a week depending on the growth 
rate. Briefly, the medium was removed, the cells washed with 10 ml of pre-warmed 
PBS and then aspirated. Further to this 5ml of pre-warmed trypsin-EDTA was added. 
The cells were incubated at 37 
o
C for 5mins and the flask gently tapped to dislodge 
cells after which the trypsin was neutralized by addition of 10 ml pre-warmed 10% 
DMEM/F-12. The cell suspension was centrifuged at 180 x g for 5 mins at RT. The 
pellet was gently resuspended in pre-warmed 10% DMEM/F-12. 
 
2.3.6 Storage of cell stocks 
Sub-confluent monolayer cultures were trypsinised and pelleted as described above. 
The pellet was then resuspended in 90% FBS and 10% DMSO. Aliquots of 1.5ml 
prepared in cryogenic vials were placed in an isopropyl alcohol-filled freezing 
container O/N at -80 
o
C and subsequently stored in liquid nitrogen. Cells recovered 
from liquid nitrogen were thawed rapidly at 37 
o
C and pelleted as before. The cell 
pellet was resuspended in pre-warmed 10 % FBS/DMEM growth medium and plated 
in a tissue culture flask. After around 6h the media was refreshed.  
 
2.4 Animal experiments 
2.4.1 Ethical approval 
C57BL/6 female mice were purchased from Charles River Ltd (Margate, UK) and 
experiments were carried out in accordance with the UK Home Office Project 
Licence (PPL70/6867). 
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A power calculation indicates the proposed study will be adequately powered (>80%) 
to detect medium to large effect sizes (r>0.50) Therefore, we will use 10 animals per 
group for (i) control, (ii) SGK1S422D, (iii) pcDNA3.1, (iv) D0, (v) D4, (vi) D10 
conditioned medium conditioned medium giving a total of 60 animals. Also, we will 
use 10 animals per group with embryo transfer for (i) control, (ii) D0, (iii) D4, (iv) 
D10 conditioned medium. Thus a total of 40 animals will be used  
(http://www.dssresearch.com/toolkit/spcalc/power_a2.asp). 
 
2.4.2 Window of endometrial receptivity 
C57BL/6 female mice (aged 6–8 weeks) were caged with vasectomized males 
overnight and those plug positive for pseudo-pregnancy, designated 1 dpc, removed to 
a separate cage. Four pseudo-pregnant female mice were subsequently killed by 
cervical dislocation at each of the following times: 3.5 dpc (pre-receptive), 4 dpc 
(early receptive) and 5 dpc (receptive). Tissue sections were stored for further 
analysis. 
 
2.4.3 In vivo gene transfer studies 
Timed matings were conducted by placing female animals with fertile males. The day 
when a vaginal plug was apparent was designated as 1 dpc. For in vivo gene transfer, 
mice were anaesthetized 1.5 dpc and subjected to laparotomy to expose the uterus. 
The HVJ-E vector system (GenomeONE-NEO) was found to be capable of delivering 
expression constructs in both luminal and glandular epithelium without discernable 
tissue toxicity. Two groups of animals were used in subsequent experiments, a control 
group with both horns transfected with 10 μg of control plasmid  pcDNA3.1; 
Invitrogen) and a study group transfected with 10 μg hSGK1S422D pIRES2eGF , an 
expression vector that encodes both eGFP and a constitutively active SGK1 mutant (a 
king gift from  rof Florian Lang, University of T bingen, Germany). Briefly, the 
uterine horns of control and study mice were injected with an equal volume of 
transfection mi   100 μl) without clamping the cervi . Then, the incision was closed 
to allow recovery of the mice. The animals were culled on 8.5 dpc. The uteri were 
either fixed in formalin or snap-frozen and stored at -80°C for further analysis. 
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2.4.4 Examination of implantation sites and determination of litter size in Sgk1-
deficient mice 
Heterozygous Sgk1-deficient mice were backcrossed to 129/SvJ Wild-Type mice for 
two generations and then intercrossed to generate homozygous Sgk1
-/-
 and Sgk1
+/+
 
littermates. The animals were genotyped by PCR using standard methods. 
Implantation events were determined in 6 to 8 week old Sgk1
-/- 
or WT female mice 
crossed with WT or Sgk1
-/-
 males, respectively, to ensure that all implanting embryos 
were heterozygous (Sgk1
-/+)  a kind gift from  rof Florian Lang, University of 
T bingen, Germany).  regnant animals were either sacrificed 8.5 dpc to assess the 
number of implantation sites or the pregnancy was allowed to continue and the 
number of pups per litter counted. The gross morphology of 18 implantation sites was 
assessed by hematoxylin and eosin (H&E) staining of transverse tissue sections. 
2.4.5 Examination of implantation sites and determination by flushing uterine 
horns 
C57BL/6 mice were used for in vivo testing. To prime the uterus, immature female 
mice were given hormonal treatment, consisting of 10 mg/kg/day β-estradiol (Sigma, 
UK) for three consecutive days followed by a single dose of 1 mg progesterone 
(Sigma, UK). The animals were then anaesthetized, subjected to laparotomy, and both 
uterine horns were injected over 5 min with 50 μl of culture supernatant from 
undifferentiated or decidualized primary HESCs or control (unconditioned) medium. 
The cervix was not clamped. The incision was then closed and the animals were 
euthanized 24 h later. Mice were sacrificed and the uterine horns either fixed in 
formalin or snap-frozen and stored at -80°C.  
 
To assess implantation, C57BL/6 female mice were mated with sterile males and the 
day of the appearance of the vaginal plug designated as 0 days post coitus (d.p.c.).  
Laparotomy was performed 2.5 d.p.c. At laparotomy, uterine horns were injected with 
conditioned or unconditioned culture medium, as described above were flushed once 
with 50 μl of various solutions or control 10 min prior to embryo transfer as described 
in fig 2.1. Cultured blastocysts (total 10; equivalent of 3.5 d.p.c.)  were transferred to 
a single treated uterine horn. The uteri were harvested 4-7 days following surgery, 
implantation sites counted, and tissues fixed in formalin or snap-frozen for further 
analysis.  
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Figure 2.1. Schematic representation of the experimental procedure 
Primary HESCs from timed endometrial biopsies were decidualized with 8-Br-cAMP 
and medroxyprogesterone acetate (cAMP/MPA) for 4 or 10 days. The medium was 
changed every 48 hours. Conditioned medium of undifferentiated and decidualized 
HESCs was then flushed through both uterine horn (100 µl per horn over 5 minutes 
without cervical occlusion) of vas mated C57BL/6 female mice undergoing 
laparatomy in the receptive period. Ten embryos, equivalent to stage 3.5 days post 
coital, were then transferred to the right horn, the abdomen closed, and the animals 
allowed to recover.  
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2.5 Bacterial Propagation of Plasmids 
2.5.1 Preparation of chemically competent bacterial for transformation by heat 
shock 
The Escherichia coli (E. coli) strain DH5α was used for the propagation of all 
plasmids. Bacteria were streaked out on L-agar plates and incubated at 37 
o
C 
overnight (O/N). A single colony was used to inoculate 5ml of L-broth, which was 
then grown O/N at 37
oC with continuous shaking. Subsequently, 100 μl of the culture 
was transferred to 100 ml of pre-warmed L-broth and further incubated at 37 
o
C with 
continuous shaking until the OD600 reached 0.2-0.4. The culture was cooled on ice for 
5 minutes (min) and the cells collected by centrifugation at 3000 x g for 7 min at 4 
o
C. 
The cell pellet was then gently resuspended in 20 ml of ice cold 100 mM CaCl2/10% 
glycerol and incubated on ice for 30 min. the cell suspension was snap frozen on dry 
ice in aliquots for 0.5 ml and stored -80 
o
C.  
 
2.5.2 Transformation of competent bacteria by heat shock 
Competent (E.  coli) cells were thawed on ice and typically 100 μl of cells were added 
to 5-10 μl of plasmid DNA. Cells were incubated on ice for 30 min, heat shocked at 
42
 o
C for 30-45 seconds and placed on ice for 2 min then 450 μl of L-broth was added 
and the cells incubated at 37 
o
C for 1 hour with continuous shaking. Finally, the cells 
were spread on L-agar plates containing 100 μg/ml ampicillin/penicillin or 30 μg/ml 
kanamycin and incubated O/N at 37 
o
C. 
 
2.5.3 Preparation of glycerol stocks 
Bacterial transformants were grown in L-broth containing 100μg/ml 
ampicillin/penicillin or 30 μg/ml kanamycin. Aliquots were stored in L-broth 
containing 50% (v/v) glycerol and stored at -80 
o
C. 
 
2.5.4 DNA manipulation 
The Qiagen High Performance Plasmid Maxi prep kit was routinely used to prepare 
up to 1.2 mg of high-copy plasmid DNA. A single bacterial colony was inculated in 
5ml L-broth supplemented with 100 μg/ml ampicillin/penicillin or 30 μg/ml 
kanamycin and incubated O/N at 37 
o
C with vigorous shaking for 8 h. subsequently, 
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150 μl of the starter culture were transferred to 150 ml of L-broth containing the 
appropriate antibiotic and incubated O/N at 37 
o
C with vigorous shaking. 
Alternatively, the culture was started from frozen glycerol stocks scraped and added 
to L-broth media. The bacteria were harvested by centrifugation at 4200 x g for 10 
min at 4 
oC. The pellet was then processed according to the manufacturer’s 
instructions. Essentially the protocol consists of alkaline-SDS lysis of bacteria cells 
followed by neutralization, adsorption of the plasmid DNA on silica in the presence 
of high salts, removal of contaminants by a spin wash step, elution of the plasmid 
DNA in a low salt buffer and if required isopropanol precipitation to concentrate 
DNA. All the necessary solutions were provided in the kit and the protocol was 
carried out as follows. The bacterial pellet was resuspended in 12ml P1 of the re-
suspension solution with the appropriate volume of RNase A solution to digest the 
liberated RNA. Cell lysis was carried out in sodium hydroxide/SDS (buffer P2), 
which denatures chromosomal and plasmid DNA as well as proteins. Buffer P3 
(acidic potassium acetate) was added to neutralize the lysate, and its high salt content 
resulted in the precipitation of chromosomal DNA, denatured proteins and cellular 
debris in detergent-salt complexes. However, the covalently closed plasmid DNA re-
natured and remained dissolved. The plasmid DNA was trapped under low salt and 
low pH condition, in pre-equilibrated (buffer QBT) anion-exchange resin. A medium 
salt solution (buffer QC) removed RNA, protein and other low molecular weight 
impurities, and subsequently a high salt wash (buffer QF) eluted the plasmid DNA. 
The DNA was precipitated out by isopropanol, washed with 70% v/v ethanol, air 
dried and finally resuspendend in endotoxin-free TE. Further purification of the 
plasmid was carried out by polyethylene glycol (PEG) precipitation. A mixture of 1:1 
40 % w/v PEG and 5M sodium chloride (NaCl) was prepared. 3 volumes of this 
solution was added to 5 volumes of plasmid DNA and left for 1h on ice. This caused 
the super-coiled plasmid DNA to precipitate out leaving the smaller DNA fragments 
in suspension. Plasmid DNA was pelleted by centrifugation at 13000 x g for 30 min at 
4 
o
C, washed twice  with 70 % v/v ethanol, air dried and finally re-dissolved in 
endotoxin-free TE. The concentration and purity of the plasmid DNA was determined 
by spectrophotometric analysis at A260 and A 260/A 280 respectively. Pure DNA should 
have A 260/A 280 ≥ 1.8. 
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2.5.5 Restriction Endonuclease Digestion 
Restriction enzyme digestions were performed at 37
o
C in the recommended buffers. 
DNA was digested with 5-10 % fold excess of enzyme with the final volume not 
exceeding 10% (v/v) glycerol. Reactions were terminated by addition of DNA loading 
buffer to 10% (v/v) of the total volume and analyzed by gel electrophoresis.  
 
2.5.6 DNA Agarose Gel Electrophoresis 
Agrose gels of 1-2% (w/v) were prepared by dissolving agarose in 1x TBE and 
heating the suspension in a microwave until the agarose dissolved, swirling 
occasionally. The solution was cooled to 55-60 
o
C, 0.2 μg/ml ethidium bromide added 
and poured to an appropriate gel tray with subsequent insertion of a comb. Once set, 
the gel was submersed in 1x TBE buffer in the gel tank and the DNA samples 
containing 10% (w/v) DNA loading buffer and the DNA markers were loaded in to 
the wells. Electrophoresis was carried out at 100-150 volts (V) until the fragments 
were resolved. DNA was visualized by illumination on a long wave ultra violet light 
box and photographed. 
 
2.6 Transient Transfections 
2.6.1 Transfection of plasmid DNA using Lipofectamine 2000 
Cells were routinely transfected using Lipofectamine 2000 reagent according to the 
manufacturer’s instructions. Cells were seeded in 6 well plates and cultured as above 
until 80-90% confluency. Prior to transfection media was changed to 1.5ml DMEM/F-
12 media without antibiotics and supplemented with 5% DCC-FBS. For each well, a 
transfection mi  was prepared as follows: 4 μg of plasmid DNA were diluted in 250 μl 
of Opti-MEM reduced serum medium and mi ed gently; 10 μl of Lipofectamine 2000 
reagent were diluted in 250 μl of  pti-MEM reduced serum medium, mixed and 
incubated at RT for 5 min; the diluted plasmid DNA and diluted Lipofectamine 2000 
reagent were combined, gently mi ed and incubated for 20 min at RT. 500 μl of the 
transfection mix were added to each well and the cells incubated at 37 
o
C in a humid 
atmosphere maintained at 5% CO2. After 24 h the media was changed and the 
treatments were given and the cells were harvested as appropriate. Cells plated in 
multisport/chamber slides were also transfected using Lipofectamine 2000 reagent. 
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The procedure was the same as above except for the following. Cells were seeded in 
100 μl of DMEM/F-12 media without antibiotics and supplemented with 5% DCC-
FBS. Each transfection mix contained 0.2 μg of plasmid DNA and 0.5 μl of 
Lipofectamine 2000 in 50 μl of  pti-MEM reduced serum medium. Upon 90-95% 
confluency, 50 μl of transfection mi  was added to each well. 
2.6.2 Transfection of siRNA using Lipofectamine 2000 
Cells were seeded in 6 well plates in 2ml DMEM/F-12 as above. Prior to transfection 
the media was changed to 1.5ml DMEM/F-12 media without antibiotics and 
supplemented with 5% DCC-FBS, until 80-90% confluency. For each well, a 
transfection mix was prepared as follows: 150 pmol of siRNA  7.5 μl of stock 
solution, 20 pmol/μl) were diluted in 250 μl of  pti-MEM reduced serum medium and 
mi ed gently; 5 μl of Lipofectamine 2000 reagent were diluted in 250 μl of  pti-MEM 
reduced serum medium, mixed and incubated at RT for 5 min. the diluted siRNA and 
diluted Lipofectamine 2000 reagent were combined, mixed gently and incubated for 
20 min at RT. 500 μ1 of the transfection mi  were added to each well. After 24h 
incubation the media was replaced and treated as indicated and then harvested when 
appropriate.  
 
2.6.3 Calcium phosphate transfection for mammalian cells 
Primary HESCs were transfected with DNA vectors or siRNA by the calcium 
phosphate co-precipitation method using the Profection mammalian transfection kit 
(Promega, UK). Calcium phosphate-mediated transfection facilitates the binding of 
Deoxyribonucleic acid (DNA) or oligonucleotides to the cell membrane and the entry 
of the DNA or oligonucleotides into the cell by endocytosis. This method entails 
mixing the DNA directly with calcium cloride (CaCl2) and a phosphate buffer to form 
a fine precipitate, which is dispersed over the cultured cells. 
 
Stromal cells were cultured in the appropriate plates and maintained with DMEM/F-
12 media supplemented with 10% (v/v) DCC-FBS, 1% (v/v) penicillin/streptomycin 
solution, 1% (v/v) L-glutamine, 1 nM estradiol and 2 mg/ml insulin was added to the 
stromal cells until they reached 80% confluency, then changed to DMEM/F-12 media 
supplemented with 2% (v/v) DCC-FBS, 1% (v/v) penicillin/streptomycin solution, 
1% (v/v) L-glutamine media overnight. The media was changed to 5% DMEM/F-12 
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media supplemented with 2% (v/v) DCC-FBS, 1% (v/v) penicillin/streptomycin 
solution, 1% (v/v) L-glutamine 1h prior to transfection at half the volume used for 
plating and maintenance of cells. The transfection mix consisted of solution A and B. 
Solution A was prepared by the addition of the required amount of expression vectors 
or siRNA to nuclease free water and vortexing the mix. Consequently, calcium 
chloride was added to a concentration of 425 mM followed by vortexing the mix and 
incubating it at RT for 5 min. While solution A was incubating, solution B, which 
consisted of 2x HEPES-buffered saline equal to the volume to solution A was 
prepared. When the 5 min incubation was over solution A was vortexed. Then whilst 
vortexing solution B, solution A was added to solution B in a drop-wise manner. The 
mix was then incubated at RT for 30 min to allow formation of the calcium phosphate 
precipitate. The transfection mix is then vortexed and dispersed on the cellsin the 
following volumes 480 μl, 120 μl or 48 μl in a well of 6-well plate, 24-well plate or 
96 well plates respectively. The cells were incubated at 37 
o
C in a humid atmosphere 
with 5% v/v CO2 for 5-10h. The cells were then washed 3 times with DMEM/F-12 
media supplemented with 10% (v/v) DCC-FBS, 1% (v/v) penicillin/streptomycin 
solution, 1% (v/v) L-glutamine, 1 nM estradiol and 2 mg/ml insulin and left treated or 
untreated in with DMEM/F-12 media supplemented with 2% (v/v) DCC-FBS, 1% 
(v/v) penicillin/streptomycin solution, 1% (v/v) L-glutamine. All transfections were 
repeated at least three times.  
 
For gene silencing transient transfection of HESCs were transfected with 20 μM 
siGENOME SMARTpool small interring RNA (siRNA) or siCONTROL non-
targeting siRNA pool (Dharmacon, UK) or 2-4 μg plasmid DNA as described above. 
 
2.7 Tissue specimens 
Endometrial biopsies were obtained from normal cycling women, women with 
infertility or those with recurrent pregnancy loss at the time of diagnostic laparoscopy, 
hysteroscopy or using the pipelle method. For protein analysis, biopsies were snap 
frozen on dry ice and stored at -80 
o
C. For RNA studies, tissues were immersed in 
RNAlater and stored at -80 
o
C. 
 
Chapter 2: Materials and Methods 
 
 82 
2.7.1  Protein Analysis 
2.7.1.1 Protein extraction from cell for Western blot analysis 
Cells were grown in 6-well plates and transfected and/or treated as appropriate. Cells 
were washed with ice cold PBS and whole cell extracts were prepared by lysing 
adherent cells directly in 100 μl of protein lysis RI A buffer containing protease 
inhibitors. Cells were scraped, transferred to 1.5 ml tubes and centrifuged at 14,000 x 
g for 15 mins at 4
o
C. The supernatants were collected in new tubes and stored at -20 
oC.  rotein concentration was determined and typically 30 μg of protein combined 
with protein loading buffer were boiled at 100 
o
C for 5 min and loaded in SDS-
polyacrylamide gels.  
 
Alternatively, protein was e tracted using 100 μl protein loading buffer previously 
heated to 90 
o
C. Cells were scraped, transferred to 1.5 ml tubes, sonicated for a few 
seconds, boiled for 5 min at 100 
o
C and centrifuged at 15,000 x g for 5 min at 4 
o
C. 
Equal volumes of each sample were loaded into the gel.  
 
2.7.1.2 Loading buffer protein extraction (Laemmli buffer) 
Loading buffer has a high detergent content, and together with the heat of this 
extraction protocol, it ensured instant and complete protein denaturation and therefore 
preservation of any post-translational modifications (i.e. sumoylation and 
phosphorylation). HESCs and Ishikawa cells were cultured in 6-well plates. An equal 
volume of loading buffer pre-heated to 85 
o
C was added to each well, scraped and 
transferred into a microcentrifuge tube. The lysates were then heated for 5 min at 100 
o
C. and these were then snap-frozen on dry ice and stored at -80 
o
C. 
 
2.7.1.3 Determination of protein concentration 
Protein concentrations were determined by using the Bradford assay reagent, which 
contain a Coommassie dye. This dye exhibits an absorbance shift when bound to 
arginine and hydrophobic amino acids residues in proteins. The bound form of the dye 
is blue and has an absorbance spectrum maximum at 595 nm. The anionic unbound 
forms are green and red. Quantification of total cell protein concentrations was carried 
out for Western analysis. A set of standards was generated using bovine serum 
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albumin (BSA) diluted in distilled water at concentrations 0,1,2,4,8,12,16,20 µg/µl, 
with a final volume of 800 µl. the protein samples to be quantitated were diluted 2:800 
in 800 µl of distilled water. A final volume of 1 ml was produced for each standard 
and sample by the addition of 200 µl of Bradford reagent. This was mixed well by 
vortexing and incubated at RT for 30 mins. Subsequently, 200 µl of each sample or 
standard was transferred in duplicate to a flat bottom optically clear 96-well plate and 
the absorbance read at 595 nm was measured using an OPTImax
TM
 microplate reader 
(Molecular Devices) and analysed using SOFTmax® PRO computer software 
(Molecular Devices). An increase, in the amount of bound dye, and therefore the 
amount of protein present in the sample, corresponded to the absorbance at 595 nm. 
The protein concentrations of the samples were then calculated by reference to the 
standards.  
 
2.7.1.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were resolved on discontinuous polyacrylamide gels using the using the 
Invitrogen Xcell SureLock Mini-cell apparatus. Gels were prepared from the solutions 
below to form the stacking and the resolving gels. The resolving gels typically 
contained 10% acrylamide, 1% SDS, 375 mM Tris-HCl pH 8.9. The stacking gel 
contained 5% acrylamide, 1% SDS and 125 mM Tris-HCl pH 6.8. Polymerization of 
both gels was initiated by the addition of TEMED and APS. The resolving gel was 
poured between the gel plates until it reached approximately 2cm from the top of the 
plates and overlaid with saturated butan-2-ol. Once the polymerization was complete, 
the saturated butan-2-ol was rinsed of and the stacking gel was added on top of the 
resolving gel and an appropriate comb inserted. Once the stacking gel had set the 
comb was removed and the gel plate fitted into the electrophoresis tank and the 
running buffer (1x) added. For proteins where the concentration had been calculated 
by the Bradford technique, an equal amount of protein sample (typically 30 µg) was 
diluted 1:1 loading buffer and denatured at 100 
o
C for 5 min. Samples were loaded 
alongside pre-stained molecular weight markers. Gels were run in 1x Western SDS 
running buffer at 80 V for approximately 30 min, which allowed slower, even entry of 
the samples into the stacking gel. The difference in pH and the density of the two gels 
allowed compaction of the samples at their boundary, which provided crisp resolution 
of the proteins on the resolving gel. Subsequently, the gels were resolved at 125 V for 
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1h or until the dye had migrated to the bottom of the gel. The gels were removed from 
the cassettes for transfer.  
 
Pre-cast 4-12% gradient gels NuPAGE Bis-Tris SDS were also used. These gels were 
run in 1x NuPAGE MOPS SDS Running Buffer using the Invitrogen Xcell SureLock 
Mini-cell apparatus. 
 
2.7.1.5 Western Blotting 
The Invitrogen XCELL II 
TM
 Blot Module was utilized to transfer resolved proteins 
from a gel onto a polyvinylidene fluoride (PVDF). The PVDF transfer membrane was 
first activated in 100% methanol. All the components, including the gel, were pre-
soaked and equilibrated in Western transfer buffer. A sandwich was created on top of 
the cathode in the following order: one sheet of Whatman filter paper, the gel, a PVDF 
transfer membrane and another piece of Whatman filter paper. Once all assembled, the 
sandwich was rolled to eliminate any bubbles and the anode plate was fitted on top. A 
voltage gradient of 25 V and 230 mA was created perpendicular to the gel for 2h. 
Negatively charged molecules migrated from the gel towards the anode and were 
deposited onto the PVDF membrane.  
 
Following transfer the PVDF membrane was air dried and then reactivated in 100% 
methanol. Subsequently, the membrane was blocked in Western blocking buffer for 30 
mins at RT and then at 4 
o
C overnight on a roller. The following day the membrane 
was washed for 5min in 1x TBS-T. The primary antibody was diluted (see previous) in 
the Western primary antibody incubation solution and then incubated for 2h at RT on a 
roller. After three x 15 min washes with 1x TBS-T, the membrane was incubated for 
1h at RT with HRP-conjugated antibody, raised against the primary antibody, diluted 
in the Western secondary antibody incubation solution. Secondary antibodies were 
from Dako unless otherwise stated. Following three x 15 min washes with 1x TBS-T, 
protein bands were visualized by enhanced chemiluminescence with ECL plus 
Western blot detection systems according to the manufacturer’s instructions and the 
membrane was subsequently exposed to autoradiography films. 
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2.7.1.6 Stripping membranes for Western Blotting 
To re-probe PVDF membranes with different primary antibodies, antibodies were 
stripped off the membranes with Western stripping buffer at 60 
o
C for 30 min with 
gentle shaking. The membrane was washed three times for 10 min with 1x TBS-T, 
blocked and incubated with antibodies as described above. 
 
2.7.2 RNA isolation and extraction 
To minimize the risk of RNA degradation and RNAse contamination, only RNAse-
free plastic ware were used. The allocated workbench for RNA use only was 
decontaminated using RNAseZAP (Ambion) and all solutions were prepared with 
diethylpyrocarbonate (DEPC)-treated water. Chloroform, isopropanol and 70 % v/v 
ethanol and microcentrifuge tubes were pre-chilled at -20 
o
C prior to the extraction.  
 
Total RNA was extracted from cells and tissues using STAT-60 reagent according to 
the manufacturer’s protocol. This reagent is monophasic solution of phenol and 
guanidine isothiocynanate that maintains the integrity of RNA whilst simultaneously 
disrupting cells and dissolving cellular components. Cells in a 6-well plate were 
directly lysed by addition of 400 μl and a cell scraper was used to ensure all cells were 
adequately covered in this lysis solution. In contrast, tissue samples were homogenised 
by hand-held homogeniser with 500 μl of STAT-60. After 5 min incubation at RT, to 
permit complete dissociation of nucleoprotein complexes, samples were transferred to 
RNase free 1.5 ml tubes. To each sample 20% volume of chloroform was added and 
the microcentrifuge tube vortexed for 15 sec and the samples were stored at -80 
o
C for 
at least 30mins. Subsequently, the tubes were then centrifuged at 12,000 x g for 30 
min at 4 
o
C to separate the solution into a lower red, phenol-chloroform phase, and 
interphase and a colourless aqueous phase. The RNA remained exclusively in the 
aqueous layer, whilst DNA and proteins were extracted into the organic phase and 
interphase. The aqueous top layer was transferred to a new pre-chilled tube and RNA 
precipitated by addition of 50% volume of ice-cold isopropanol. Samples were then 
vortexed and incubated for 10 min at RT and centrifuged at 12000 x g for 15 min 
producing a white RNA pellet. The supernatant was discarded and the RNA pellet 
washed with 1:1 volume of 70% v/v ethanol and centrifuged at 12000 g for 15 min. 
Purified RNA was air-dried, dissolved in a suitable volume of DEPC treated water and 
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stored at -80 
o
C. RNA concentration was determined at A260 using a 
spectrophotometer (ND-1000, NanoDrop). Pure RNA has an A260/A280 ratio of 1.8-2.1 
and lower ratios indicate the presence on contaminants such as proteins and phenols. 
 
2.7.3 Gene Expression Analysis using Real Time Quantitative PCR (RTQ-PCR)  
2.7.3.1 Principle. 
The measurement of mRNA levels was used as an indication of gene expression. This 
involved initial removal of genomic DNA from samples, followed by first strand 
complimentary DNA (cDNA) synthesis and then relative quantification of the target 
template using specific primer pairs and RTQ-PCR. 
 
RTQ-PCR is based on detection of a fluorescent signal produced proportionally to the 
PCR product during each cycle, i.e. in real time, as opposed to the end point detection 
by conventional quantitative PCR methods. RTQ-PCR assays are characterised by a 
wide dynamic range of quantification, high sensitivity and high precision (264). 
Several detection chemistries can be used. The simplest, most economical and 
commonly used is SYBR green which is a dye that binds all double stranded DNA 
molecules. It has an undetectable fluorescence when it is in its free form, but once 
bound it emits fluorescence; the more double stranded amplicons are produced the 
more fluorescence signal will exist. Laser light is emitted via optical fibres leading to 
excitation of fluorophores within the samples, and in the resulting fluorescence signal 
is directed to a spectrograph attached to a charged coupled device camera detector. 
 
 SYBR green is also able to detect non-specific PCR products such as primer-dimers 
and therefore assays require careful optimization.  In the ABI StepONE sequence 
detection system (Applied Biosytems), the software calculates the change in 
fluorescence intensity (ΔRn) due to amplification. This calculated by the equation 
ΔRn= Rn+ - Rn-, where Rn+ is the fluorescence emission of the product at each time 
point and Rn
-
, is the fluorescence emission of the baseline usually between 3-15 
cycles. The baseline is a measure of the background fluorescence where there is no 
detectable increase in fluorescence emission due to PCR products. The computer 
software constructs amplification plots of ΔRn vs cycle number. During the early 
cycles of amplification, the ΔRn values do not e ceed the baseline. As the reaction 
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proceeds, the change in fluorescence intensity reaches a threshold, which is defined as 
statistically significant point above the baseline, usually determined as 10 times the 
standard deviation of the baseline, from cycles 3-15. The threshold cycle (Ct) is then 
calculated by determining the point at which the fluorescence crosses the chosen 
threshold limit that correlates to the initial amount of target quantity. Therefore Ct 
values decrease linearly with increasing input target quantity (265).  This real time 
monitoring of exponential nucleic acid amplification is more accurate and sensitive 
than assessment of final product in conventional PCR. 
 
2.7.3.2 Primer Design and Optimization 
The length and location of the PCR primers were chosen using the Primer 3 Output 
Program. To avoid co-amplification of contaminating genomic DNA, primers were, 
when possible designed, on different exon or intron-exon boundaries. Sequences were 
obtained from the Ensembl Human Genome database (www.ensembl.org). In order to 
reduce the possibility of amplifying genomic DNA that was not complimentary from 
the sample, the primer pairs were designed within a short sequence of DNA crossing 
an intron-exon boundary. The software created a list of 4 primer pairs which all had 
melting temperatures (Tm) between 58-60 °C and length of 14-28 bases (product of 
approximately 100-200 bp). This program also screens for primer-primer 
complementary sequences that causes primer-dimer (self and cross dimers) and 
secondary structure formation within each primer, also known as the hairpin 
formation, so as to avoid a false positive signal. This was achieved by avoiding 
primers with 3’ ends that were complementary and those where more than one 
intramolecular bond or three intermolecular bonds were possible. Furthermore, a run 
of three or C or G bases at the 3’ end was avoided to prevent mis-priming. 
 
All primer pairs were optimized with annealing temperatures around 60°C. 
Lyophilized primers were diluted in DEPC-treated water to storage concentration of 
100 pmol/μl and later diluted again to a working concentration of 20 pmol/µl.  
 
2.7.3.3 Optimization of primer concentration 
Prior to analysis of mRNA abundance in samples, the concentrations of primers were 
optimized. Each pair was optimized using a combination of forward and reverse 
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primer concentrations ranging from 50 nM to 900 nM using a fixed amount of cDNA 
template. This ensured that the selected primer concentrations provided the optimal 
magnitude of signal generated by the PCR at the cycle at which a significant increase 
in signal was first detected. Hence, optimal primer concentration was chosen based on 
the lowest Ct and highest Δ Rn. Furthermore, following RTQ-PCR, the amplified 
DNA was run in 1.5% TAE buffered agarose gel alongside a marker to confirm that 
the correct size of product was amplified. See appendix II and III for primers used. 
 
2.7.4 Removal of genomic DNA 
Total RNA preparations may contain small quantities of genomic DNA which would 
be amplified along with the target mRNA and produced false negative results. DNase 
I, Amplification Grade from Invitrogen was used to eliminate such contamination 
according to the manufacturer’s instructions. Briefly, 1 μg of total RNA was incubated 
for 15 min at RT with 1 U DNase I in the presence of 1 x DNase I reaction buffer in a 
total volume of 10 μl made up with DE C-treated water. The reaction was stopped by 
the addition of 0.5
 μl 25 mM EDTA and incubation at 65 oC for 15 min. 
 
2.7.5 cDNA synthesis 
To generate complimentary deoxyribonucleic acid (cDNA) from total RNA, the 
SuperScript™ First Strand Synthesis System for RT-PCR kit from Invitrogen was 
used according to the manufacturers’ instructions. 8 μl of DNase I-treated RNA was 
mixed with 1
 μl deo yribonucleotide triphosphate  dNT ) mi   10 mM of each dAT , 
dTTP, dGTP, dCTP) and 1
 μl  ligo  dT) 12-18 (0.5
 μg/μl) and the volume made up to 
10 μl with DE C-treated water. Samples were incubated at 65 oC for 5 min and placed 
on ice for at least 1 min. A master mix (for n+1 samples) was prepared consisting of 2 
μl 10  RT buffer, 4 μl 25 mM MgCl2, 2 μl 0.1 M DTT and 1 μl RNase  UT  40 U/ 
μl). 9 μl of the master mi  were added to each RNA/primer mi , samples collected by 
centrifugation and incubated at 42 
o
C for 2 min. 1
 μl  50 U) SuperScript II Reverse 
Transcriptase was then added to each reaction and samples incubated for a further 50 
min at 42 
o
C. The reactions were terminated by incubation at 70 
o
C for 15 min to 
increase the sensitivity of the PCR; residual RNA template from the newly synthesised 
cDNA-RNA hybrid molecule was digested with 1 μl RNase H  2 U) for 20 min at 37 
o
C. cDNA samples were stored at -20 
o
C.  
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2.7.6 Amplification of Target cDNA 
Detection of relevant mRNA was performed with SYBR Green Master Mix. All 
reactions were set up in a 96-well plate as follows: 1 μl cDNA template, 12.5 μl SYBR 
green mastermi  and an appropriate ratio of primers in a total volume of 25μl made up 
with DEPC-treated water. Negative controls without cDNA template were included. 
All measurements were performed in triplicate in the ABI StepONE Sequence 
Detection System (Applied Biosystems). The plate was heated at 95°C for 10 mins in 
order to activate the AmpliTaq Gold DNA polymerase. Subsequently, 40 cycles of 
95°C for 15sec (denaturation), 60°C for 1 min (annealing and extension) were 
performed for amplification. Data analysis was carried out using the ΔΔ-Ct method. 
L19 and cyclophilin represent non-regulated human and murine genes, respectively, 
and their expression was used to normalize for minor variances in input RNA amount 
or reverse transcriptase efficiencies. 
 
2.8 Cell cycle phase analysis by propidium iodide staining. 
Flow cytometry analysis was used to determine the proportion of cells in different 
phases of the cell cycle within a population. The principle of this procedure involved 
staining the DNA within the cells with a fluorescent dye. A fluorescence activated 
cell sorter (FACS) then analysed each cell individually and sorted them according to 
the level of fluorescence (hence DNA content). Cells in G1 (Gap1) phase are diploid 
(2n), while those in G2 (Gap2) and just prior to mitosis (M phase) contain twice the 
amount (4n). Those cells in S (Synthesis) are synthesizing DNA and their DNA 
content ranges from 2n to 4n. HESCs were cultured in 6-well plates until they reached 
confluency and transfected with NT, SGK1, ST2, IL-33 siRNA or WT Catalse and 
subsequently treated with 0.5 µM 8-Br-cAMP and 1µM MPA. Briefly, the 
supernatants and trypsinized cells from each well were transferred to 15 ml microfuge 
tubes. These were subjected to centrifugation at 4000 rpm for 10 min, resuspended in 
150 µl of 2 % w/v BSA in PBS, followed by further centrifugation at 9000 rpm for 2 
min subsequently, the cells were fixed by resuspending in 1 ml of 90 % v/v ethanol 
and stored at -20 
o
C. Prior to FACS analysis, the cells were pelleted by centrifugation, 
washed twice in PBS and resuspended in a solution containing 5 mg/ml RNAase A 
and 10 mg/ml PI in PBS and incubated at 37 
o
C for 30 min. PI is a fluorescent 
molecule (excitation at 488 nm), which intercalated in between the bases of DNA 
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with a stoichiometry of one dye per 4-5 bases. After the incubation period, the 
samples were evaluated using a FACSCanto (Beckton Dickinson) and final analysis 
performed using Flowjo software (Treestar, USA). 
 
2.9 Proliferation assay 
To assess proliferation, undifferentiated HESCs were first transfected in 6-well plates 
with NT, SGK1, ST2, IL-33, HSC70 siRNA or WT Catalase and then were 
decidualized with 0.5 µM 8-Br-cAMP and 1µM MPA as appropriate. At the 
designated time point 10 µl of CellTitre 96
®
 Aqueous one solution cell proliferation 
assay (Promega) was added to each well, and the plate incubated for a further 1h at 37 
o
C in a humidified air supplemented with 5% CO2. All HESC cultures were incubated 
for the same amount of time to ensure that the measurements were comparable 
between different time points. The assay solution contained an electron coupling 
reagent, phenazine ethosulfate (PES) and an MTS tetrazolium compound, which was 
bio-reduced by viable cells. The resultant coloured formazan product was soluble in 
culture medium and therefore the absorbance was recorded on a 450 Bio-rad 
microplate reader (Bio-Rad laboratories, Inc, Hercules, CA) at 490 nm. The 
absorbance was directly proportional to the number of viable cells. 
 
2.10 Measurement of cellular oxidation 
Cultured HESCs, seeded into 96-well black plates with clear bases, were maintained 
in 10% DCC-FBS/DMEM until confluency. Cells were first transfected with either 
siRNA targeting SGK1 or non-targeting oligos and then decidualized for 72 hours 
before being pulsed with 250 μM hydrogen peroxide. Thirty minutes prior to 
measuring the cellular o idation status, cultured HESCs were loaded with 30 μM 
2’7’-dichlorofluorescin (DCF), washed twice, and measurement taken every 2 min for 
a 30 min period using a fluorimeter (Softmax Pro) with excitation and emission 
wavelengths of λ 485 and λ 535 nm, respectively. To normalize the measurements, 
the plates were then stained with propidium iodine  10 μg/ml) in N -40 (1%), placed 
on an orbital shaker for 15 min, and fluorescence measured at excitation and emission 
wavelengths of λ 535 and λ 600 nm, respectively. 
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2.11 Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a biochemical technique used to detect the presence of an antibody or an 
antigen in a sample and was performed according to the manufacturer’s protocol  R 
and D Systems). Briefly, HESCs were cultured and treated where appropriate and the 
supernatant was harvested and stored at -20 
o
C. A 96 well microplate was coated 
antigen (capture antibody) in PBS and covered with an adhesive plastic and incubated 
O/N at RT. The plate was aspirated and washed with wash buffer for a total of three 
washes and incubated with blocking buffer (reagent diluent) for 2 h at RT. The plate 
was then washed again. 100 μl of the standard or the sample was added to the wells 
and incubated for a further 2h at RT and then subsequently washed. 100 μl of the 
detection antibody diluted in reagent diluent was added to the appropriate wells for 2 
h at RT and then washed as previously. 100 μl of the working dilution of streptavidin-
HRP was added to each well and incubated for 20 min at RT and covered in foil 
followed by the washes. To the plate 100 μl of the substrate solution was added to 
each well. The plate was covered in foil and incubated for 20 min at RT and then 50 
μl of stop solution was added to quench the reaction. The optical density of each well 
was immediately read using a microplate reader (Softmax Pro) at a wavelength of λ 
450 nm. Analysis of the concentration of secreted proteins were calculated by 
deduction from a standard curve of absorbance plotted from a set of standards 
 
2.12 Confocal immunofluorescence microscopy 
Cells were cultured in chamber slides typically in DMEM/F-12 media supplemented 
with 10% (v/v) DCC-FBS, 1% (v/v) penicillin/streptomycin solution, 1% (v/v) L-
glutamine, 1 nM estradiol and 2 mg/ml insulin. In some experiments, transient 
transfections were performed using the CaPO4 method. Cells were washed with PBS 
and fixed in 4% PFA at RT for 30 min and then permeabilized using 0.5% Triton X-
100 for 30 min at RT. Cells were washed two times in PBS and blocked with 
immunofluorescence blocking solution for a further 30 min at RT. 100-150 μl of 
primary antibody diluted in immunofluorescence antibody dilution solution were then 
added to each well and incubated in a humidified chamber O/N at 4 
o
C. Typically, the 
primary antibody was omitted in control slides (primary antibodies and dilution see 
above). After 4 washes with PBS for 5 min secondary antibodies diluted in 
immunofluorescence antibody at RT for 1h. The secondary antibody used was Alexa 
Chapter 2: Materials and Methods 
 
 92 
Fluor 488 goat-anti rabbit. Following 3 washes with PBS for 5 min. Nuclei were 
counterstained with DAPI and images acquired on a Leica SP5 confocal microscope. 
 
2.13 Immunohistochemistry 
Tissues were fixed in neutral buffered formalin O/N at RT. Sections embedded in 
paraffin were cut at 5 μM (Leica RM 125) and immunohistochemistry performed 
using Vectastain Elite ABC kit. Sections were dewaxed in histoclear, rehydrated in 
descending ethanol solutions (2 min changes of 100%, 100% and 70% alcohol) and 
rinsed in water. For slides in which antigen retrieval step was required slides were 
incubated for 30 min at 50 
o
C in 1 mM EDTA, pH 8.0. Slides were allowed to cool at 
RT and were washed two times in PBS containing 1% (v/v) 30 % hydrogen peroxide 
for 30 min. slides were then rinsed in PBS and blocked in immunohistochemistry 
blocking solution, using serum from the species in which the secondary antibody was 
raised, in a humidified chamber for 30 min at RT. Following blocking, 100-150 μl of 
primary antibody diluted in immunohistochemistry primary antibody dilution solution 
were added to each section and slides placed in a humidified chamber and incubated 
overnight at 4 
o
C. In control slides the primary antibody was either omitted (primary 
antibody and dilutions please see above). Slides were rinsed twice in PBS for 5 min 
and incubated with secondary antibody diluted to 1:100 in immunohistochemistry 
secondary antibody solution for 1 h at RT. Slides were washed again twice with PBS 
for 5 min and the ABC complex, supplied in the kit, added to each section and 
incubated in a humidified chamber at RT for 30 min. the ABC complex was made 30 
min before required by mixing 10
 μl of reagent A and 10 μl of reagent B in 1 ml of 
PBS. The setections were then washed twice in PBS for 5 min and antibody detected 
by incubating the sections with DAB solution for 1 min or until the signal developed. 
The slides were washed in water for 5 min, counterstained in haematoxylin for 1 min 
(For antibodies which stain the nucleus this step was left out), differentiated in acid 
alcohol for 30 sec, rinsed in water, dehydrated in a series of ascending alcohols, 
cleared in histoclear and mounted in DPX. 
 
2.14 Statistical analysis 
Data was analyzed with the statistical package Graphpad Prism  (Graphpad software 
Inc, CA, USA). Statistical analysis was performed using Student’s t-test for 
Chapter 2: Materials and Methods 
 
 93 
comparison or one-way analysis of variance (ANOVA). In some cases, logarithmic 
transformations were performed to obtain normality and homoscedascity. Variable 
that were not normally distributed were compared by the Kruskal-Wallis test, 
followed, when appropriate by the Mann-Whitney U test for paired comparisons. 
Results were expressed at standard deviations (SD) or means ± standard error of the 
mean (SEM). Statistical significance was assumed when P < 0.05. 
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3.1 Introduction 
Compared to most mammalian species, human reproduction is considered inefficient. 
Monthly fecundity rates in fertile couples are low, on average 20% (208). Large-scale 
structural chromosomal imbalances, caused predominantly by mitotic non-
disjunction, are considered to be the primary cause of human embryo wastage (266). 
A confined period of endometrial receptivity synchronizes implantation events in 
species with multiple gestations and ensures that pregnancy occurs under the right 
maternal conditions. For example, many species are capable of delaying implantation 
by temporarily suspending embryo development, a process termed ‘diapause’, which 
is reversed when the endometrium signals an optimal metabolic and hormonal 
intrauterine milieu (267). Since there is no evidence that human embryos are able to 
uncouple pre- and post-implantation development, and multiple gestations are 
relatively rare, therefore a restricted period of endometrial receptivity may serve to 
prevent implantation of chromosomally chaotic but highly invasive embryos.  
 
A striking feature of the human endometrium is that acquisition of a receptive 
phenotype in the mid-secretory phase of the cycle coincides with decidualization of 
the stromal compartment, irrespective of pregnancy.  Progesterone responses in this 
cellular compartment that underpin the receptive phenotype are mediated by signals 
derived from the underlying stromal cells (268). The decidual process is indispensable 
for pregnancy in all species with invasive placentae. As illustrated by several murine 
models, absent or impaired endometrial decidualization inevitably compromises 
placental formation and pregnancy (126, 137).  
 
Successful implantation is the end result of a complex molecular dialogue between a 
receptive, hormonally primed uterus and a mature, activated blastocyst. Although the 
molecular and cellular mechanisms responsible for implantation are not well 
understood, it is clear that multiple signals are needed to synchronize blastocyst 
maturation and uterine receptivity, including sex steroid and peptide hormones, 
growth factors, cytokines, and immunological factors. Abnormalities in one or more 
of these factors can lead to pregnancy failure (spontaneous abortion) or defective 
implantation with resultant downstream clinical complications (such as pre-eclampsia 
or preterm labour).  
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Klemmt et al., 2006 reported that levels of prolactin and IGFBP-1 secreted by 
decidualizing endometrial stromal cells derived from women with endometriosis are 
reduced in comparison with women without endometriosis. Their studies 
demonstrated that the endometrium from women with endometriosis displays 
morphologically normal but biochemically abnormal responses during the window of 
implantation. In this context, abnormal remodeling of the extracellular matrix of 
endometrial stroma and aberrant integrin expression have been associated with 
implantation defects, suggesting that in women with endometriosis, the signaling 
cascade leading to decidualization might be impaired, potentially decreasing the 
biochemical maturation required for correct implantation. Rather surprisingly, very 
little is known regarding how abnormal cyclic differentiation of endometrial stromal 
cells into specialized decidual cells predisposes to RPL. Strikingly, these obstetric 
disorders are more prevalent in women with a history of RPL. 
 
3.2 Results 
3.2.1 In vivo expression levels of PROK1 and PRL during the Window of 
Implantation. 
I speculated that impaired decidualization of the stromal compartment may facilitate 
delayed implantation of compromised embryos by prolonging the window of 
endometrial receptivity, as suggested by the population study of Wilcox et al., (104). 
To test this hypothesis, endometrial biopsy samples were collected from three 
different patient groups that spanned the window of implantation LH+7-11. Fertile 
controls (FER; n=10) were women who had at least 2 children, who had regular 
menstrual cycles, had not used hormonal preparations in the preceding 3 months and 
did not have a history of fertility problems (including PCO or PCOS). A regular cycle 
was defined as that of an inter-menstrual interval between 25 and 35 days, with no 
more than a 4-day variation from one cycle to the next. Unexplained infertility (INF; 
n=10) was defined as conception delay of 24 months or more after excluding 
anovulation, tubal blockage, pelvic adhesions, endometriosis or impaired semen 
quality. RPL (n=10) was defined as three or more consecutive pregnancy losses 
before 24 weeks gestation.  The RPL, infertile and the control groups were aged 
between 28 and 38 years of age (Appendix IV; Table 3.1).  
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Transcript levels of Prokineticin 1 (PROK1; also known as Endocrine gland derived 
vascular endothelial growth factor) and PRL from RPL and infertile were compared 
with the control cohort.  As show in Fig. 3.1 A, patients experiencing RPL were 
associated with significantly higher endometrial PROK1 mRNA levels compared to 
the INF and FER groups.  PROK1 expression levels were similar in the INF or FER. 
PRL levels were approximately 100-fold lower in the RPL group compared to that of 
INF or FER cohorts (Fig 3.1 B).  
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3.2.2 Elevated PROK1 levels is associated with biochemical losses. 
To investigate if there was any association in transcript levels of PROK1 and PRL in 
early or late pregnancy losses, biopsies were taken from women who had experienced 
either biochemical (early) or fetal  late) losses. A ‘biochemical’ loss  BI CHEM; 
n=10) was defined as a miscarriage at 4–6 weeks gestation with ultrasound evidence 
of either an intrauterine pregnancy sac with no fetus or retained products of 
conception. A ‘fetal’ loss  n=10) was defined as a pregnancy failure between 6–13 
weeks gestation with prior ultrasound evidence of fetal development (Appendix IV; 
Table 3.2). Analysis of an independent sample set demonstrated that elevated PROK1 
transcript levels are primarily associated with biochemical rather than fetal RPL, 
whereas no such association was found with PRL (Fig. 3.1 C & D). 
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Figure 3.1 In vivo PROK1 and PRL transcript levels in timed endometrial 
samples of RPL patients and control (CON) subjects, consisting of fertile (FERT) 
volunteers and  infertile (INF) patients without a history of RPL 
PROK1 (A) and PRL (B) mRNA levels, normalized to L19 transcript levels, are 
expressed in arbitrary units (a.u.). PROK1 and PRL mRNA levels, respectively (C & 
D), in RPL patients with recurrent biochemical (biochem; n = 10) or fetal (n = 10) 
pregnancy failure.  Data represent the means of triplicate determinations using 
standard curve method. Note the logarithmic y-axes. Horizontal bars indicate the 
median expression in each group. ***, P < 0.001 and ****, P< 0.0001 using the 
Mann-Whitney U Test. 
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3.2.3 Aberrant expression of PROK1 and PRL in decidualizing primary stromal 
cells is associated with RPL  
I have shown that PRL is downregulated and PROK1 is upregulated in tissue samples 
obtained from patients with RPL. Klemmt et al., 2006 described that stromal cells 
derived from endometriotic lesions retained in vivo tissue markers (269). I 
hypothesized that this observation might be recapitulated in vitro in cultured HESCs 
taken from RPL patients. Primary cultures were established from 9 RPL patients and 
12 fertile controls (Con) (Appendix IV; Table 3.3). HESCs, purified from samples 
taken randomly in the cycle, were passaged once, allowed to grow to confluency, and 
then decidualized using 8-Br-cAMP and MPA (cAMP/MPA) over a time-course 
lasting 8 days and total RNA extracted. qRT-PCR was performed and the expression 
of both PROK1 and PRL at the transcript level was measured. PRL mRNA levels did 
not differ between the two groups in undifferentiated stromal cells or in cells 
decidualized for 2 days. Strikingly, after 4 days of differentiation, the rise in PRL 
transcript levels was several magnitudes higher in the control group than compared to 
RPL samples and this was maintained till 8 days of differentiation (Fig. 3.2). By 4 
days of treatment with 8-Br-cAMP and MPA transcript levels of PROK1 rose in both 
the RPL and the control group but there was no statistical significance in either group. 
Surprisingly, PROK1 levels at day 8 in the control but not RPL group declined 
markedly. In parallel to this secreted levels of PRL and PROK1 were measured using 
ELISA. The difference in PROK1 and PRL mRNA expression between the RPL and 
the control group at the secreted protein level was maintained by 8 days of treatment 
in vitro (Fig 3.3). 
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Figure 3.2 RPL is associated with aberrant expression of PRL and PROK1 in 
decidualizing primary HESC cultures. 
PROK1 (A) and PRL (B) mRNA levels, normalized to L19 transcript levels and 
expressed in arbitrary units (a.u.), were determined in undifferentiated HESCs (day 0) 
or cultures decidualized with 8-Br-cAMP and MPA (cAMP/MPA) for 2, 4 or 8 days. 
A total of 9 primary cultures were established from RPL patients and 12 from control 
(CON) subjects. Data are the means of triplicate determinations using standard curve 
method. Horizontal bars indicate the median expression in each group Note the 
logarithmic y-axes. ****, P < 0.0001 using the Mann-Whitney U test. 
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Figure 3.3 RPL is associated with impaired PROK1 and PRL secretion by 
decidualizing HESCs.  
Secreted PROK1 (A) and PRL (B) levels accumulated over 48 hours in the 
supernatants of confluent primary HESC cultures decidualization with 8-Br-cAMP 
and MPA for 8 days. Primary cultures were established from 10 RPL patients and 10 
control (CON) subjects. Horizontal bars indicate the median expression in each group. 
****, P< 0.0001 using the Mann-Whitney U test. 
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This expression profile in cultured cells supported the notion that an impaired 
decidual response, leading to prolonged endometrial receptivity and impaired embryo 
selection, is the primary uterine defect in RPL. Two additional observations are worth 
highlighting. First, the scale of difference in PROK1 and PRL expression between the 
RPL and control group was not only high. At mRNA level aswell as at the secreted 
protein level the pattern of expression in all samples corresponded to the clinical 
phenotype. Secondly, HESCs purified from endometrial samples were taken 
randomly in the cycle and maintained their phenotype despite being in prolonged 
culture. This suggests, that the ability to mount a decidual response is perturbed in 
RPL, rather than the signals responsible for differentiation. 
 
  
Chapter 3: Results I 
 
 104 
3.2.4 hCG Responses in Decidual Cells Are Disrupted in RPL 
Human chorionic gonadotropin (hCG) is one of the earliest and most abundant 
glycoproteins secreted by syncytiotrophoblast. The main role of hCG during 
pregnancy is to maintain progesterone production by the corpus luteum. However, 
Reshef et al., 1990 suggested a role for this glycoprotein in modulating endometrial 
function. I speculated that aberrant differentiation of HESCs observed in RPL patients 
would interfere directly with the maternal response to embryonic signals. To test this, 
I examined the effects of hCG on PRL and PROK1 expression in 20 additional 
cultures (Appendix IV; Table 3.4). HESCs were decidualized with 8-Br-cAMP and 
MPA for 72 hours in the presence or absence of hCG (10 nM), total RNA was 
extracted and subjected to qRT-PCR. As reported previously (270), decidualization in 
the presence of hCG inhibited PRL mRNA in all control cultures. However, it failed 
to inhibit PRL expression in RPL cultures. The relative effect of hCG on decidual 
PRL mRNA expression in both clinical groups is presented in Fig 3.4 A. Strikingly, 
the mean reduction induced by hCG in control samples was 62% whereas a modest 
but consistent increase 30% was noted in the RPL group. PROK1 mRNA levels were 
also inhibited by approximately 50% upon hCG treatment of decidualizing control 
cultures whereas the opposite response, a 4-fold increase, was observed in RPL 
cultures (Fig. 3.4 B). The results confirm that expression of decidual marker genes in 
primary cultures correlates with the clinical phentotype of the patients. In addition, 
these data suggest that RPL is associated with aberrant programming of HESCs to 
embryonic signals and that perturbed endometrial preparation prior to conception will 
have profound consequences on embryo-maternal interactions in pregnancy. 
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Figure 3.4 RPL is characterised by aberrant hCG responses in decidualizing 
HESCs.  
Primary cultures from RPL patients (n = 10) and control women (n = 10) were 
decidualized with 8-Br-cAMP and MPA for 72 hours in the presence or hCG or alone. 
The data show the percentage change (± SEM) in PRL (A) and PROK1 (B) mRNA 
levels upon hCG treatment of control and RPL cultures, relative to the expression 
levels in cultures treated with vehicle (dotted lines); *, P< 0.05 using the Student’s t-
test.  
 
 
 
 
 
 
 
 
*  
* 
* 
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 3.3 Discussion 
Miscarriage is the commonest complication of pregnancy. In addition to the physical 
trauma, miscarriage and especially RPL, is associated with considerable 
psychological morbidity with a third of patients attending specialist clinics suffering 
from clinical depression (213). Moreover, a history of RPL increases the risk of a 
variety of adverse obstetric outcomes in a subsequent on-going pregnancy. While 
numerous anatomical, endocrine, immunological, thrombophilic and genetic 
perturbations have been associated with RPL, none are specific or prevalent.  
 
In this chapter, I provide evidence that impaired decidual programming of the 
endometrium is an important mechanism underlying RPL. This is based primarily on 
the observation that expression of PRL, a highly sensitive and specific decidual 
marker gene in the endometrium (75, 271) is grossly impaired in RPL patients, both 
in vivo as well in primary cultures subjected to a decidualizing stimulus. However, I 
also obtained evidence that uterine receptivity is enhanced and prolonged in RPL 
patients, which in turn may facilitate delayed implantation of compromised embryos. 
Differentiating HESCs abundantly express PROK1, a cytokine that promotes embryo-
uterine interaction via induction of LIF in endometrial epithelial cells (272, 273). The 
levels of this pro-implantation cytokine were significantly higher in timed 
endometrial samples from RPL patients, especially in women with a history of 
predominantly very early (biochemical) pregnancy losses. More strikingly, the 
induction of PROK1 in decidualizing endometrial cultures from control women was 
transient, with levels declining after 4 days of differentiation, whereas the levels 
continued to rise in cultures established from RPL patients.  
 
Upon decidualization HESCs acquire a secretory phenotype, characterized by the 
expression of various marker genes such as PRL and PROK1. PRL is a key decidual 
gene widely used as a marker of decidualization (274). PRL in HESCs is implicated 
in a wide range of functions including trophoblast growth, angiogenesis, modulation 
of the immune system and, in a paracrine manner, regulation of epithelial cell 
differentiation (275). Additionally, this hormone is expressed in pituitary lactotrophs, 
hematopoietic cells and dermal fibroblasts (276). The PRL gene in the endometrium 
and lymphocytes is transcribed from an alternative promoter upstream of a non-
coding exon, located approximately 6-kb upstream of the pituitary-specific 
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transcriptional start-site (277). Its expression is under the control of a transposable 
element, termed MER20, which emerged in evolution upon divergence of eutherian 
(placental) from non-placental mammals (278, 279). MER20 is located at -395/-148 
relative to the decidual PRL transcription start-site and contains response elements for 
many transcription factors indispensable for decidualization and pregnancy, including 
F X 1, the homeobo  protein H XA11, C/EB β, and  R (279-281). 
 
PROK1 is a secreted protein that signals via the G-coupled protein receptor PROKR1 
(282). The structure, size, signaling and biological activities are similar to that of the 
chemokine superfamily (282) The highest expression of PROK1 is in steroidogenic 
tissues such as ovary, endometrium and placenta in both human and murine models. 
PROK1 can regulate a variety of biological process such as cell proliferation, 
angiogenesis and induction of fenestrae of capillary endothelial cells (282). The 
promoter of the PROK1-encoding gene possesses putative binding sites for hypoxia-
inducing factor-1. The expression of PROK1 is indeed induced by hypoxia, 
presumably an essential property for an angiogenic factor. PROK1 has since been 
hypothesized as the first example of a tissue-specific angiogenic factor (283). PROK1 
is constitutively expressed in the gonads, but can also be found in B cells, T cells, and 
in inflamed tissues (284, 285). It is possible that the main site of PROK1 action is on 
circulating immature monocytes, such that PROK1 could act as a systemic regulator 
of myeloid development and/or monocyte-derived cell responses (285) and therefore 
capable of modulating immune responses. Expression of PROK1 in inflamed tissues 
suggests it may modify macrophage function locally. Endometrial PROK1 is induced 
by progesterone and its expression peaks during the secretory phase of the human 
menstrual cycle. PROK1 regulates endometrial expression of a host of genes known 
to be important for implantation (273). Thus taken together, PRL and PROK1 
demonstrate important roles during receptivity and during early pregnancy. 
 
Additionally, differentiating HESCs abundantly express PROK1, a cytokine that 
promotes embryo-uterine interaction via induction of LIF in endometrial epithelial 
cells (286). The levels of this pro-implantation cytokine were significantly higher in 
timed endometrial samples from RPL patients, especially in women with a history of 
predominantly very early (biochemical) pregnancy losses. More strikingly, the 
induction of PROK1 in decidualizing endometrial cultures from the control women 
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was transient, with levels declining after 4 days of differentiation, whereas the levels 
continued to rise in cultures established from RPL patients. These data suggest that 
uterine receptivity is enhanced and prolonged in RPL patients, which in turn may 
facilitate delayed implantation of compromised embryos. The concept of enhanced 
endometrial receptivity in RPL is supported by a previous study demonstrating that 
affected women express lower levels of MUC1, an anti-adhesion molecule that 
contributes to the barrier function of luminal epithelium (215, 287).  
 
Furthermore, RPL is associated with paradoxical endometrial responses to embryonic 
hCG signaling, characterized by induction rather than inhibition of PRL and PROK1 
expression in decidualizing HESCs. The ability of hCG to inhibit decidual PRL 
expression is in agreement with a previous study (270). Interestingly, hCG has been 
shown to transiently induce PROK1 in Ishikawa cells, a cancer cell line widely used 
as model for uterine epithelial cells, which was followed by increased LIF expression 
(286). Collectively, these observations indicate that under normal circumstances, hCG 
signaling may first transiently enhance uterine receptivity upon contact of the embryo 
with the luminal epithelium but upon implantation antagonize continuous receptivity 
by inhibiting decidual PROK1. The mechanism of normal hCG signalling in decidual 
cells remains to be defined (18), which is a prerequisite for understanding the 
disrupted transcriptional responses in RPL. Irrespective of the underlying pathway, a 
dysregulated response in pregnancy is likely to jeopardize the integrity of the feto-
maternal interface. hCG, besides its luteotrophic role in early pregnancy, directly 
stimulates angiogenesis and limits cell death responses in the maternal decidua (288, 
289).  
 
Although the expression analysis was confined to PRL and PROK1, the data 
demonstrates that endometrial programming in preparation of pregnancy is both 
quantitatively and qualitatively different in RPL, characterized by impaired 
decidualization of resident stromal cells, prolonged endometrial receptivity and a 
dysregulated maternal response to embryonic signals. This pathological pathway 
explains several established clinical features of RPL. For example, in view of the 
excess of chromosomally abnormal pre-implantation human embryos (97), the 
likelihood of euploidic pregnancy failure can be predicted to increase with the number 
of miscarriages, which is indeed the case (290). Failure to limit the window of 
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endometrial receptivity also accounts for delayed implantation of severely 
compromised embryos and subsequent very early pregnancy loss (104). A primary 
defect in the decidual response may further explain why the incidence of miscarriage 
drops dramatically after 12 weeks gestation (213). The last few weeks of the first 
trimester of pregnancy are particularly perilous for the conceptus as it coincides with 
intense vascular remodelling, the onset of placental perfusion and a dramatic increase 
in oxygen tension at the feto-maternal interface (291). ROS trigger a pro-apoptotic 
pathway in undifferentiated HESCs, which is selectively silenced upon differentiation 
into decidual cells (195). Thus, an adequate decidual response is critical to prevent 
cell death, necrosis, and bleeding at the feto-maternal interface, especially when 
challenged by oxidative stress signals towards the end of the first trimester.  
 
In summary, decidualization of the endometrium is essential to establish a functional 
feto-maternal interface. I now provide evidence that cyclic decidualization of the 
human endometrium may have emerged as an essential defence mechanism against 
implantation of compromised embryos and conversely, that failure to express an 
adequate decidual phenotype negates embryo selection at the time of implantation 
leading to persistent pregnancy wastage. These observations establish a novel and 
unifying mechanism for both euploidic and aneuploidic pregnancy losses. 
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4.1 Introduction 
In the previous chapter, I have provided evidence that impaired decidualization of the 
endometrium prior to conception predisposes for subsequent pregnancy failure, either 
by prolonging the implantation window or by disabling natural embryo selection.  I 
illustrated that differentiating HESCs abundantly express PROK1, a cytokine that 
promotes embryo-uterine interaction via induction of LIF in endometrial epithelial 
cells (286). The levels of this pro-implantation cytokine were significantly higher in 
timed endometrial samples from RPL patients, especially in women with a history of 
predominantly very early (biochemical) pregnancy losses. 
 
The uterine endometrium consists of two distinct cellular components, the stromal 
cells and the cells of the epithelium. The cellular changes during the WOI include the 
transformation of the fibroblast-like endometrial stromal cells into larger and rounded 
decidual cells, as well as the growth and development of secretory glandules and the 
emergence of pinopodes on the luminal epithelium (292). In parallel, modulations in 
the expression of different cytokines, chemokines, and other inflammatory mediators 
take place.  
 
The immunology of pregnancy is complex, in that the mother must tolerate the 
“foreign” fetus and thus requires a degree of immunosuppression whilst on the other 
hand it needs to maintain immune function to fight off infection. One mechanism, 
which is involved in successful pregnancy maintenance, is the proposed switch from 
the T helper-1 (Th1) cytokine profile (i.e. IFN-γ and IL-2) to the dominance of a T 
helper-2 (Th2) profile (i.e. IL-4, IL-5, IL-13 and IL-10) (293).  Th1 and Th2 cell 
subsets originate from undifferentiated T helper -0 (Th0) cells under the influence of 
IFN-γ and IL-4, respectively. Pregnancy hormones such as progesterone and 17 -
oestradiol promote the Th2 cell profile and are likely to be in part responsible for the 
Th2 bias associated with pregnancy (292). However, poor pregnancy outcome may be 
associated with an increase in Th1 cytokines and a concomitant decrease in Th2 
responses, thus cytokines might be important in the pathogenesis of pregnancy loss 
(177) .  
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LIF is the most intensively studied factor regarding uterine receptivity. LIF is a 
pleiotropic cytokine, whose crucial role in successful implantation was established in 
mice (294). In addition to this, decidual HESCs produce a multitude of other 
cytokines to include IL-11 and IL-15. Previous research has shown that these 
cytokines provide chemotactic signals for specialised uterine natural killer (uNK) 
cells, which in turn are a rich source of angiogenic factors (295). Indeed, studies of 
pregnant transgenic mice deficient in uNK cells found abnormally straight and narrow 
uterine spiral arteries, suggesting a role of such immune cells in the remodelling of 
the spiral arteries (296-298).  
 
Interleukin-1 Receptor-Like-1 (IL1RL1 or ST2) was identified as an orphan receptor 
of the Toll-like/Interleukin-1 (IL-1) super-family (57, 299, 300). ST2 exists in four 
isoforms, however only two of these, the transmembrane ST2 (ST2L) and the soluble 
ST2 (sST2) isoforms, have been studied in detail (299). Importantly, the expression of 
these two isoforms is under the control of two distinct promoters. The remaining two 
variants arise from alternative splicing of pre-mRNA (301). Its ligand is IL-33 or IL-
1F11 is now regarded as the 11
th
 member in the IL-1 superfamily of cytokines, which 
includes IL-1α, IL-1β and IL-18 (302). IL-33 mediates its biological effects by 
interacting with the receptor ST2L and IL-1 Receptor Accessory Protein (IL1RAP), 
activating intracellular molecules in the NF-κB and MA  kinase signaling pathways 
that drive production of type 2 cytokines from polarized Th2 cells (299, 303, 304).  
 
It was first identified as a nuclear factor in endothelial cells. Subsequently it was 
shown that IL-33 is a potent pro-inflammatory danger signal, or alarmin, released 
from necrotic cells upon trauma or infection (299). As a nuclear factor, IL-33 may be 
involved in transcriptional repression and regulation of chromatin compaction by 
promoting nucleosome-nucleosome interactions (300). The pro-inflammatory effects 
of IL-33, however, require cellular release and binding to its cell-surface receptor, 
consisting of ST2. ST2L is widely expressed on effector immune cells, including T 
lymphocytes, NK and NKT cells, eosinophils, basophils, and mast cells, enabling IL-
33 to drive the host defence to pathogens and innate immune responses (302).Secreted 
sST2 binds and inhibits IL-33, thus serving as a potent anti-inflammatory mediator 
(299). 
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In the previous chapter, the pattern PROK1, a pro-inflammatory implantation 
cytokine, in decidualizing HESCs has a biphasic response. Furthermore, analysis of 
mid-secretory endometrial biopsies demonstrated that RPL is associated with 
increased levels of PROK1. 
 
In this chapter, I elucidate if a pro-inflammatory response can be extended to other 
inflammatory mediators and if an acute pro-inflammatory event is critical to initiate 
the window of implantation. I will investigate the role of the ST2/IL-33 signaling 
pathway in mounting a prolonged decidual response and its consequence on 
pregnancy. I will also delineate the effects of silencing the ST2/IL-33 pathway on the 
decidual response.  
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4.2 Results 
4.2.1 The IL-33/ST2L/sST2 axis in decidualizing HESCs 
Manual mining of existing microarray data revealed that decidualization of human 
endometrial stromal cells in vitro is associated with transcriptional activation of 
IL1RL1, the gene that encodes for the IL-33 receptor (57, 299, 300) (57). To 
investigate the expression pattern of ST2 in decidualizing HESCs, total-ST2 as well 
as ST2L specific primers were designed. Primary HESC cultures were grown to 80% 
confluency and subsequently remained untreated or treated with 8-Br-cAMP (0.5 
mM) and the synthetic progestin, Medroxy-Progesterone Acetate (MPA; 10
-6
 M) for 
2, 4, 6 or 8 days. qRT-PCR-analysis shows that total-ST2 transcripts are highly 
induced upon decidualization (Fig 4.1A). Interestingly, there is a reciprocal decrease 
in ST2L mRNA transcripts upon decidualization, in parallel cultures whole cell 
lysates were subjected to Western blot and confirmed at protein level the decrease of 
ST2L (Fig 4.1B). To explore if soluble ST2 and IL-33 are secreted upon 
decidualization, time-course cultures of HESCs were examined. The data suggests 
that the decidual process is associated with a gradual release of soluble ST2 in the 
culture medium, correlating with the Western blot and qRT-PCR data (Fig 4.1C). 
However, soluble IL-33 is rapidly secreted at day 2 followed by a transient decline 
over a time course lasting 8 days (Fig 4.1D) this was also confirmed at mRNA 
transcript level and from whole cell extracts (Fig 4.1E). Confocal microscopy 
confirmed that IL-33 is almost exclusively nuclear in undifferentiated cells. Exposure 
to a decidualizing signal for 12 hours was sufficient to induce IL-33 cytoplasmic foci, 
suggesting active secretion (Fig 4.1 F). 
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Figure 4.1. The IL-33/ST2L/sST2 axis in decidualizing HESCs  
(A) Total ST2 transcript levels were measured in primary HESC cultures treated with 8-
Br-cAMP (cAMP) and MPA for the indicated time-points. (B) ST2L mRNA levels, 
expressed in arbitrary units (A.U.), were determined in primary cultures decidualized for 
2 - 8 days (upper panel). Total cell lysates from parallel cultures were probed for ST2L 
expression (lower panel). (C) The culture supernatant was harvested every 48 h and the 
levels of accumulated sST2 determined by ELISA. (D) Induction and release of IL-33 in 
decidualizing cells. Il-33 mRNA and protein was readily detectable in undifferentiated 
HESCs. IL-33 mRNA levels increased rapidly in response to cAMP and MPA (upper 
panel) but total cellular protein levels gradually declined upon decidualization (lower 
panel). (E) Il-33 rapidly accumulated in culture supernatant in response to cAMP and 
MPA signalling (F) HESCs cultured on chamber slides were decidualized for 12 h and 
stained for IL-33 expression (green). The nuclei were visualized with DAPI (blue). The 
over layed images were captured by confocal microscopy. Scale bar: 25 μm. β-actin 
served as a loading control. Quantitative data represents the means (± SD) of biologically 
triplicate experiments.  
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4.2.2 cAMP-dependent IL-33 expression drives an anti-inflammatory response 
when treated with progestins 
The convergence of the cAMP and progesterone pathways drives the decidual 
phenotype in HESCs. To further explore the regulation of ST2 and IL-33 expression, 
HESCs were treated with either 8-Br-cAMP (0.5mM) or MPA (10
-6 
M) or IL-33 
(10ng/ml) alone or in combination for a total of 72 hours. My findings reveal that 
induction of IL-33 transcripts is cAMP dependent and transcript levels are further 
induced with exogenous treatment of IL-33 (Fig. 4.2A). Induction of both Total-ST2 
and ST2L transcripts in decidualizing HESCs was dependent upon MPA signalling 
with cAMP having an inhibitory effect. IL-33 signaling enhances total-ST2 mRNA 
levels in HESCs decidualized with cAMP/MPA (Fig 4.2B) but reduces the expression 
of transcripts that encode for the ST2L (Fig. 4.2C). Next, I examined the possibility 
that activation of the ST2 receptor may lead to auto-regulation. To test this 
hypothesis, the supernatants of the cultures were examined by ELISA, revealed that 
IL-33 enhances the expression of the soluble ST2 (Fig 4.2D). Thus, cAMP-dependent 
IL-33 expression cooperates with progestins to mount an anti-inflammatory response, 
exemplified by up- and down-regulation of sST2 and ST2L, respectively. 
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Figure 4.2 Induction of ST2 and IL-33 expression is differentially regulated 
Primary HESC cultures were treated with either 8-Br-cAMP (cAMP) or MPA, in the 
presence or absence of (0.1 ng/ml) IL-33, for 72h and (A-C) total RNA subjected to 
qRT-PCR analysis. (D) Secreted ST2 levels accumulated over 72h were measured 
using an ELISA. The data represent the mean (± SD) of biologically triplicate 
experiments.  
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4.2.3 A transient pro-inflammatory decidual response confers endometrial 
receptivity 
The pattern of IL-33 induction in decidualizing HESCs paralleled that of PROK1, a 
pro-inflammatory implantation cytokine. I postulated that the bi-phasic regulation 
could extend to other inflammatory mediators expressed by differentiating HESCs. To 
test this hypothesis, I investigated the kinetics of changes in inflammatory mediator 
production upon the decidual process. Primary cultures were treated with 8-Br-cAMP 
and MPA for 2 (D2) and 8 (D8) days or left untreated. Total RNA was extracted and 
was subjected to a qRT-PCR array to measure the expression of 84 genes associated 
with inflammatory cytokines and receptor signaling. To identify the relevant targets 
of the cooperation between inflammatory mediators and their receptors, I then 
compared 2 days or 8 days of decidualization with undecidualized HESCs. With a 
1.5-fold change in gene expression was arbitrarily selected as a cut-off level at 2 days 
of decidualization. 70- genes were up-regulated and only 3 transcripts (CCL11, IL-10, 
and TNF-α; see Appendix V; Table 4.1) were down-regulated. By 8 days of 
differentiation, 12 transcripts remained elevated but 34 were now lower compared to 
their expression in undifferentiated cells (Fig. 4.3 A&B). Thus IL-33 release and 
induction of its trans-membrane receptor in HESCs is part of a substantive but 
transient differentiation-dependent pro-inflammatory response, involving many 
chemokines, interleukins, and other mediators 
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Figure 4.3 Heat map demonstrating the biphasic inflammatory response in 
primary HESCs decidualized with 8-Br-cAMP and MPA treated for 2 (D2) or 8 
(D8) days.  
Total mRNA was isolated and analyzed at a transcriptomic level using qRT-PCR to 
detect transcript levels of inflammatory mediators. (A) Gene expression was studied 
using a 96-well signaling RT
2 rofiler™ inflammatory mediators  CR array. Relative 
gene expression quantification was based on the comparative threshold cycle 
ΔΔ
CT 
method (with normalization of the raw data to the housekeeping genes). An average 
result from three different primary cultures is shown. Heatmap made using MATLAB 
software, UK (B) Bar graph visualizing the number of inflammatory genes regulated 
and classification of pro-inflammatory mediators in primary cultures treated with 8-
Br-cAMP and MPA for either 2 or 8 days. Average of 3 experiments is shown. 
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4.2.4 The pro-inflammatory phase of the decidual process secretes soluble factors 
to render the endometrium receptive. 
 A pro-inflammatory response is associated with the window of implantation in vivo 
and previous studies have shown that secreted molecules from the stroma 
communicate with the developing conceptus during the window of implantation 
(110). It is speculated that these soluble factors secreted by stromal cells during the 
pro-inflammatory phase of the decidual process could serve as signals that render the 
endometrium receptive. To investigate the role of secreted cytokines and other 
inflammatory mediators, HESCs were grown to confluency and subsequently 
decidualized with 8-Br-cAMP and MPA and harvested every 48 h over 10 days. 
Immature C57BL/6 female mice were given a single dose of 1 mg progesterone 
and 10-mg/kg/day β-estradiol for a total of three days to prime the uterus. 
Uterine horns were then flushed at laparotomy with either 100 μl of culture 
supernatant from undifferentiated HESCs, or from cells decidualized for either 4 or 10 
days. The cervix was not occluded. The animals were culled 24 hours later and the 
uterus harvested. Total RNA was extracted and subjected to qRT-PCR analysis. The 
results demonstrated that a single flush of the uterine lumen with supernatant at day 4 
timepoint of decidualization was sufficient to up-regulate pro-implantation genes (Lif, 
Bmp2, Il-1β, Wnt4, Hb-egf, and Hoxa10) in a sustained fashion in the murine 
endometrium (Fig 4.4). This response was accompanied by a strong increase in Il-33 
and St2l transcripts. With the exception of Hb-egf, and Hoxa10, the ability of HESCs 
to generate paracrine signals that activate receptivity genes was lost upon 10 days of 
decidualization. Transient loss of Sgk1 expression and activity in luminal epithelium 
is another important feature of the window of implantation (305). Conditioned 
medium from undifferentiated HESCs strongly up-regulated Sgk1 mRNA levels 
whereas this induction was less pronounced in response to signals from HESCs 
decidualized for 4 days There was no histological evidence of damage to the uterus in 
response to the procedure or the flushing. 
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Figure. 4.4 Expression of receptivity genes in the mouse uterus in response to 
HESC signals.  
The uterine horns of hormonally primed C57BL/6 female mice were injected with 
either unconditioned medium (UM), culture supernatant from undifferentiated HESCs 
(D0), or from cultures decidualized for 4 or 8 days (D4 and D10, respectively). qRT-
PCR was used to determine uterine expression 24 h later of the following  transcripts: 
leukemia inhibitory factor (Lif), interleukin 1-β  Il-1β), heparin binding EGF  Hb-
egf), bone morphogenetic protein 2 (Bmp2), wingless-related MMTV integration site-
4 (Wnt4), homeobox protein 10 (Hoxa10), Il-33, trans-membrane ST2 (St2l) and 
serum- and glucocorticoid-inducible kinase 1 (Sgk1). Transcript levels were 
normalized to the levels of Cyclophilin-B (Cyclo) mRNA and expressed in arbitrary 
units (A.U.). The results represent mean expression (± SD). A total of 6 uterine horns 
were analyzed in each treatment group. *, P < 0.05; **, P < 0.01; ***, P < 0.001 
using the Students t-test. (In vivo experiments were performed by Dr J Nautiyal) 
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4.2.5 Decidualizing HESCs produce factors conducive of pregnancy 
To substantiate the observation that a transient pro-inflammatory decidual response 
confers endometrial receptivity, I reasoned that the effect of flushing the uterus would 
be restricted in time; we opted for an in vivo embryo transfer approach. Uteri of 
recipient pseudopregnant female mice mated with sterile males 2.5 days prior to 
surgery were flushed (100 μl) once with culture supernatant from undifferentiated 
HESCs (D0) or from cultures decidualized for 4 or 10 days (D4 and D10, 
respectively) 10 minutes prior to embryo transfer. A total of 10 cultured blastocysts 
(3.5 D.P.C.) were transferred to a single treated uterine horn. The uteri were harvested 
3 days following surgery, implantation sites counted and tissues fixed or snap-frozen 
for further analysis. Of the 60 embryo transferred in each treatment group, 42 (70%) 
and 45 (75%) embryos failed to implant upon prior exposure of the uterine lumen to 
signals from undifferentiated HESCs or cells decidualized for 10 days, respectively 
(Fig 4.5 A & B). This contrasted to a successful implantation rate of 71% after 
flushing with conditioned medium of HESCs differentiated with 8-Br-cAMP and 
MPA for 4 days. Thus, decidualizing HESCs transiently produce factors conducive of 
pregnancy in this interspecies model. These implantation sites appeared histologically 
normal. In contrast, several pathological features were noted following exposure of 
the uterine lumen to secreted factors from undifferentiated HESCs or cells 
decidualized for 10 d, including focal bleeding and immune cell infiltration around 
the conceptus  (Fig 4.5 C & Appendix V; Table 4.2)  
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Figure 4.5 Decidualizing HESCs transiently produce factors permissive of 
embryo implantation in the mouse uterus.  
(A) Sterile mated C57BL/6 female mice were subjected to laparotomy and both 
uterine horns gently flushed with culture supernatant from undifferentiated HESCs 
(D0) or from cultures decidualized for 4 or 10 days (D4 and D10, respectively). Ten 
embryos (equivalent to stage 3.5 D.P.C.) were then transferred to the right horn. Each 
treatment group consisted of 6 animals. The number of implantation sites in the right 
horn was determined 6.5 D.P.C. Implantation rate was significantly higher after 
exposure to signals from D4 compared to D10 or D0 HESCs cells (P < 0.001). (B) 
Macroscopic appearance of uteri at 6.5 D.P.C. (Scale bar; 1 cm). (C) H&E staining of 
representative implantation sites. Pathological features such as a poor decidual 
response with pyknotic karyorrhectic stromal cell nuclei (arrow heads) were often 
seen at implantation sites following exposure to soluble factors secreted by D0 
HESCs cells. Implantation sites in uteri pretreated with conditioned medium of D4 
HESCs appeared normal, showing trophoblast (T) invasion and development of large 
decidual (D) cells. Epithelial cells were also absent from these implantation sites. 
Petecchia and focal bleeding (arrows heads) and leukocyte infiltrations (*) were seen 
at suspect implant sites in uteri pretreated with D10 HESC supernatants. These sites 
often showed a luminal epithelium and small, non-decidualized stromal cells, 
suggestive of failed implantation.  Scale bar: 100 μm). (In vivo experiments were 
performed by Dr Z Webster & H&E staining was done in collaboration with Dr J 
Steel) 
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4.2.6 ST2L knockdown attenuates induction of decidual markers and induces 
cell death 
The simultaneous induction of ST2L and release of stored IL-33 suggested activation 
of an autocrine pathway, perhaps involved in the coordinated expression of pro-
inflammatory genes in decidualizing cells. To test whether the ST2/IL-33 pathway 
modifies this differentiation process, primary HESC cultures were first transfected 
with either non-targeting siRNA or oligos targeting ST2 or IL-33 and subsequently 
decidualized with 8-Br-cAMP and MPA for 72 h. The siRNA knockdown approach 
for ST2 and IL-33 was effective and selective at the protein level (Fig 4.6 A). I 
observed that there was a degree of cell death in cells targeted with siRNA- ST2. 
Western blot analysis further demonstrated that cleaved poly-(ADP-ribose)-
polymerase-1 (cPARP), an apoptotic marker, upon knockdown with siRNA targeting 
ST2 increased compared to siRNA non-targeting cells. qRT-PCR analysis 
demonstrated that ST2 knockdown abolished both PRL and IGFBP1 mRNA 
expression. Nonetheless, knockdown of IL-33 did not change the levels of prolactin 
however; levels of IGFBP1 were attenuated (Fig 4.6 B&C). Functionally, IL-33 
knockdown did not change the cell viability of HESCs decidualized with 8-Br-cAMP 
and MPA and this was confirmed by MTS assay (Fig. 4.6 B). In contrast, proliferation 
was modestly but consistently reduced upon ST2 knockdown (Fig. 4.6 D). Flow 
cytometry of parallel cultures stained with propidium iodide (PI) demonstrated a 2-
fold increase in the number of dead or dying cells, containing less than <2N DNA, 
upon knockdown targeting ST2 (Fig. 4.6 E). In contrast, no discernible increase in the 
apoptotic cell fraction was observed in decidualized HESC or in knockdown of IL-33.  
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Figure 4.6 ST2 knockdown in HESCs induces cell death.  
HESCs, transfected with non-targeting, ST2, or IL-33 siRNA and then treated with 8-
Br-cAMP (cAMP) and MPA for 72 h. Cells were harvested for protein, mRNA and 
for flow cytometry (A) Whole-cell lysates from were immunoprobed for anti-ST2, 
anti-IL-33 and cleaved-poly (ADP-ribose) polymerase (c-PARP). β-actin served as a 
loading control. (B) Total RNA collected subjected to qRT-PCR analysis. (C) ST2 
knockdown inhibits the secretion of decidual markers, PRL and IGFBP1 whilst IL-33 
knockdown attenuates the expression of IGFBP1 transcripts only. (D) The viability of 
HESCs, transfected first with non-targeting (NT) siRNA, IL-33 or ST2 targeting 
siRNA and then decidualized, was measured and expressed relative (%) to the number 
of viable cells in mock-transfected, undifferentiated cells (dotted line); *, P< 0.01 
using Students t test. (E) The percentage of dead or dying cells (<2N;) and viable cells 
(G0/G1, S, and G2/M) was determined by flow cytometry of ethanol-fixed propidium 
iodide-stained cells. Results are representative of 3 independent experiments. The 
data represent the mean (± SD) of biologically triplicate experiments. 
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4.2.7 IL-33 silencing prevents the induction of pro-inflammatory genes 
To test the hypothesis that IL-33 is required for initiation of the pro-inflammatory 
process, I combined siRNA-mediated knockdown of IL-33 complex with a PCR-array 
analysis of inflammatory mediators and their receptors. HESCs were either 
transfected with NT siRNA or siRNA targeting IL-33 and treated with 8-Br-cAMP 
and MPA for 48 hours. Total RNA was harvested and subjected to qRT-PCR analysis 
using the RT
2
Profiler
™
 array. Following, knockdown of IL-33 there was attenuation 
of most of the inflammatory mediators and their receptors; 24 genes were up-
regulated and 61 down-regulated (Fig. 4.7 A&B). IL-33 silencing not only prevented 
the induction of many pro-inflammatory genes in decidualizing cells but also lowered 
the expression of several inflammatory mediators, especially interleukins and 
chemokines, below the levels present in undifferentiated HESCs (See Appendix V; 
Table 4.3). Taken together, the PCR array analyses show that IL-33 knockdown is 
sufficient to qualitatively transform the early pro-inflammatory response associated 
with HESC differentiation into an anti-inflammatory response akin to that observed 
upon prolonged decidualization. 
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Figure 4.7 Heat map demonstrating the blunted inflammatory response in 
primary HESCs targeted with siRNA IL-33.  
Total mRNA was isolated and analyzed at a transcriptomic level using qRT-PCR to 
detect transcript levels of inflammatory mediators. (A) Gene expression was studied 
using a 96-well signaling RT
2 rofiler™ inflammatory mediators  CR array. Relative 
gene expression quantification was based on the comparative threshold cycle method 
ΔΔ
CT (with normalization of the raw data to the included housekeeping genes). Each 
bar represents a result from three different primary cultures. Heatmaps made using 
MATLAB software. (B) Bar graph visualizing the number of inflammatory genes 
regulated and classification of pro-inflammatory mediators in primary cultures 
targeted with NT oligo or siRNA IL-33. An average of 3 experiments is shown. 
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4.2.8 Autocrine IL-33 signaling in HESCs facilitates embryo implantation.  
I examined the functional consequences of the altered decidual inflammatory 
response upon IL-33 knockdown. HESCs were transfected first with non-targeting or 
IL-33 siRNA and then treated with 8-Br-cAMP and MPA. Conditioned media that 
accumulated over a 48h period were collected from independent primary cultures 
decidualized for a total of 4 days. C57BL/6 female mice were vas mated and a 
laparotomy was performed at 2.5 D.P.C. and both uterine horns were flushed with 
either conditioned medium of non-targetting oligos HESCs or conditioned medium of 
si-IL-33 targeted HESCs. 100 µl was flushed in each horn over 5 minutes without 
clamping of the cervix and the injected fluid was allowed to run freely through the 
uterine lumen. 10 embryos (equivalent to stage 3.5 D.P.C.) were transferred to the 
right horn, the abdomen closed, and then the animals were sacrificed at 6.5 D.P.C. 
The number of implantation sites counted and tissue collected. Uterine flushing 
experiments in pseudopregnant female mice demonstrated that IL-33 knockdown 
prior to decidualization of HESCs has dire consequences for pregnancy, reducing the 
implantation rate of transferred embryos from 90% (45 implantation sites out of 50 
transferred embryos) to 14 % (7 implantation sites out of 50 transferred embryos; P< 
0.0001) (Fig. 4.8 A& B). Furthermore, uterine exposure to this altered decidual 
inflammatory response prior embryo transfer again seems to compromise the 
formation of a functional decidual-placental interface in the few implantation sites 
(Fig. 4.8 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Results II  
 
 131 
 
 
 
 
Figure 4.8 IL-33 knockdown in decidualizing HESCs impairs embryo 
implantation.  
(A) Vas mated C57BL/6 female mice were subjected to laparotomy and both uterine 
horns gently flushed with culture supernatant from primary HESC cultures first 
transfected with non-targeting (NT) or IL-33 siRNA (si IL-33) and then decidualized 
for 4 (D4) with 8-Br-cAMP and MPA. Ten embryos (equivalent to stage 3.5 D.P.C.) 
were then transferred to the right horn. Each treatment group consisted of 5 animals. 
The number of implantation sites in the right horn was determined at 9.5 D.P.C. 
Implantation was dramatically reduced following exposure to culture supernatant 
from IL-33 deficient D4 HESCs. ***, P < 0.001 using Students t test. (B) 
Macroscopic appearance of uteri at 9.5 D.P.C. (Scale bar: 1 cm). (C) H&E staining of 
representative implantation sites. Upper panel shows a normal early pregnancy 
following flushing of uterine lumen culture supernatant from primary HESCs 
transfected with NT siRNA. Note the placental (P) primordium, fusion of allantois 
(A) to chorion, and fetal (F) tissue. Lower panel; exposure to culture supernatant from 
IL-33 deficient HESCs decidualized for 4 days (D4) resulted in an array of 
pathological features in early pregnancy, including focal bleeding at the feto-maternal 
interface (arrows). Irregularity and pinkness of the amniotic fluid suggest collapse of 
the amnion and coagulation of its content  *).  Scale bar: 100 μm). (In vivo 
experiments were performed by Dr Z Webster & H&E staining was done in 
collaboration with Dr J Steel). 
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4.2.9 The IL-33/ST2L/sST2 axis is deregulated in decidualizing HESCs from 
RPL.  
I have previously showed that the decidual response is divergent between primary 
HESC cultures established from RPL and non-RPL subjects. To determine whether 
the aberrant decidual response, associated with RPL, also encompasses the IL-
33/ST2L pathway, I established primary cultures from 8 RPL patients and 12 controls 
(Appendix V; Table 4.4). HESCs, purified from samples taken randomly in the cycle, 
were passaged once, allowed to grow to confluency, and then decidualized with 8-Br-
cAMP and MPA over a time-course lasting 8 days. Total ST2 transcript levels in both 
groups were comparable in undifferentiated HESCs and upon decidualization total 
ST2 transcripts increased in a time-dependent manner (Fig. 4.9 A). As shown 
previously in Fig. 4.1B levels of ST2L transcripts level decrease by day 8 of 
differentiation. However, transcript levels of ST2L in the RPL group were markedly 
increased by day 8 of differentiation, almost 10-fold higher compared with control 
cultures (Fig. 4.9 B). Thus, the data provides compelling evidence that the ability of 
HESCs to reduce ST2L expression and mount an anti-inflammatory response is 
impaired in RPL, even in primary cultures. Additionally, the secretion of sST2 and 
IL-33 was also measured by ELISA in the supernatant of decidualizing primary 
HESCs established from either controls (n=16) or women with recurrent pregnancy 
loss (n=15) (Fig 4. 9 C and Appendix V; Table 4.4). Unexpectedly, sST2 secretion 
was significantly lower in decidualizing HESCs from recurrent pregnancy loss 
patients compared with infertile women. Furthermore, two distinct clusters appeared 
to be present in the infertile group. The top cluster, representing relatively high levels 
of sST2 secretion, consisted of primary cultures established from infertile patients 
with inflammatory conditions, such as tubal disease and Asherman’s syndrome. The 
bottom cluster represented samples from patients with either unexplained infertility or 
polycystic ovaries (Fig. 4.9 C). Secreted IL-33 followed a similar biphasic response as 
seen in Fig. 4.1E. Even more strikingly was the difference in IL-33 secretion between 
the two clinical groups. In control cultures, approximately 10-times more IL-33 was 
secreted by day 4 compared with day 10 of decidualization whereas the reversed was 
true for RPL cultures (P<0.0001) (Fig. 4.9 D).  
 
To further investigate if the role of this pro- inflammatory- pro implantation response 
is deregulated in RPL patients, I reasoned that the effect of flushing the uterus with 
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supernatants from HESCs from RPL patients treated with 8-Br-cAMP and MPA (for 
a total of 10 days) could impact on embryo implantation in the mouse uterus.  Briefly, 
uteri of recipient pseudopregnant female mice mated with sterile males 2.5 days prior 
to surgery were flushed once with 100 μl of supernatant 10 minutes prior to embryo 
transfer. Ten cultured blastocysts (3.5 D.P.C) were transferred to the right uterine 
horn. The uteri were harvested 4 days following surgery, implantation sites counted 
and uterine tissue fixed or snap-frozen for further analysis. Of a total of 40 embryos 
were transferred in each group. After exposure of the uterine lumen to secreted factors 
only 16 (40%) embryos implanted when flushed with media from undifferentiated 
cells and 21 (52%) embryos implanted when exposed to media from cells 
decidualized for 4 days. This was significantly lower when compared to the 29 
(72.5%) embryos that implanted following flushing with conditioned medium from 
primary RPL cultures decidualized for 10 days. Moreover, H&E analysis of the 
implantation sites revealed several abnormalities in animals flushed with day 0 and 
day 10 supernatants, including focal bleeding, aberrant spacing of embryos and twin 
implantation sites (Fig. 4.9 E & Appendix V; Table 4.2), rendering it unlikely that 
many would have survived pregnancy. 
  
Chapter 4: Results II  
 
 134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Deregulated IL-33/ST2 activity in decidualizing HESCs from RPL subjects is 
associated with early pregnancy failure.  
(A & B) Primary cultures, passaged once, from control (n=12) and RPL (n=8) subjects were either left 
untreated (D0) or treated with 8-Br-cAMP and MPA (cAMP/MPA) for 2 (D2) or 8 (D8) days. Total 
ST2 and ST2L transcript levels, normalized to L19 mRNA, were measured and expressed in arbitrary 
units (A.U.) using the standard curve method. (C & D) Additional cultures were from control (n=15) 
and RPL (n=16) subjects were treated with cAMP/MPA. The medium was changed every 48 hours. 
Accumulated levels of secreted sST2 and IL-33 were measured at 4 (D4) and 10 (D10) days of 
treatment. Horizontal bars indicate the median expression in each group. Note the logarithmic y-axis. *, 
P < 0.05; ***, P < 0.001 ***, P < 0.001; ****, P< 0.0001 using the Mann-Whitney U Test. (E) The 
murine implantation model was used to examine the consequences of a prolonged and disordered pro-
inflammatory response in decidualizing HESCs from RPL patients. In each treatment group, a total of 
40 embryos were transferred in 4 animals. The number of implantation sites (left panel) in the right 
horn was determined 72 h after blastocyst transfer .The right panel shows a representative implantation 
sites. Note the haemorrhagic resorption (arrows) and poor decidualization response in the D0 and D10 
HESC supernatant treatment groups.  Scale bar: 100 μm). (In vivo experiments were performed by Dr 
Z Webster & H&E staining was done in collaboration with Dr J Steel). 
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4.3 Discussion 
Pregnancy is proposed to be an event requiring a predominance of anti-inflammatory 
mediators, such as IL-10 and IL-5. It was noted that pathologies associated with 
humoral responses, such as lupus erythematosus, are known to flare up during 
pregnancy, whereas cell mediated ones, such as rheumatoid arthritis, often enter in 
remission. These observations formed the basis for the T helper cell type 1/ 2 
(Th1/Th2) paradigm. The model was developed in mice in 1995 (306). It was shown 
that placentae from abortion prone mice were deficient in their production of anti-
inflammatory cytokines, which was companied by increased levels of local 
inflammatory cytokines. The recombinant IL-10, anti-IFN- γ or pento ifillin  anti-
TNF agent) reduced the resorption of pups, while anti-IL-10 increased the resorption 
rate in the abortion prone mating. Moreover, induction of an inflammatory response 
by LPS was associated with fetal demise and premature labour (175). These results 
indicated that local anti-inflammatory cytokines could play a vital role in the survival 
of the fetal allograft by counteracting deleterious inflammatory cytokines. These 
findings in mice were later extended to humans. Excess IFN-γ and TNF-α production 
have been associated with IVF failure and miscarriage (307). Another study showed 
that maternal peripheral blood mononuclear cells (PBMCs) from women with a 
history of recurrent miscarriage responded differently on placental antigens in co-
culture than PBMCs from controls, showing a bias towards Th1-type reactivity in 
women with a history of recurrent miscarriage (308, 309).  
 
However, the Th1/Th2 theory was soon challenged by a variety of data. Anti-IL-10 
did not have an effect on the resorption rate in non-abortion prone mice (175, 182). 
Much of our understanding of endometrial receptivity is derived from mouse knock-
out studies. Relatively few of these cytokine gene knock-out studies have shown 
effects on reproduction and they were mainly Th1 cytokines, whereas IL- 4 and IL-10 
knock-out mice did not show an effect on their fertility (126). However, an increasing 
body of evidence showed that uNK cells accumulate in the endometrium during the 
implantation period and uNK cell knock-out mice showed reproductive defects but do 
remain fertile (310). It has become clear that it is not as straightforward as previously 
thought. Although the established pregnancy may indeed be a Th2 phenomenon, Th1 
activity is required during the early implantation period. Implantation is a process of 
aggression in which maternal and embryonic signals induce a state of controlled 
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inflammation, which increases the production of both pro-inflammatory cytokines, 
inducing angiogenesis and increased vascular permeability, but also anti-
inflammatory cytokines (311). The results presented in this chapter, provide 
preliminary data, that reveals a pro- and then an anti-inflammatory response 
underpins receptivity. Also, it strengthens the enunciation that the Th1/Th2 paradigm 
is obsolete.  
 
My study shows that cAMP signaling drives the expression of IL-33 in HESCs 
whereas progestins upregulate ST2 transcripts. The presence of IL-33 in human 
endometrium is not unexpected as this cytokine is abundantly expressed in various 
mucosal and epithelial barrier tissues (312, 313). Its nuclear expression combined 
with the absence of a peptide signal for export led to the notion that IL-33 is released 
primarily upon tissue injury or infection and through binding to ST2L on immune 
cells, responsible for initiating tissue inflammation (312, 314).  
 
 Further, this study also suggests that IL1-RL1 and IL-33 is expressed in the human 
endometrium and decidualization of HESCs is associated with strong induction of the 
ST2 receptor isoforms, ST2L and sST2. Time-course analyses revealed that HESCs, 
subjected to the differentiation stimuli cAMP and MPA, lead to the transient 
induction of ST2L mRNA and protein as early as day 2. The expression of ST2L is 
subsequently down-regulated in a time-dependent manner whereas sST2 is induced 
and secreted instead. Importantly, ST2L is known to be associated with Th2-mediated 
inflammation, whereas sST2, which is the decoy receptor to IL-33, plays a key role in 
the attenuation of such potentially harmful immune responses (315, 316).  
 
I provide data indicating that the transient expression of ST2L in decidualizing 
HESCs drives Th-2 mediated responses essential for early implantation events. 
Indeed, early embryo implantation is associated with recruitment of specialised 
immune cells to the invading blastocyst (317). However, these inflammatory 
responses to embryo implantation must be tightly controlled in order to avoid 
indiscriminate damage of the feto-maternal interface, which would inevitably lead to 
pregnancy loss. It is striking that expression of ST2L in decidualizing HESCs is 
followed by the secretion of the soluble receptor. Notably, recent studies showed that 
viable cells could release IL-33, for example in response to cellular stretch or 
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mechanical strain (318). It is therefore not inconceivable that the profound changes in 
cell shape and actin dynamics upon decidualization trigger nuclear export and 
secretion of IL-33 via an unconventional pathway.  
 
This biphasic response suggests that decidualizing cells may initially promote an 
inflammatory response but then play a critical role in attenuating the potentially 
harmful Th2 responses. The expression of the two ST2 isoforms is under the control 
of distinct promoters (301), suggesting that decidualization of HESCs triggers a 
dynamic switch in promoter usage.  
 
Binding of IL-33 to ST2L on the cell surface of differentiating HESCs establishes an 
autocrine pathway that drives an acute phase response, characterized by coordinated 
induction of interleukins, chemokines, C-reactive protein and several other 
inflammatory mediators. STL2 activity in decidualizing cells is intrinsically self-
limiting as IL-33 combined with continuous progestin signaling decreases 
transmembrane receptor levels and stimulates the secretion of the anti-inflammatory 
decoy receptor sST2. Transition from the pro- to anti-inflammatory phase of the 
decidual process is further characterized by suppression of many pro-inflammatory 
genes below basal levels in undifferentiated stromal cells and the induction of the Th2 
cytokines IL-5 and IL-10.  
 
Several lines of evidence indicated that activation of the IL-33/ST2 pathway in 
HESCs is critical for a successful pregnancy. First, only during the pro-inflammatory 
phase did differentiating HESC secrete factors that heightened the expression of 
murine receptivity genes (Fig 4.10), enabling efficient implantation of transferred 
mouse blastocysts.  
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Figure 4.10. Decidualizing HESCs induces a self-limiting autoinflammatory 
response that controls the transient expression of uterine receptivity genes.  
The decidual transformation (decidualization; green) of the endometrium is primarily 
under maternal control and initiated in the mid- to late secretory phase of each cycle. 
(A) Activation of a pro-inflammatory response (red; induction of genes such as IL-33, 
PROK1, ST2L) HESCS of normal patients drives an inflammatory response that 
controls the temporal expression of receptivity genes, thus the window of 
implantation (purple). (B) A prolonged inflammatory response (blue) or failure to 
constrain this response is associated with pregnancy loss by allowing out-of-phase 
implantation in an unsupportive uterine environment by prolonging receptivity (note 
longer WOI; purple and abnormal/decreased decidualization; green). 
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Secondly, that implantation in the mouse uterus was actively impaired upon exposure 
to signals from undifferentiating HESCs, from decidualizing cells in the anti-
inflammatory phase and from decidualizing cells first transfected with IL-33 siRNA. 
Importantly, while some embryos did implant under these conditions, a high 
proportion of the resultant implantation sites exhibited pathological features, 
including focal bleeding and excessive immune cell infiltration. Further, that 
sequential activation of the IL-33/ST2L/sST2 axis is deregulated in primary HESCs 
from RPL subjects and likely to cause a prolonged window of implantation. Again, 
many implantation sites showed pathological features, emphasizing that the peri-
implantation milieu has profound consequences for the subsequent developmental 
trajectory of the conceptus. Thus, a prolonged and disordered auto-inflammatory 
response in resident stromal cells seems to cause considerable collateral damage, 
resulting in bleeding, excessive recruitment of local immune cells, and possibly 
maternal immune-intolerance of the fetal semi-allograft.  
 
Taken together, in this chapter I provided preliminary evidence that confirm that the 
cellular response to identical differentiation signals is profoundly divergent between 
primary cultures established from RPL and control subjects. Strikingly, this study 
revealed that secretion of sST2 by decidualizing primary cultures established from 
biopsies of patients suffering from RPL was significantly lower compared with 
infertile women. In addition, the expression of ST2L from women with RPL was 
markedly higher compared with samples from control.  
 
Various studies suggest that sST2 is a ‘decoy’ receptor capable of sequestering IL-33 
in order to attenuate the inflammatory responses (299, 319, 320). In agreement, 
evidence shows that pre-exposure to sST2 reduces the production of Th2 cytokines in 
a mouse model of allergen-induced pulmonary inflammation (319). In addition, sST2 
levels are found to be elevated in the sera of patients with asthma, as well as in other 
Th2-dominant conditions, such as systemic lupus erythematosus and idiopathic 
pulmonary fibrosis, further reinforcing the significance of sST2 in IL-33-induced 
inflammation (319, 321, 322). Interestingly, sST2 has been shown to bind 
macrophages and repress the expression of pro-inflammatory cytokines (323). 
Evidently, administration of sST2 in vivo following a lipopolysaccharides (LPS) 
challenge significantly reduces the production of the pro-inflammatory cytokines IL-
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6, IL-12, and IFN- (323-325). These data suggest that sST2 is currently considered a 
key regulator of immune responses by limiting IL-33-dependent pro-inflammatory 
responses and that the IL-33/ST2 signalling pathway is shown to confer and modulate 
tissue-specific inflammatory responses.  
 
Beyond its immuno-regulatory role, sST2 has also emerged as a biomarker of disease. 
For example, serum levels of sST2 are elevated in patients with acute exacerbations 
of bronchial asthma (316, 319). Interestingly, the level of sST2 in decidualizing 
HESCs established from infertile patients, clustered into two distinct sub-groups. The 
group of patients with high levels of sST2 had inflammatory causes of infertility, such 
as Asherman’s syndrome and tubal disease. Conversely, the cluster with the lower 
sST2 levels represented patients with either unexplained infertility or ovulatory 
polycystic ovary syndrome.  
 
Moreover, these results indicate that defects in the expression of the two isoforms 
may be associated with specific reproductive disorders. Importantly, sST2 is known to 
play a role in endotoxin tolerance (323), suggesting that women with low levels of 
secreted sST2 may be less able to combat infection, which may in turn contribute to 
pregnancy complications, such as pre-term labour (326, 327). Importantly, the 
differences in expression between these two clinical groups reinforce the concept that 
expression and secretion of the soluble receptor is needed to ensure integrity of the 
feto-maternal interface.  
 
Further, the data provides novel insights into the nature and pathological 
consequences of aberrant decidualization, although the underlying molecular 
mechanism requires further elucidation. Emerging evidence indicates that profound 
changes in chromatin structure, exemplified by genome-wide redistribution of 
transcriptionally repressive and permissive histone marks, precede the expression of a 
decidual phenotype in HESCs (328). Hence, it is possible that the primary defect in 
RPL may lie in epigenetic programming of endometrial stromal cells, or their bone 
marrow-derived stem/progenitor cells (17).   
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5.1 Introduction 
Embryo-maternal interactions are strictly dependent upon the endometrium 
expressing a receptive phenotype. Two broad approaches have been taken to identify 
uterine factors critical for implantation. Animal models, especially gene deletion 
studies in mice, have provided invaluable insights into the molecular repertoire that 
underpins early embryo-endometrial interactions (126). In addition, expression 
profiling of human endometrium during the luteal phase of the cycle has extensively 
been used. Together, these studies suggest that endometrial receptivity to implantation 
depends on expression or activation of an evolutionarily conserved network of 
factors, which include growth factors, cytokines and their receptors (e.g. HB-EGF, 
LIF, PROK1) (272, 294, 329), cell adhesion molecules and ligands  e.g. αvβ3 
integrin, trophinin, L-selectin ligand) (330-332), signal intermediates and downstream 
transcription factors (e.g. HOXA10, STAT3, p53) (271, 333-335). Yet it has proven 
difficult to unequivocally implicate these factors in reproductive failure in women or 
to exploit them for therapeutic purposes.  
 
SGK1, a serine/threonine protein kinase with considerable homology to AKT, is a key 
hormone-dependent regulator of sodium transport in mammalian epithelia through its 
ability to inhibit the ubiquitin ligase Nedd4-2, thereby enhancing the expression of 
epithelial sodium channels (ENaC) (238, 336). Like AKT, SGK1 functions 
downstream in the PI3K cascade by targeting FOXO transcription factors and 
modulating NF-κB signaling. It is therefore implicated in cell survival responses 
(223).  
 
SGK1 in the human and murine endometrium is rapidly induced in response to a rise 
in progesterone levels, first in epithelial cells and then in the underlying decidualizing 
stroma (337). Moreover, increased expression of SGK1 in the luminal epithelium 
during the mid-secretory phase of the cycle has been linked to unexplained infertility 
(129). 
 
As outlined in the previous chapter, the IL-33/ST2 complex not only critically 
regulates the window of implantation in HESCs but also failure of HESCs to 
constrain a host-defense-like response can lead to pregnancy failure. Hence, I 
    Chapter 5: Results III 
 
 143 
postulated that impaired cycle-dependent expression of SGK1 in endometrium of 
patients with RPL and infertility might contribute to the pathogenesis of the disease. 
 
5.2 Results 
5.2.1 Endometrial SGK1 expression in infertility and RPL 
 
Like PRL, SGK1 is dependent on PKA activation but its expression is further 
enhanced by progesterone or progestins. I assessed the expression level of SGK1 in 
timed endometrial biopsies that spanned the window of implantation. SGK1, 
transcript levels were measured in endometrial samples from women with proven 
fertility (FER; n=9) and patients with either unexplained infertility (INF; n=9) or a 
history of RPL (n=9), defined here as 3 or more consecutive miscarriages. As 
previously reported (129), SGK1 transcripts levels in mid-secretory endometrium 
were higher in infertile patients when compared to fertile controls (Fig. 5.1A). 
However, the opposite was true for RPL patients. SGK1 mRNA levels in this patient 
group was lower not only compared with infertile patients but also to fertile controls 
(Fig. 5.1A). Analysis of 18 additional endometrial samples from RPL patients 
demonstrated that SGK1 transcript levels are comparable between those whom 
experienced predominantly biochemical miscarriages and those with fetal pregnancy 
losses (Fig. 5.1B). Immunohistochemistry staining of mid-secretory endometrial 
samples using a SGK1 phospho-specific antibody demonstrated that SGK1 activity in 
the luminal and glandular epithelial compartments was higher in infertile patients, 
especially when compared with RPL samples (Fig. 5.1C). Notably, phospho-SGK1 
immunoreactivity in the decidualizing stromal cells underlying the luminal epithelial 
cells also appeared lower in RPL samples.  
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Figure 5.1 Deregulated SGK1 expression and activity is associated with 
infertility and recurrent pregnancy loss (RPL).  
(A) Biopsies, taken 7 to 11 days after the pre-ovulatory luteinising hormone (LH) 
peak, from patients with three or more consecutive first trimester pregnancy losses 
(RPL; n=9), fertile controls (FER; n=9), or unexplained infertility (INF; n=9) were 
analyzed for the expression of SGK1 transcripts using RTQ-PCR. Note logarithmic 
scale. (B) Analysis of additional timed endometrial biopsies from RPL patients 
revealed no difference in SGK1 mRNA levels between women suffering 
predominantly from persistent biochemical (biochem; n=10) or fetal loss (fetal; n=8). 
A ‘biochemical’ loss was defined as a miscarriage at 4-6 weeks gestation with 
ultrasound evidence of either an intrauterine pregnancy sac with no fetus or retained 
products of conception. A ‘fetal’ loss was defined as a pregnancy failure between 6-
13 weeks gestation with prior ultrasound evidence of fetal development. Transcript 
levels were normalized to the housekeeping gene L19. (C) Immunostaining for 
phospho-SGK1 is greatly reduced in the endometrium of patients with RPL (scale 
bar: 100 m). Statistical significance was determined using Mann-Whitney U test. *, 
P < 0.05; **, P < 0.01; ***, P < 0.001. (Immunostaining was done in collaboration 
with Dr J Steel). 
A B 
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5.2.2 Expression and activity of SGK1 is deregulated in RPL  
Western blot analysis was performed for total and phospho-SGK1 on protein samples 
prepared from secretory endometrial tissue biopsies obtained from patients with RPL 
and INF patients. Total and especially phospho-SGK1 levels were considerably 
higher in the endometrium of infertile compared with RPL patients (Fig. 5.2 A). 
SGK1 mRNA transcript levels were measured by qRT-PCR in the control and RPL 
samples to determine the specificity of the hCG response on decidual SGK1 
expression. Culturing, differentiating HESCs in the presence of hCG still significantly 
lowered SGK1 transcript levels by 49% in control samples whereas a minimal 
reduction (17%) was observed in RPL patients (Fig 5.2 B). Thus, despite the much 
lower induction of SGK1 of compared to PRL (Chapter 3; fig 3.4) mRNA levels in 
decidualizing HESCs, hCG- dependent inhibition was still apparent although not in 
the RPL group. Lack of hCG response in the RPL group reaffirms the hypothesis that 
RPL patients have an abnormal modulation of endometrium gene expression. 
 
Taken together these results suggest that enhanced endometrial SGK1 activity during 
the putative window of implantation may compromise embryo implantation. 
Conversely, insufficient endometrial SGK1 activity does not appear to interfere with 
embryo implantation but may be detrimental for the subsequent survival of the 
conceptus. 
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Figure 5.2 Aberrant SGK1 expression and activity is associated with recurrent 
pregnancy loss (RPL).  
(A) Total protein lysates from snap-frozen biopsy samples were subjected to Western 
blot analysis and immunoprobed with antibodies specific to pan and phospho-SGK1. 
-actin was used as a loading control. SGK1 levels in total tissue lysates of mid-
secretory endometrial biopsies from individuals with recurrent pregnancy loss or 
unexplained infertility. (B) Culturing differentiating HESCs in the presence of hCG 
significantly lowered SGK1 transcript levels in control samples whereas a minimal 
reduction was observed in RPL samples (n=5; mean ±SD). Statistical significance 
was determined using Students t test. *, P< 0.05.  
 
 
 
 
* 
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5.2.3 Reduction of SGK1 expression during the period of receptivity  
In order to describe the kinetic profile of SGK1, immunohistochemistry staining for 
phospho- SGK1 was performed on murine uterus sections, over the pre-receptive to 
refractory phase of pseudo-pregnancy. C57BL/6 females were caged with 
vasectomized males overnight and those plug positive for pseudo-pregnancy 
(designated day 1; D.P.C ) removed to a separate cage. Uteri (n=5) were collected at 
each of the following times: third day at 21.00 (D3.5; pre-receptive), fourth day at 
21.00 (D4; receptive), fifth day at 9.00 (D5; refractory; a gift from Dr A Sharkey). As 
illustrated in Figure 5.3 the expression pattern of phospho-SGK1 decreases during 
pregnancy. During the pre-receptive phase of the cycle, there is intense phospho-
SGK1 staining in the luminal epithelium and glandular compartments. By the 
receptive phase, phospho-SGK1 reactivity decreases but staining is still also visible in 
the glands. The lowest reactivity with phospho-SGK1 is observed in the post-
receptive phase of the cycle.   
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Figure 5.3 Immunostaining for phosphorylated SGK1 expression during the 
putative window of endometrial receptivity in the mouse uterus.  
(A) Low (x100; upper panels) and high (x400; lower panels) magnification of 
immunostained tissue sections at 3.5 D.P.C (pre-receptive), 4.0 D.P.C (receptive) and 
5.0 D.P.C (refractory). The decline in phosphorylated SGK1 levels was particularly 
striking in the luminal epithelium (Magnification x400).  (Immunostaining was done 
in collaboration with Dr J Steel) 
 
 
 
 
 
 
 
 
 
 
 
    3.5 D.P.C    4.0 D.P.C   5.0 D.P.C 
    Chapter 5: Results III 
 
 149 
5.2.4 Increased SGK1 activity in luminal endometrial epithelium blocks 
implantation 
To establish if enhanced SGK1 activity is sufficient to prevent embryo implantation, I 
selectively overexpressed SGK1 in the uterine epithelial compartment in mice and 
assess the consequences on embryo implantation. Using the HVJ-E vector system 
(338), the uteri of 6 C57BL/6 mice were injected 1.5 D.P.C with hSGK1S422D 
pIRES2eGFP, an expression vector that encodes for a single transcript that translates 
into enhanced green fluorescent protein (eGFP) and a constitutive active SGK1 
mutant (SGK1S422D) (339). The uteri of control mice were injected with an equal 
volume of transfection mix (100 µl/per horn) containing 10 µg of wtSGK1 cDNA 
(Con). The animals were culled 8.5 D.P.C. Five of 7 control animals achieved 
pregnancy, all with 7 implantation sites each (Fig. 5.4A). In contrast, there was not a 
single implantation site in animals expressing the constitutively active SGK1. 
Moreover, SGK1 overexpressing uteri appeared smaller and weighed approximately 
half of that of non-pregnant control mice (Fig. 5.4A). Histological examination 
showed no damage of the luminal epithelium in mice transfected with either SGK1 
S422D or control wtSGK1 cDNA.  
 
In addition to an obvious reduction in uterine size and weight, morphometric analysis 
revealed reduced glandular area and decreased distance between luminal epithelial 
cells upon expression of the constitutive active SGK1 mutant (Fig 5.4B), while 
cellular height was unaffected. Total protein lysates from snap-frozen whole tissue 
sections subjected to Western blot analysis and probed for the expression of eGFP and 
phospho-SGK1 confirmed that the in vivo gene transfer had been effective (Fig 5.4C). 
Increased SGK1 activity is known to down-regulate the ubiquitin-protein ligase 
Nedd4-2, which in turn enhances the expression and activity of the epithelial sodium 
channels (ENaC) (257).  
 
In agreement, transfection of constitutively active SGK1 into the uterine lumen 
resulted in simultaneous downregulation of Nedd4-2 and upregulation of ENaC 
expression (Fig 5.4C). Immunohistochemistry also showed markedly enhanced total 
and phospho-SGK1 and ENaC immunoreactivity in uteri transfected with SGK1S422D 
compared to non-pregnant control uteri, although the differences were largely 
confined to the luminal epithelium and underlying glands (Fig 5.4D). The results 
    Chapter 5: Results III 
 
 150 
provide unequivocal evidence that increased SGK1 activity in the uterine luminal 
epithelium abolishes embryo implantation. The dramatic effect on uterine size and 
weight was unexpected but in keeping with the critical role of SGK1 in 
osmoregulation (336).  
 
In sum, expression of a constitutively active SGK1 mutant in the luminal epithelium 
perturbs endometrial osmoregulation. Compared to non-pregnant animals transfected 
with the control plasmid, expression of the constitutive active SGK1 mutant also 
resulted in a decrease in the distance between luminal epithelial cells and total 
endometrial glandular area.   
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Figure 5.4 Increased SGK1 activity in the luminal epithelium blocks embryo 
implantation.  
(A) Gross uterine morphology 7 d after transfection (8.5 D.P.C) of a control plasmid 
(pcDNA3.1) or the constitutively active mutant SGK1S422D expression vector. Five out of 
seven control mice achieved pregnancy, all with seven implantation sites each (middle panel). 
There were no implantation sites in any of the mice transfected with SGKS422D (n = 7). (B) 
Morphometric analysis of the average (±SEM) cellular width of luminal endometrial 
epithelial cells and glandular area in control and SGK1S422D-transfected animals. (C) Total 
protein lysates from snap-frozen uterine samples, were subjected to Western blot analysis 
using eGFP, phosphorylated (p-) SGK1, NEDD4-2, and α–EnaC antibodies (D) 
Immunostaining of corresponding uterine tissue sections for total SGK1, p-SGK1 and α-
ENaC.  Scale bars: A, 1 cm; D, 100 μm). (In vivo experiments were performed by Dr M 
Christian & Dr J Nautiyal and immunostaining was done in collaboration with Dr J Steel). 
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5.2.5 SGK1 activity in the luminal epithelium abolished or attenuated expression 
of a subset of genes that are involved in uterine receptivity and decidualization  
The complete failure of implantation in response to increased endometrial SGK1 
activity prompted expression analysis of a panel of genes that confer uterine 
receptivity during the window of implantation in the mouse (4.5 D.P.C.). SGKS422D 
selectively abolished or attenuated the induction of leukemia inhibitory factor (Lif), 
heparin-binding EGF (Hbegf) and homeo box A10 (Hoxa10) (Fig. 5.5A -upper 
panel). The regulation of other implantation genes, perhaps more relevant for the 
post-implantation uterine response, such as bone morphogenetic protein 2 (Bmp2), 
Indian hedgehog (Ihh), and wingless-related MMTV integration site 4 (Wnt4) (Fig 5.5 
A -bottom panel) (340-342) were not significantly affected. In addition to α -ENaC, 
constitutive SGK1 activity at 4.5 D.P.C also up-regulated the expression of cystic 
fibrosis transmembrane conductance regulator (Cftr), a chloride channel implicated in 
in vitro fertilization treatment failure (343). This was also confirmed at protein level 
using Western blotting. 
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Figure 5.5 Analysis of endometrial receptivity genes.  
(A) Expression of murine Lif, Hbegf, Hoxa10, Bmp2, Ihh, and Wnt4 transcripts was 
determined in uterine horns 3 days after transfection (4.5 D.P.C) with a control plasmid 
(pcDNA3.1; n=6) or an expression vector that encodes the constitutively active mutant 
SGK1S422D (n=8). Expression levels were compared to those in wild type female animals 
(n=4) that were not mated. (B) SGK1 upregulates the expression of ENaC and cystic fibrosis 
transmembrane conductance regulator  CFTR) in the mouse uterus. E pression of α -ENaC 
and CFTR transcripts was determined in uterine horns 3 days after transfection (4.5 D.P.C) 
with a control plasmid (pcDNA3.1; n=6) or an expression vector SGK1S422D (n=6; upper 
panels). Parallel tissue sections were processed for Western blot analysis and immunoprobed 
for α -ENaC and Cftr  lower panels). β -ACTIN served as a loading control. Data are 
presented as means (± SD). Statistical significance was determined using Students t-test, *, 
P< 0.05; **, P < 0.01; ***, P < 0.001. (In vivo experiments were performed by Dr M 
Christian & Dr J Nautiyal). 
    Chapter 5: Results III 
 
 154 
5.2.6 Lack of SGK1 activity in decidualizing endometrium leads to pregnancy 
loss 
The transient loss of SGK1 activity in the luminal epithelium is essential to render the 
endometrium receptive to implantation. Accordingly, SGK1 should be dispensable for 
implantation but perhaps not for the subsequent decidual response and placenta 
formation. To test this hypothesis, I first determined the number of implantation sites 
and pups per litter in Sgk1
–/–
 female mice crossed with wild-type (WT) males and in 
WT females with Sgk1
–/–
 males, thereby negating the potential contribution of the 
offspring’s genotype (A kind gift from Prof F Lang, University of Tübingen, 
Germany). While the number of implantation sites at 8.5 D.P.C was maintained in 
Sgk1
−/−
 females, the average litter size was significantly reduced, indicating an excess 
of 30% spontaneous fetal loss (Fig. 5.6 A). Morphological assessment of implantation 
sites in Sgk1
–/– 
mice using Hematoxylin & eosin stained longitudinal tissue sections 
were obtained at 8.5 D.P.C from wildtype (WT) female mice crossed with Sgk1
–/–
 
males (left panels) and Sgk1
–/– 
females with WT males (right panels). In WT females, 
all embryos had differentiated into endoderm, mesoderm and ectoderm, with an 
amniotic cavity, amnion and chorion present, and an ectoplacental cone. Although 
orientation varies, the implantation sites appeared healthy. Based on serial 5 μm 
sections, the average implantation site in WT females measured approximately 325 
μm in width. In pregnant Sgk1–/– females, some embryos had differentiated almost as 
well as in WT females but most were small and underdeveloped. Based on serial 5 μm 
sections, implantation sites in Sgk1
–/–
 females measured between 150 and 210 μm. 
Occasional twin pregnancies were observed and several implantation sites were 
characterized by local bleeding, neutrophil aggregates and fetal demise (Fig 5.6 B).  
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Figure 5.6 Spontaneous pregnancy loss in Sgk1
−/−
 pregnant mice.  
(A) Mean (± SD) number of implantation sites at 8.5 D.P.C and pups per litter in 
Sgk1
−/− 
female mice crossed with WT males (n = 8) and WT females with Sgk1
−/−
 
males (n = 8). (B) H&E staining of implantation sites at 8.5 D.P.C in WT females 
crossed with Sgk1
−/− 
males and Sgk1
−/− 
female mice with WT males. The implantation 
sites in pregnant Sgk1
−/−
 female mice were invariably smaller, with evidence of early-
onset fetal growth retardation, bleeding and inflammation at the decidual-placental 
interface  arrows). Scale bar, 100 μm. Statistical significance was determined using 
Students t-test. **, P < 0.01). (In vivo experiments were performed by Dr G Puchchakayala 
& Dr M Föller and immunostaining was done in collaboration with Dr J Steel). 
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5.2.7 Increased cell death at the materno-fetal interface is associated with Sgk1
–/– 
mice 
Apoptosis is a physiological phenomenon at the feto-maternal interface (344, 345).  
To investigate whether apoptosis was increased in pregnant Sgk1
–/– 
mice parallel 
sections were subjected to terminal transferase-mediated dUTP nick end-labeling 
(TUNEL) (Fig 5.7 upper panels) and activated Caspase-3 staining (lower panels). The 
results indicate that the normal apoptotic responses at the fetomaternal boundaries are 
enhanced in pregnant Sgk1
–/–
 mice, especially at the site of bleeding (arrows). Insert 
in the top left panel shows positive TUNEL labelling in the mouse mammary gland 
(positive control). The overall increase in uterine cell death was confirmed by 
Western blot analysis of total uterine protein lysates for the expression of cleaved 
PARP1 (Fig 5.7 B). Thus, lack of SGK1 in the decidua of pregnant mice seems to 
trigger a series of pathological events that are akin to human miscarriage, including 
uterine bleeding, early-onset growth restriction and fetal demise. 
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Figure 5.7 Increased apoptosis at the feto-maternal interface in pregnant Sgk1
–/–
 
mice.  
(A) Tissue sections, obtained at 8.5 D.P.C from WT female mice crossed with Sgk1
–/–
 
males (left panels) and Sgk1
–/–
 females with WT males (right panels), were subjected 
to terminal transferase-mediated dUTP nick end-labeling (TUNEL; upper panels) and 
activated Caspase-3 staining (lower panels). The results indicate that the normal 
apoptotic responses at the fetomaternal boundaries are enhanced in pregnant Sgk1
–/–
 
mice, especially at the site of bleeding (arrows). Insert in the top left panel shows 
positive TUNEL labelling in the mouse mammary gland (positive control). (Scale bar 
100 μm). (B) Western blot analysis of total uterine protein lysates for the expression 
of cleaved PARP1. (In vivo experiments were performed by Dr G Puchchakayala & 
Dr M Föller and immunostaining was done in collaboration with Dr J Steel). 
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5.2.8 SGK1 expression response in vitro is impaired in RPL patients 
Early human pregnancy events cannot be studied directly, although the decidual 
response is recapitulated upon differentiation of primary HESCs. To examine the role 
of SGK1 in human pregnancy failure, HESCs were established from subjects with 
RPL and control subjects. Primary cultures were then decidualised with 8-Br-cAMP 
and MPA over a time course lasting 8 days and total RNA was extracted and 
subjected to qRT-PCR. SGK1 transcript levels in both groups were comparable in 
undifferentiated HESCs and increased upon decidualization in a time-dependent 
manner (Fig. 5.8). However, this increase was markedly blunted in the RPL group and 
by 4 d of differentiation, almost 258% lower compared to control cultures (P < 
0.001). 
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Figure 5.8 Lack of SGK1 transcripts in primary decidualizing HESCs 
established from women suffering from pregnancy loss  
(A) Primary cultures were established from women with RPL (n = 9) and from 
control subjects (n = 11). qRT-PCR was used to measure the expression levels of 
SGK1 transcripts in undifferentiated cultures (d0) and in cultures decidualized with 8-
Br-cAMP (cAMP) and medroxyprogesterone acetate (MPA) for the indicated time-
points. Transcript levels were normalized to the housekeeping gene L19 and 
expressed in arbitrary units (AU) using the standard curve method. The SGK1 
transcript levels between the clinical groups did not differ significantly (P >0.05) in 
undifferentiated HESCs. Horizontal bars indicate the median expression in each 
group. Note: logarithmic scale. Data are presented as means (± SEM). Statistical 
significance was determined using Mann Whitney U-test *** indicates P < 0.001. 
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5.2.9 SGK1 knockdown causes cell death 
To provide insight into the mechanism of pregnancy wastage, small interfering RNA 
(siRNA) was used to examine the functional consequences of SGK1 silencing on 
decidual cell function in primary HESC cultures. Knockdown was highly efficient 
(Fig. 5.9A), but there was degree of cell death upon SGK1 silencing in decidualizing 
but not undifferentiated cells. This was confirmed by immunoprobing of total cell 
lysates for cleaved poly(ADP-ribose) polymerase-1 (c-PARP-1), a marker of 
apoptosis (Fig. 5.9A). Oxidative stress is a major mechanism of endometrial cell 
death, especially in pregnancy (195). To determine if SGK1 regulates the cellular 
oxidation status, primary cultures were transfected with non-targeting or SGK1 
siRNAs and then decidualized for 72 hours, loaded with 2’,7’-Dichlorofluorescin 
diacetate (DCF; a cell permeable oxidation-sensitive fluorescence probe), and pulsed 
with 250 µM hydrogen peroxide.  
 
As shown in Fig. 5.9 B, the basal oxidation status in decidualizing cells was 
considerable higher upon SGK1 knockdown and the cells were less able to scavenge 
exogenous free radicals. Silencing was also confirmed using confocal microscopy. 
Primary HESCs cultured on chamber slides were transfected with either non targeting 
(NT) or SGK1 siRNA, decidualized for 72 h with cAMP and MPA, loaded with 
MitoTracker dye (red) and stained for SGK1 expression (green). The nuclei were 
visualized with DAPI (blue) (Fig 5.9 C). Note that the typical transformation of 
spindle-like fibroblast to more rounded decidual cells, with larger nuclei and more 
abundant cytoplasm, was maintained upon SGK1 knockdown.  
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Figure 5.9 Knockdown of SGK1 in endometrial stromal cells.  
(A) Primary HESC cultures were first transfected with either non-targeting (NT)- or 
SGK1-siRNA and then decidualized for 4 d and collected for qRT-PCR or western 
blot analysis. Total cell lysates were probed for SGK1 and cleaved-poly(ADP-ribose)-
polymerase-1 (cleaved PARP-1) expression. β -actin served as a loading control. (B) 
The oxidation status of decidualizing cells transfected with NT- or SGK1-siRNA, as 
determined before and after treatment with 250 μM H2O2 using 2’7’-
dichlorofluorescein. (C) In parallel cultures HESCs were stained with antibodies to 
SGK1 (green) MitoTracker dye (red) and DAPI (blue; nuclei) were analyzed by 
confocal microscopy.  Scale bar: 25 μm). ***, P< 0.0001 using Students t test.   
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5.2.10 SGK1 prevents oxidative cell death in decidualizing endometrium  
Compared with undifferentiated HESCs, decidual cells acquire a remarkable 
resistance to oxidative cell death (35). This is characterized by induction of various 
free radical scavengers, most notably superoxide dismutase 2 (SOD2), thioredoxin 
(TXN) and glutathione peroxidase 3 (GPX3), and partly due to the downregulation of 
the proapoptotic gene FOXO3a. Therefore, oxidative stress and alteration in the 
oxidative status of the cells may point towards an imbalance between the amount of 
endogenous ROS, and the antioxidant enzymes that are part of the cellular defence 
mechanism leading to cell death. Furthermore, evidence suggests that the 
transcription factor FOXO3a and some of the voltage-gated potassium channels are 
physiological substrates of SGK1 in vivo and exerts a protective role in oxidative 
stress situations (346).  
 
In agreement, qRT-PCR analysis revealed that SGK1 silencing in vitro perturbs the 
expression in decidualizing cells of several major free radical scavenging molecules, 
SOD2, TXN, peroxiredoxin-2 (PRDX2) and GPX3 (Fig 5.10 A). The expression of 
the same factors was significantly lower in decidualizing primary cultures from RPL 
patients compared with controls (Fig 5.10 B), although the difference was less 
pronounced compared with siRNA-mediated SGK1 silencing. Furthermore, mRNA 
expression of the murine homologs was also markedly lower in pregnant Sgk1-
deficient mice compared with WT controls (Fig 5.10 C).  
    Chapter 5: Results III 
 
 163 
 A    B    C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 SGK1 deficiency impairs antioxidant defences in decidual cells.  
(A) qRT-PCR was used to measure the expression levels of SOD2, TXN, PRDX2 and 
GLRX transcripts in primary HESC cultures first transfected with non targeting (NT) 
or SGK1 siRNA and then decidualized for 4 d (left panel). (B) Expression levels were 
also determined in decidualizing primary HESC cultures established from RPL and 
control subjects (middle panel). Horizontal bars indicate the median expression in 
each group. Note logarithmic y-scale (C) The same transcripts were also measured in 
uteri of pregnant Sgk1
–/–
 female mice crossed with WT males (n=6) and WT females 
with Sgk1
–/–
 males (n=6; right panel). Statistical significance was determined using 
Students t-test (Graphs in panel A&C; data are presented as means (± SD).) and Mann 
Whitney U-test (Graphs in panel B), * P < 0.05; ** P < 0.01; *** P < 0.001. (In vivo 
experiments were performed by Dr G Puchchakayala & Dr M Föller). 
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5.2.11 Catalase rescues decidual cells devoid of SGK1 from oxidative cell death. 
Decidualization of HESCs is dependent upon activation of the NADPH oxidase 
NOX-4–p22PHOX complex and endogenous free radical production (347). As SGK1 is 
essential for the induction of various reactive oxygen species scavengers in decidual 
cells, I inferred that unopposed endogenous pro-oxidant activity would be the primary 
cause of loss of cell viability upon knockdown of this kinase. I speculated that 
expression of a potent free radical scavenger would rescue decidual cells devoid of 
SGK1 from oxidative cell death. This was indeed the case. As shown in Fig. 5.11, 
transfection of an expression vector that encodes catalase, a highly efficient enzyme 
that functions to catalyze the decomposition of hydrogen peroxide to water and 
oxygen (348), rescued decidualizing HESCs from oxidative cell death caused by 
SGK1 knockdown, as measured by Western blot analysis of c-PARP-1 expression 
(Fig. 5.11 A) and in a cell viability assay (MTS-assay) (Fig 5.11 B), demonstrating 
that expression of catalase not only reverses the oxidative apoptosis in SGK1-
deficient decidual cells but also promotes proliferation. These results were confirmed 
by flow cytometry of ethanol-fixed propidium iodide-stained cells (Fig 5.12).  
  
    Chapter 5: Results III 
 
 165 
A            B      
 
 
 
 
 
Figure 5.11 Co-transfection with catalase rescues decidual cells devoid of SGK1 
from oxidative cell death.  
(A) Primary HESC cultures were first transfected with non-targeting (NT) or SGK1 
siRNA or in combination with catalase and then decidualized for 4 days. Cultures 
were harvested for Western blot analysis. Total cell lysates were probed for SGK1 
and cleaved PARP expression. -Actin served as a loading control. (B) Primary 
HESC cultures, transfected as indicated, were plated in 96-well plates and 
decidualized with cAMP and MPA for the indicated time points. Cell viability, 
assessed by MTS assay, was normalized to the viability of undifferentiated cells. Data 
are presented as means (± SD). 
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Figure 5.12 Overexpression of catalase rescues decidualizing cells from oxidative 
cell death induced by SGK1 silencing.  
Primary HESC cultures, first transfected as indicated, were decidualized with cAMP 
and MPA for 2, 4, or 8 d. The percentage of dead or dying cells (<2N; indicated 
within each figure on the left) and viable cells (G0/G1, S, and G2/M; indicated within 
each figure on the right) was determined by flow cytometry of ethanol-fixed 
propidium iodide-stained cells. 
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5.2.12 Loss of SGK1 impairs the endometrial decidual response 
I then assessed the decidual response by monitoring the expression of three highly 
induced decidual marker genes, IGFBP1, TIMP3, and LEFTY2 (57, 349-351). In 
primary cultures, SGK1 knockdown did not negate but deregulated the induction of 
these markers (Fig 5.13 A), characterized by lower expression of LEFTY2 and 
IGFBP1 but increased levels of TIMP3, a gene transiently induced upon HESC 
differentiation. Again, this deregulated pattern of expression was recapitulated in 
decidualizing primary cultures from RPL subjects (Fig 5.13 B) with the exception of 
Igfbp1, in pregnant Sgk1
–/–
 mice. Notably, increased Igfbp1 expression in vivo does 
not necessarily infer a heightened decidual reaction but may reflect a compensatory 
maternal response to a suboptimal or failing pregnancy (Fig 5.13 C). In agreement, 
expression of Prl8a2, a mouse decidual marker gene related to human PRL, was 
significantly lower in Sgk1
–/–
 animals (Fig. 5.13 D) though levels of Prok1 did not 
change (data not shown). 
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Figure 5.13: SGK1 deficiency deregulates the expression of decidual markers in vitro and in 
vivo.  
(A) Expression of IGFBP1, TIMP3, and LEFTY-A in primary HESCs first transfected with non 
targeting (NT) or SGK1 siRNA and then decidualized with cAMP and MPA for 72 h. Three 
independent primary cultures were subjected to qRT-PCR analysis. The results denote means (± 
SD). (B) Expression of the same decidual markers was also determined in undifferentiated HESCs 
(0 d) or cultures decidualized with cAMP and MPA for 8 d. Primary cultures were established 
from RPL individuals and control subjects. Horizontal bars indicate the median expression in each 
group. (Note: logarithmic y-axis). (C) The mouse homologues were also measured in uteri of 
pregnant Sgk1
–/–
 female mice crossed with WT males (n=6) and WT females with Sgk1
–/–
 males 
(n=6). The expression levels of Prl8a2, a mouse decidual marker gene was measured. Statistical 
significance was determined using Students t-test (means ± SD; Graphs in panels A, C & D) and 
Mann-Whitney U-test (Graphs in panel B) *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 
0.0001. (In vivo experiments were performed by Dr G Puchchakayala & Dr M Föller). 
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5.2.13 SGK1 expression and activation is regulated by LEFTY-A. 
 Previously it was shown that unexplained infertility has also been linked to impaired 
endometrial expression of LEFTY2, encoding LEFTY-A, a member of the 
transforming growth factor-β superfamily that antagonizes Nodal signalling (352). 
Like SGK1, endometrial LEFTY-A secretion is markedly reduced during the window 
of implantation and in vivo gene transfer leads to implantation failure in mice (351, 
353). Analysis of timed endometrial biopsies confirmed higher LEFTY2 transcript 
levels in the infertile group but also revealed lower expression in RPL subjects when 
compared to fertile controls (Fig 5.14 A). Furthermore, treatment of Ishikawa cells, a 
widely used endometrial epithelial cell line, with recombinant LEFTY-A not only 
rapidly increased SGK1 transcript (Fig 5.14 B) and protein levels (Fig 5.14 C) but 
also enhanced phosphorylation of this kinase. Conversely, SGK1 deficiency in 
decidualizing stromal cells interferes with LEFTY-A expression (Fig 5.13 A). Thus, it 
appears likely that perturbation of a broader regulatory circuit in the endometrium, 
involving LEFTY-A and SGK1, underpins reproductive failure. 
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Figure 5.14 LEFTY-A regulates SGK1 expression and activation.  
(A) Timed mid-secretory endometrial biopsies from RPL subjects (n=7), fertile 
controls (FER; n=7), or unexplained infertility (INF; n=7) were analyzed for the 
expression of LEFTY-2 transcripts using qRT-PCR. Transcript levels were 
normalized to the housekeeping gene L19. (Note: logarithmic scale). (B) The 
expression of SGK1 transcripts was determined using Ishikawa cells, treated for 2 to 
24 h recombinant LEFTY-A (5 ng/ml), by qRT-PCR. (C) Ishikawa cells were treated 
with recombinant LEFTY-A (5 ng ml-1) at the indicated time-points. Total (t-) and 
phosphorylated (p-) SGK1 levels determined by Western blot analysis. Statistical 
significance was determined using Students t-test, **, P < 0.01; ***, P < 0.001. 
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5.3 Discussion 
In this chapter I demonstrate that deregulation during the secretory phase of the cycle 
of a single kinase, SGK1, in the endometrial luminal epithelium or decidualizing 
stroma is associated with implantation failure and miscarriage, respectively. Further, 
the mechanisms by which SGK1 dysregulation causes these reproductive phenotypes 
appear very different, in keeping with the multifaceted function of this kinase.  
 
As reported previously (129), I also found that endometrial SGK1 expression, at 
mRNA and protein level, as well as activity is enhanced in women experiencing 
unexplained infertility. SGK1 is rapidly induced in response to progesterone signaling 
(136, 354), although a transient decline in expression in luminal epithelial cells 
frames the limited period of endometrial receptivity, at least in mice (355). I 
demonstrated that a sustained increase in SGK1 activity, confined to the luminal 
epithelium and communicating proximal glands, is sufficient to abolish implantation 
and to shrink the entire uterus, reflected at the cellular level by a marked decrease in 
glandular area and epithelial cell width. Cyclic regulation of the fluid environment in 
the uterine lumen is essential for key reproductive events, including sperm transport, 
embryo development and transport, and implantation (356-359). Oestrogens cause 
fluid secretion whereas progesterone promotes fluid absorption, mediated by 
amiloride-sensitive ENaC expressed on the apical surface of luminal and glandular 
epithelial cells. Thus, a sustained increase in SGK1 activity, which in addition to 
ENaC activates a variety of other ion channels, could lead to implantation failure by 
causing premature uterine ‘closure’, characterised by complete apposition of the 
epithelium of the opposing uterine walls.  
 
Other mechanisms may, however, be equally important. For example, it appears likely 
that the reorganization of the actin cytoskeleton that underpin the morphological 
changes induced by SGK1 will have a profound effect on the expression and signal 
transduction of adhesion molecules that control embryo-maternal interactions. 
Moreover, implantation, at least in rodents, involves apoptosis of uterine epithelial 
cells in response to signals derived from an implanting blastocyst, a process referred 
to as displacement penetration (360). Thus, continuous SGK1 activity during the 
implantation window possibly renders the luminal epithelium resistant to these 
embryo-derived pro-apoptotic signals.  
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Once the luminal epithelium is breached, survival of the conceptus is strictly 
dependent on the maternal decidual response and the formation of a functional 
placenta. In humans, the feto-maternal interface is characterised by an abundance of 
macrophages and specialized uterine natural killer cells, deep interstitial and 
intravascular trophoblast invasion, and transformation of spiral arteries into low-
resistance, high-capacity vessels (361, 362). Placentation in mice is comparable, 
although trophoblast invasion and vascular remodelling are less pronounced. 
Inflammation and profound changes in local perfusion and oxygen tension at the feto-
maternal interface inevitably generate ROS, capable of damaging nucleic acids, 
proteins and lipids if levels surpass the cellular antioxidative defenses. Not 
surprisingly, HESCs become remarkably resistant to oxidative stress upon 
differentiation in decidual cells. This increased resistance in decidualizing HESCs is 
partly attributable to the induction of various free radical scavengers but also reflects 
silencing of stress-activated JNK signalling and FOXO3a expression, a pro-apoptotic 
transcription factor that mediate ROS-dependent apoptosis in undifferentiated HESCs 
(363-365).  
 
I provide unequivocal evidence that SGK1 activity regulates the redox status and 
antioxidant defenses in decidualizing HESCs. Unexpectedly, SGK1 silencing was 
sufficient to cause oxidative cell death in decidualizing cells maintained under 
standard culture conditions. Similarly, while Sgk1
-/-
 female are fertile, there was 
evidence of fetal resorption and reduced litter sizes when the animals were kept under 
standard husbandry conditions.  
 
Interestingly, in addition to a host of antioxidant defence genes (Sod2, Txn, Gpx3, 
Prdx2, Glrx), the expression of Prl8a2, which encodes for DPRP produced by the 
murine but not human decidua, was also impaired in pregnant Sgk1
-/-
 animals. 
Homozygous Prl8a2
-/-
 mice are fertile and have normal litter sizes (366). However, a 
reduction in ambient oxygen levels during pregnancy causes massive destruction of 
feto-maternal interfaces in DPRP-deficient but not WT mice, highlighting the 
importance of this decidual cytokine, as well as SGK1, in protecting pregnancy from 
environmental insults. The corollary of these observations implies that impaired 
SGK1 expression in the decidua of early pregnancy predisposes for subsequent 
oxidative damage, cell death, focal bleeding and, ultimately, pregnancy loss.  
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Importantly, these observations indicate that SGK1 expression is impaired in cycling 
mid-secretory endometrial samples, and in differentiating primary HESC cultures 
established from biopsies taken randomly during the cycle (367), raising the 
possibility that women at risk of pregnancy failure can be identified and treated prior 
to conception.  
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6.1 General summary  
In this thesis, I provide several lines of evidence indicating that decidualization 
establishes paracrine gradients that control differentiation in a distinct and temporal-
spatial order that underpins implantation. Failure to acquire an adequate decidual 
response could facilitate delayed implantation of abnormal embryos and compromise 
subsequent placental formation. While many studies strongly suggest that inadequate 
embryo selection at the time of implantation is causal to pregnancy loss, the role of 
the decidualizing stromal cells in this process had not yet been investigated. The data 
presented in this thesis suggests that endometrial programming in preparation of 
pregnancy is both quantitatively and qualitatively different in RPL, characterized by 
impaired decidualization of resident stromal cells, prolonged endometrial receptivity 
and a dysregulated maternal response to embryonic signals. Preliminary data indicates 
that uterine receptivity is controlled by the activation of feedback loops in 
decidualizing stromal cells underlying the luminal epithelium that trigger the 
sequential expression of pro- and anti-inflammatory gene networks and deregulation 
of IL-33/ST2 axis in HESCs is associated with a non-supportive pregnancy. Further, I 
present evidence that endometrial SGK1 governs several cellular functions in 
decidualizing HESCs critical for the integrity of the materno-fetal interface and SGK1 
is required to be downregulated in the luminal epithelium during the period of 
receptivity in order for implantation to occur.  
 
6.2 The “Selection Failure” hypothesis.  
Compared with controls, RPL was associated with significantly higher endometrial 
PROK1 mRNA levels and lower PRL transcript levels. Intuitively, the results seem to 
suggest that the regulatory signals that control differentiation of endometrial stromal 
cells into specialized decidual cells are perturbed in RPL. Thus, theoretically, 
disruption in one or more of the endocrine or paracrine signals involved in regulating 
the decidual phenotype could be causal to RPL. Increased endometrial PROK1 and 
decreased PRL levels fit well with the concept that enhanced uterine receptivity but 
decreased embryo recognition. I propose that there could be a defect or failure in 
“selection” and this may underpin R L. 
 
As mentioned briefly in the Introduction, PRL is a peptide hormone and cytokine, 
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involved in regulating growth and differentiation of a number of epithelio-
mesenchymal organs. Secretion of PRL, under the control of the tissue specific 
decidual PRL promoter, indicates the extent of stromal cell differentiation in human 
endometrium (76, 368). PRL secretion is induced by progesterone, insulin, IGF-1 and 
PRL releasing factor (76). Activation of the PKA pathway through cAMP further 
enhances the expression of this decidual marker.  
 
PROK1 is an angiogenic and permeability-enhancing factor expressed in the 
endometrium of women of reproductive age. PROK1 displays differential expression 
across the menstrual cycle, with elevation in the secretory phase. Moreover, 
prokineticin receptor expression coexists with PROK1, but this expression does not 
change across the menstrual cycle. Implantation requires communication between a 
receptive endometrium and a healthy blastocyst. This maternal–embryonic cross-talk 
involves local mediators within the uterine microenvironment and PROK1 has been 
implicated in the regulation of a host of implantation-related genes (286) including 
LIF, which has been shown to promote adhesion of trophoblast cells to extracellular 
matrix proteins, in vitro (286). Previous studies suggest that PROK1 can play an 
important role in implantation and early pregnancy by inducing vascular remodeling 
and increasing vascular permeability. By activating the calcineurin/NFAT pathway to 
induce the expression of IL-8 (369, 370) possibly creating a pro-inflammatory pro- 
angiogenic environment for an implanting blastocyst. Further work needs to be done 
to verify if this pathway is indeed implicated in RPL. 
 
Angiogenesis is a highly regulated and complex process dependant on numerous 
angiogenic and angiostatic signals, including integrins, junctional molecules, 
angiopoietins, growth factors, cytokines and chemokines (371). Briefly, it comprises a 
series of steps starting with vasodilatation in response to metabolic cues, primarily 
hypoxia. This leads to increased permeability and destabilization of the vessel wall 
allowing infiltration of angiogenic factors that activate receptors on endothelial cells 
to release proteases that degrade the ECM. Angiogenic factors also stimulate 
endothelial cell proliferation and migration, finally leading to lumen formation (371).  
 
At the end of the first trimester of pregnancy, the feto-placental unit is exposed to a 
three-fold increase in prevailing oxygen concentrations due to the onset of maternal 
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blood flow (291). First trimester placental tissues are highly sensitive to oxygen due 
to the low concentrations of the principal antioxidant enzymes. In miscarried 
pregnancies, the onset of the circulation is both premature and disorganized, and 
levels of placental oxidative stress and trophoblast degeneration are much higher than 
normal (372). Thus in keeping with other studies (164), the results suggest that 
increased levels of PROK1 can lead to over excessive preimplantation angiogenesis 
and that decrease of PRL, impairs the decidual response leading to oxidative stress 
resulting in miscarriage.  
 
A recent study on endometriosis, demonstrated that purified eutopic endometrial cells 
from affected patients continue to respond differently to hormonal stimuli when 
compared with primary cultures from disease-free controls (269). To investigate 
whether cultures from RPL and non-RPL patients respond differently, endometrial 
samples taken randomly in the cycle, the stromal cells, the cultures passaged the 
cultures once and then decidualized the cells in vitro in a time course lasting 8 days. 
After 4 days of differentiation, the rise in PRL transcript levels was several 
magnitudes higher in the control group when compared with RPL samples. PROK1 
levels continued to rise with comparable kinetics in all decidualizing cultures until 
day 8 when expression in the control but not RPL group declined markedly. Thus, the 
perturbed PROK1 and decidual PRL expression in secretory endometrium in vivo was 
perfectly recapitulated upon decidualization in primary cultures from RPL patients, 
even when the cultures were established from biopsies taken randomly in the cycle.  
 
In addition to attenuated PRL production and prolonged and enhanced PROK1 
expression, RPL was found to be associated with a complete dysregulation of both 
markers upon treatment of primary cultures with hCG, a glycoprotein hormone 
abundantly expressed by the implanting embryo. The observation that hCG 
antagonizes decidual PRL expression has also been reported by others (270), yet the 
physiological consequences of this response in early pregnancy remain to be clarified. 
However, the inhibitory effect of hCG on PRL mRNA expression was not observed in 
primary cultures established from patients with RPL. Taken together, there appears to 
be a coordinated system, regulating human implantation and early pregnancy 
development, whereby, developmentally competent blastocysts producing high local 
hCG-concentrations may be able to modulate their individual window of receptivity. 
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Moreover, implantation, at least in rodents, involves apoptosis of uterine epithelial 
cells in response to signals derived from an implanting blastocyst, a process referred 
to as displacement penetration (360). New data suggests that hCG might improve the 
uterine environment upon implantation by suppressing apoptotic responses in the 
maternal decidua under oxidative stress (373, 374). First, hCG augments SOD2 
expression via FOXO1, thereby enhancing the free radical–scavenging potential of 
decidualized HESCs. Second, hCG antagonizes Bax expression and induces Bcl-2 
under oxidative stress (373, 374). My findings suggest that, rather than being caused 
by disturbances in maternal or embryonic signals, aberrant decidualization of HESCs 
disables materno-embryo signaling, thereby deregulating the expression of decidual 
marker genes. In other words, RPL appears to be a consequence of the intrinsic failure 
of endometrial stromal cells to close the window of receptivity and to express an 
appropriate decidual phenotype.  
 
It has been previously reported that there is an association between implantation 
occurring later in the luteal phase and pre-clinical pregnancy loss (104). Increasing 
evidence suggests that a less stringent ‘selection’ process within the endometrium will 
allow embryos of low viability to implant, presenting as a clinical pregnancy before 
miscarrying (110, 287). This concept was first proposed by Quenby et al., (375), 
based on the observation that the endometrium of RPL patients expresses lower levels 
of MUC1, an anti-adhesion molecule that contributes to the barrier function of 
luminal epithelium (376). The concept of ‘selection’ is further supported by the recent 
observation of a reduced interval between pregnancies in women with RPL compared 
to that reported by normally fertile women (216). Consistent with this concept, I show 
that HESCs of women with RPL demonstrate abnormal decidualization in vitro. This 
phenotype may result in the window of implantation being extended, while reducing 
the ability of the decidualized endometrium to be ‘selective’ in response to embryo 
quality (5).  
 
In keeping with this notion, decidualized HESCs from fertile women were able to 
adjust their migratory activity in response to the quality of an embryo. RPL derived 
HESCs from RM women failed to discriminate between high- and low-quality 
embryos (377). This inability to discriminate with respect to migration between low- 
and high-quality embryos may be regarded as a failure of nature’s quality control and 
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the hypothesis of “Selection Failure” for women with R L is further substantiated 
(215). This hypothesis proposes that ‘selection failure’ results in the endometrium 
being super-receptive. Thus, preventing the endometrium to select high- from low-
quality embryos leading to the implantation of low-quality embryos and, as their 
development fails, leading to pregnancy loss (Fig 6.1). 
 
Clinically, lack of embryo selection often manifests in rapid conceptions followed by 
repeated aneuploidic pregnancy loss. However, failure to mount an adequate decidual 
response will invariably compromise placenta formation (361, 364), leading to 
pregnancy failure irrespective of the fetal karyotype. By restricting the window of 
implantation, the continuously changing endometrial environment is aligned to meet 
the requirements of an implanting blastocyst. Prolonged or unfettered endometrial 
receptivity carries an obvious risk of implantation of developmentally delayed or 
compromised embryos (216). Further, asynchrony between endometrial and embryo 
development in early pregnancy may trigger a spectrum of pathological events, 
leading to miscarriage or predispose for obstetrical complications associated with 
defective placentation, such as pre-eclampsia and fetal growth restriction (5, 104).  
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Figure 6.1: Selection Failure hypothesis 
In order for optimal female reproductive investment and to maximize offspring 
fitness, the endometrium requires to have a “quality control” mechanism to prevent 
implantation of developmentally incompetent embryos. In some women, moderate 
and severe subfertilities defined by MFRs of 5 and 1%, respectively, may actually 
have low receptivity (Yellow) and high selectivity of embryo quality (Blue) 
accounting for their infertility. At the other end of the spectrum, superfertile couples 
achieve 94 and 100% of pregnancies within 3 and 6 months, respectively. These 
women may have a low selection threshold (Orange), thereby facilitating delayed 
implantation of abnormal embryos accounting for their heightened receptivity or 
“superfertility” (Green). Disturbances in the decidual process are likely to contribute 
to dysfunction of implantation and placentation, with implications for early pregnancy 
loss and disturbed placental and fetal development.  
 
  
 Receptivity 
 High receptivity 
(Green) 
 Low selectivity 
(Orange) 
 Presents as RPL 
 Low receptivity 
(Yellow) 
 High selectivity 
(Blue) 
 Presents as infertility  
 
Selectivity 
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However, even after three consecutive miscarriages, many RPL patients will 
ultimately achieve a successful pregnancy (213), suggesting that this intrinsic failure 
may relate to a modifiable programming event in endometrial cells, as suggested by 
the ‘menstrual preconditioning’ hypothesis (45). Sustained programming of cellular 
responses likely involves epigenetic changes like DNA methylation or post-
translational histone tail modifications. Interestingly, inflammatory signals are 
important epigenetic modifiers (217), which raise the possibility that the tissue trauma 
associated with menstrual events between pregnancies may provide cues that 
dynamically modulate subsequent decidual responses in the endometrium (218). In 
fact, the ability of local tissue injury to modify subsequent decidual responses has 
been long recognized and increasingly exploited for clinical purposes. Karow et al., 
(220) reported that an endometrial biopsy decreases subsequent miscarriage rates, 
especially in subfertile patients, a finding confirmed in several more recent 
observational studies (221, 222). Additionally, albeit indirect, evidence to support the 
beneficial effect of endometrial injury on successful implantation comes from the 
observation that scar tissue from previous endometrial surgery (or Cesarean section) 
becomes an attractive site of implantation. Taken together, these reports suggest that 
it is possible that the success of implantation is secondary to the development of an 
injury-induced inflammatory reaction (378). 
 
6.3 Transient inflammatory response renders the endometrium receptive  
Menstrual preconditioning and the repeated inflammatory events and tissue trauma 
associated with each cycle may be crucial to sensitize the endometrium to 
environmental signals and coordinate a precise spatio-temporal decidual response (45)  
Receptivity is a transient endometrial state and dependent on paracrine signals from 
decidualizing stromal cells underlying the luminal epithelium. A recent study 
demonstrating that progesterone, acting on its receptor in stromal cells, induces the 
basic helix-loop-helix transcription factor Hand2 (379). Hand2 allows neighboring 
epithelial cells to exit the cell cycle and to enter a differentiation pathway leading to 
the window of implantation (379). Thus, sequential activation of bidirectional 
paracrine signal cascades between the stromal and epithelial compartments within the 
endometrium triggers the receptive endometrial phenotype and couples it to the 
decidual response upon embryo implantation (380, 381). I postulated that bi-phasic 
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regulation as seen PROK1 profile could extend to other inflammatory mediators 
expressed by differentiating HESCs. Mounting a highly coordinated but transient 
inflammatory response could render the endometrium receptive. 
 
HESCs are shown to rapidly release IL-33, a key regulator of host defense and innate 
immune responses, upon decidualization. In parallel, differentiating HESCs 
upregulate the IL-33 transmembrane receptor ST2L and a host of other pro-
inflammatory mediators before mounting a profound anti-inflammatory response that 
includes downregulation of ST2L and increased secretion of the soluble decoy 
receptor sST2. Only during the transient pro-inflammatory phase of the decidual 
process did HESCs secrete factors permissive of embryo implantation in mice. IL-33 
knockdown in HESCs deregulated this inflammatory response and exposure of mouse 
uteri to conditioned media from these cultures prior to embryo transfer caused 
implantation failure and early pregnancy loss. Furthermore, the sequential activation 
of the IL-33/ST2L/sST2 axis was disordered in differentiating endometrial cultures 
established from women suffering RPL and associated with a prolonged but non-
supportive pro-implantation response.  
 
My findings show that uterine receptivity is controlled by the activation of 
autoregulatory feedback loops in decidualizing stromal cells underlying the luminal 
epithelium that trigger the sequential expression of pro- and anti-inflammatory gene 
networks. Decidualizing HESCs mount a highly coordinated but transient 
inflammatory response that renders the endometrium receptive. Failure of HESCs to 
constrain this pro-inflammatory response prolongs the window of implantation and 
inflammatory cells resident in the uterus or recruited in response to decidualization 
could participate in the determination of pregnancy progression. 
 
6.4 Mechanism of reproductive failure: role of endometrial SGK1 
Despite decades of investigation, a clear mechanistic understanding of how the uterus 
supports implantation and maintains pregnancy is still lacking, although numerous 
putative markers of receptivity to embryo implantation have been proposed 
(Chapter1: Table 1.1 & 1.2), none of these have then successfully been implicated in 
human reproductive failure. 
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My results show unequivocally that manipulation of SGK1, in the uterus is sufficient 
to trigger a series of pathological events, leading to either implantation failure or 
pregnancy loss. The first evidence to implicate SGK1 in implantation failure came 
from the microarray screen of mid-secretory endometrial biopsies from fertile women 
and patients suffering from unexplained infertility (129). SGK1 is rapidly induced in 
response to progesterone signaling (129). A transient decline in endometrial SGK1 
expression and activity in luminal epithelial cells frames the window of receptivity in 
fertile women. In unexplained infertility, luminal SGK1 activity remains high 
throughout the implantation period (129) whilst in women who experience RPL, 
expression and activity of SGK1 is much lower when compared to the controls. 
 
SGK1 is a key regulator of fluid transport over mammalian epithelia, including the 
kidney (223). It exerts this function by phosphorylating and inhibiting the ubiquitin 
ligase NEDD4-2, which in turn enhances the expression of ENaC and other ion 
transporters (223, 382). Consequently, the sustained SGK1 activity in the luminal 
epithelium during the implantation window perturbed uterine osmoregulation, 
characterized at the cellular level by a marked decrease in glandular area and 
epithelial cell width (305). In fact, numerous solute and ion channels are regulated in 
the human endometrium across the cycle but surprisingly little is know about their 
function in the implantation process (137, 383). Besides its impact on trans-luminal 
fluid transport, other mechanisms contribute to SGK1-mediated implantation failure. 
For example, constitutive SGK1 activity interferes with the expression of key 
molecules that control embryo-maternal interactions, including Lif, Hb-egf, and 
Hoxa10 (305). (137). SGK1 functions downstream in the phosphatidylinositol-3-
kinase (PI3K) cascade and is implicated in cell survival responses (241). Thus, 
continuous SGK1 activity during the implantation window possibly renders the 
luminal epithelium resistant to embryo-derived pro-apoptotic signals. 
 
Relative SGK1 deficiency is a hallmark of the mid-secretory endometrium of patients 
suffering recurrent pregnancy loss (305). The consequences of this are two-fold. First, 
lack of SGK1 activity in the luminal epithelium seems to negate its barrier function, 
which in turn may increase the likelihood of implantation of developmentally 
abnormal embryos. Second, differentiation of stromal cells into specialized decidual 
cells is associated with a gradual reduction in AKT phosphorylation and a reciprocal 
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induction in SGK1 expression and activity (305). This transition is impaired in 
decidualizing stromal cells of RPL subjects, even when purified and differentiated in 
culture. Inflammation and vascular changes at the feto-maternal interface inevitably 
generate ROS, which cause indiscriminate damage if levels surpass cellular anti-
oxidative defences (347). Not surprisingly, the decidual cells surrounding the early 
pregnancy sac are remarkably resistant to oxidative stress, partly caused by the 
induction of various free radical scavengers (28) and partly by the silencing of stress 
signaling pathways that mediate ROS-dependent apoptosis (195).  
 
SGK1 in decidualizing cells controls the induction of a host of antioxidant defence 
genes, including GPX3, SOD2, TXN, PRDX2 and GLRX (305). Consequently, a 
relative lack of SGK1 activity leads to cellular oxidation, perturbed redox signaling, 
and increased vulnerability to environmental stress signals (305). This pathological 
pathway is recapitulated upon Sgk1 ablation in mice. Female Sgk1-null mice are 
fertile and embryos breach the luminal epithelium unhindered. However, induction of 
antioxidant defence genes in early pregnancy is grossly disrupted, resulting in 
bleeding at a number of implantation sites, early-onset fetal growth restriction and 
fetal demise (305). However, the mechanistic underpinnings of these phenotypes 
associated with deregulation of SGK1 expression remain unknown and further studies 
are required. 
6.4 Concluding remarks 
Reproduction in humans is unique in two major aspects. First, the incidence of 
chromosomally abnormal and developmentally compromised human pre-implantation 
embryos is exceptionally high and, second, the uterus decidualizes spontaneously 
each cycle, a process responsible for the menstrual shedding of the endometrium in 
the absence of a viable pregnancy. These reproductive traits are in fact functionally 
linked, with the decidual process enabling the mother to limit investment in 
compromised pregnancies.  
 
Asynchrony during decidualization can lead to a cascade of events resulting in 
pregnancy complications. In this thesis I have provided fundamental insights into 
mechanisms, which control receptivity and the decidual response. I demonstrate that 
failure of the endometrium to acquire a receptive phenotype can result in infertility. 
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Conversely, RPL is associated with impaired decidualization prolonged endometrial 
receptivity, and pathological ‘superfertility’.  
 
Acknowledging a quality control function within the endometrium might change the 
commonly held view that in women, all pregnancy losses are ‘pathological’. Instead, 
perhaps immune-mediated loss in certain circumstances is a normal and valuable 
aspect of optimal reproductive function. A revised paradigm in our thinking about 
infertility and miscarriage might help guide research on these conditions and shed 
new light on their clinical management. For example, it will be important to 
determine whether repeated unexplained miscarriage in some women reflects a 
reduced quality control threshold that enables poor quality pregnancies to progress 
beyond inbuilt checkpoints, or alternatively whether thresholds are set too high in 
some women.  
 
Though my work has answered some important questions many new questions arise. 
Cellular ‘memory’ suggests that the endometrial decidual response is subject to 
epigenetic programming in humans (361), which in turn raises the possibility how the 
use of profiling of DNA or histone modifications prior to conception could be used to 
develop and monitor the effectiveness of medical interventions for RPL. Secondly, 
how stem cells in the endometrium alter the responsiveness to receptivity and 
decidualization? And the role of the other immune cells in the endometrium and how 
their contribution plays a role in the maintenance of pregnancy.  
 
Many RPL patients receive either no treatment or are treated empirically with a 
variety of drugs, albeit with little or no evidence of clinical efficacy. Moreover, drug 
intervention in early pregnancy is highly restricted because of teratogenic concerns. 
These findings raise the possibility that, by defining the mechanisms underpinning the 
endometrial phenotype in RPL, biomarker and/or strategies can be developed to 
predict and prevent pregnancy complications prior to conception. Such pre-pregnancy 
strategy has potentially far-reaching consequences for the management of RPL 
patients and, possibly, of women at increased risk of late obstetrical complications 
associated with defective placentation, such as pre-eclampsia, fetal growth restriction 
and preterm birth (125). Combined with an alarming rise in maternal co-morbidities 
that impact on fetal wellbeing and programming in utero, such as obesity and 
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gestational diabetes, the full ramifications of today’s failure to invest in strategies that 
improve pregnancy outcome will only become apparent in decades to come (384). 
Addressing this exigent challenge starts with the identification of key uterine 
regulators that can be targeted to restore fertility and / or to prevent pregnancy 
complications (125).  
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6.5 Future work  
Although the endometrial luminal epithelium is the primary barrier in the 
implantation process, the progesterone responses in this cellular compartment that 
underpin the receptive phenotype are mediated by signals derived from the underlying 
stromal cells. Moreover, although dysregulation of epithelial receptivity markers may 
account for the excess of genetically abnormal pregnancies in RPL patients, it does 
not explain why many affected women will experience a mixture of chromosomal and 
non-chromosomal losses. 
 
The menstrual cycle not only results in cyclical remodeling of the endometrium but 
also in a remodeling of the chromatin landscape. Epigenetics has a paramount role in 
development and differentiation and is associated with many diseases such as cancers 
and endometriosis. Epigenetic effectors regulate the epigenome in different ways. 
They can act either directly (i.e. DNMTs, histone modifying proteins) or indirectly 
such as cofactors which can recruit the modifiers or act as stabilizers and reinforce the 
interaction between enzymes and the chromatin. Chromatin associated proteins and 
the epigenetic marks themselves are often docking stations that facilitate binding to 
the chromatin or hamper it, possibly by causing steric hindrance. A more accurate 
insight in the understanding of epigenetic changes during decidualization and the 
expression profile of epigenetic effectors in health and in disease is essential for the 
identification of biomarkers, possible causes and, perhaps in not a very distant future, 
possible cures of numerous reproductive disorders. 
 
One in seven couples have difficulties conceiving and in excess of 30,000 IVF 
treatment cycles fail annually in the UK alone, usually because of embryo 
implantation failure. Approximately 15% of clinically recognized pregnancies, 
conceived spontaneously or not, miscarry. Together with pre-clinical losses, the true 
incidence is closer to 30-50%, rendering miscarriage the most common complication 
of pregnancy. Recurrent pregnancy loss (RPL), defined as three or more consecutive 
miscarriages, is a prevalent disorder that affects 1-2% of couples. Beside the physical 
trauma, miscarriage is associated with considerable psychological morbidity. It is 
increasingly accepted that many obstetrical complications originate from an adverse 
uterine environment during the peri-implantation period. Yet, little or no progress has 
been made over the last few decades in preventing obstetrical disorders associated 
   Chapter 6: General Summary 
 
 188 
with defective placental function, such as fetal growth restriction and preeclampsia. In 
the UK, 10% of babies are born prematurely, many requiring intensive care and 
having long-term health problems. In addition, there is an alarming rise in maternal 
co-morbidities that impact on fetal wellbeing and programming in utero, such as 
obesity and gestational diabetes. Thus, investment in reproductive health is paramount 
to prevent chronic ill health in future generations. The development of new strategies 
that overcome reproductive failure and improve pregnancy outcome requires in-depth 
understanding key uterine regulators that control early implantation events. One such 
uterine key regulator, implicated in both infertility and miscarriage, is the serum- and 
SGK1. 
 
Increased SGK1 activity in vivo resulted in enhanced expression and activity of the 
epithelial sodium channels, mediated by the down-regulation of its the ubiquitin-
protein ligase Nedd4-2. This in turn perturbed uterine fluid handling and completely 
abolished embryo implantation. Further investigation in to the deregulation of ion 
channels, carriers and pumps underpinning SGK1-dependant implantation failure 
warrants further investigation and its relevance to female infertility. Implantation was 
not impaired in Sgk1-deficient mice, although there was evidence of bleeding and 
inflammation at the feto-maternal interface in early pregnancy and subsequent fetal 
demise. RPL in patients was also associated with lower SGK1 induction in 
decidualizing human endometrial. Preliminary evidence suggests that deregulation of 
SGK1 activity in luminal epithelium leads to hyper-influx recruitment of specialized 
uNK cells. SGK1 is a potent inhibitor of notch signaling, a pathway that regulates cell 
fate decisions by facilitating short range interactions. Emerging evidence implicates 
this pathway with embryo attachment and decidualization. The mechanism of 
recruitment and the contribution of these cells to subsequent reproductive failure are 
not known. 
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Hammersmith Hospitals  
                                                                                                   
NHS Trust 
 
 
Division of Paediatrics, Obstetrics and Gynaecology,  
Imperial College London 
 
Information for Women  
 
 
Title of project: Research into the womb lining and fertility. 
 
You are being invited to take part in a research study. Before you decide whether you 
wish to participate or not, it is important for you to understand why the research is 
being done and what it will involve. Please read the following information carefully 
and discuss it with relatives, friends and your GP, if you wish. If there is anything that 
is not clear, or if you have any further questions, please do not hesitate to ask. Take 
time to decide whether you would like to take part or not. You should not take part in 
this study if you do not wish to. If you decide not to take part, your treatment will not 
be affected by your decision. If you do decide to participate, please let us know 
beforehand if you are currently involved in another study. You are free to withdraw at 
any time without explanation and any subsequent treatment will not be affected.  
 
The womb lining sheds and regenerates once every month, when you have a period it 
is this lining coming away. The womb lining is the site where the embryo attaches 
and commences growing to become a pregnancy. We are doing research looking for 
reasons why the womb lining in some diseases may be less receptive to an embryo. 
This research involves testing for products (such as proteins) in the womb lining, 
which may be important for the embryo to attach. 
 
You have been asked to take part in this study because you will be having an 
operation in a few days time. The doctor’s looking after you will be removing part of 
your womb lining as part of your treatment. A small part of the womb lining is 
removed from you womb while you are under anaesthetic. This does not cause you 
extra pain, discomfort or inconvenience. Normally, unless you request otherwise, you 
excess womb lining is disposed of once sufficient has been sent off for diagnosis. 
However, if you agree to take part in the research, the doctor looking after you will 
ensure that the spare womb lining is passed to us for study in the laboratory. Extra 
tissue will not be taken for the purposes of the research. There is no risk to you from 
donating some of your womb lining above that of the surgical procedure which you 
will soon undertake. It will leave no long term effects because your womb lining 
regenerates every month. 
 
After you have donated the tissue the researchers will not need to see you again and 
there is no need for you to visit the GP. Although there is no immediate medical 
benefit to you from taking part, the information that we get from this study may help 
us to treat women in the future who experience problems with infertility. 
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Women who are pregnant cannot take part in this study and those at risk of a 
pregnancy will have a pregnancy test performed to exclude the possibility of 
pregnancy.  
 
 
The researchers working on these samples will not know which samples belong to 
which women, as they will have been coded (given a reference number) and there will 
be no way of tracing the samples back to individual donors. It is possible that the 
results from the research study could be published in a medical or scientific journal. 
However, please be reassured that you will not be identified in any such publication. 
Confidentiality of data is therefore assured. 
 
If you do suffer any adverse effects because of your participation in this study, you 
will be compensated through the Imperial College School of Medicine’s ‘No Fault’ 
Compensation Scheme.  
 
This work is currently funded by the Medical Research Council and The Wellcome 
Trust. No member of staff is being paid for including you in this study. 
 
For further information, please contact: 
Professor Jan Brosens on 020 7594 2164 (email: j.brosens@imperial.ac.uk) 
 
Thank you for taking part in this study. You will be given a copy of the information 
sheet to keep. 
 
(Version 00.2: 18 / 11 / 2008) 
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Sample Collection, Contact & Clinical Details 
 
 
SAMPLE COLLECTION: 
 
 Obtain endometrial sample by pipelle or curette (more = better) 
 
 Put the sample in sterilin with normal saline or culture medium 
 
 Organize transport to lab. 
 
 
 
CONTACT DETAILS: 
 
Prof Jan Brosens:   02075942164 
    07740628462 
Ms Madhuri Salker:  07984404469 
Lab numbers:   02075942130 
    02075942134 
 
 
PATIENT DETAILS (please complete): 
 
Age:_______________________ 
 
Recurrent miscarriage: Y/N 
 
Time-to-pregnancy: <3 months, < 6 months, > 6months (please encircle) 
 
Infertility: Y/N 
 
Endometriosis/tubal/male factor/unexplained/PCOS (please encircle) 
 
Other:______________________  
 
LMP:______________________ 
 
Parity:_____________________ 
 
Current treatment:_______________________ 
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Participant Consent Form 
 
Title of project: 
 
Establishment of primary cell cultures using biopsy samples of human 
endometrium as a model to investigate decidualization and implantation. 
 
The participant should complete the whole of this sheet him or herself. 
 
(please tick each statement if it applies to you) 
 
 
I have read the Information Sheet for Patients and 
Healthy Volunteers.               
 
I have been given the opportunity to ask questions and 
discuss this study.          
 
I have received satisfactory answers to all my questions.     
 
I have received enough information about the study.      
 
 
 
The study has been explained to me by:  
Prof/Dr/Mr/Mrs/Ms_______________________________________ 
 
I understand that I am free to withdraw from 
the study at any time, without having to give a reason for 
withdrawing and without affecting my future medical care.     
 
I agree to take part in this study. 
 
 
 
 
Signed.................................................................................Date................................. 
 
(NAME IN BLOCK 
CA ITALS).............................................................................................…………….. 
 
 
 
Investigator’s signature....................................................…Date: .............................. 
 
(NAME IN BLOCK 
CA ITALS)...................................................................................……………………..
. 
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Human qRT-PCR primers 
  
   Appendix 
 
 195 
 
Table 2.1 Human qRT-PCR primer pairs  
 
 
 
Gene 
 
Forward Primer 
 
Reverse Primer 
L19 GCGGAAGGGTACAGCCAA GCAGCCGGCGCAAA 
IGFBP1 CGAAGGCTCTCCATGTCACCA TGTCTCCTGTGCCTTGGCTAAAC 
PRL AAGCTGTAGAGATTGAGGAGCA
AAC 
TCAGGATGAACCTGGCTGACTA 
PROK1 GTGCCACCCGGGCAG AGCAAGGACAGGTGTGGTGC 
GPx3 GAAGTAACTGAAGGCCGTCTCA
TC 
CACGGATTTCTTCCTGAACAAA
G 
SOD2 AATTGCTGCTTGTCCAAATCAG TCCCCAGCAGTGGAATAAGG 
TXN TGTGGATGACTGTCAGGATGTT
G 
TGTCCCTTCTTAAAAAACTGGA
ATG 
SGK1 TTCCTATCGCAGTGTTTCAGTTC
TT 
 
CACACTCACACGACGGTTCAC 
 
Total-ST2 TCCAAAATTTATTGTCCTACCAT
TGA 
GATCCTTGAAGAGCCTGACAAT
TC 
TM-ST2 TTACAAGACTAGGAATGATGGA
AAGCT 
TGGCCCCATCTGTACTGGAT 
IL-33 CACCCCTCAAATGAATCAGG GGAGCTCCACAGAGTGTTCC 
TIMP3 GACGCCTTCTGCAACTCCGACA TCCTCGGTACCAGCTGCAGTAG 
LEFTYA TGGCATGCTGATTACAAGATAC
AG 
GCCTTCTGCGTTTGTTAGAGA 
PRDX2 GGT CCA GGC CTT CCA GTA CA ACG TTG GGC TTA ATC GTG 
TCA 
GLRX2 TTA AGA ATT CGC TCA AGA 
GTT TGT GAA CTG C 
GAG CTC TAG ATT ACT GCA 
GAG CTC CAA TCT G 
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Appendix III 
 
Murine qRT-PCR primers 
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Table 2.2 Murine qRT-PCR primer pairs 
 
 
Gene 
 
Forward Primer 
 
Reverse Primer 
Lif GTCAACTGGCTCAACTCAA
CG 
TACGCGACCATCCGATACAGC 
Hoxa10 GCCCCTTCCGAGAGCAGCA
AAG 
AGGTGGACGCTGCGGCTAATCTCT 
Wnt4 ACCTGGAAGTCATGGACTC
G 
TCAGAGCATCCTGACCACTG 
Pr GGTGGGCCTTCCTAACGAG GACCACATCAGGCTCAATGCT 
Bmp2 GGGACCCGCTGTCTTCTAGT TCAACTCAAATTCGCTGAGGAC 
Ihh GCTTCGACTGGGTGTATTAC
G 
GCTCGCGGTCCAGGAAAAT 
Er-α CCTCCCGCCTTCTACAGGT CACACGGCACAGTAGCGAG 
Er-β CTGTGATGAACTACAGTGTT
CCC 
CACATTTGGGCTTGCAGTCTG 
Prl8a2 TGCTCAGATCCCCTTGTGAT AGCTGGTGGGTTTGTGACAT 
Sod2 CCAAAGGAGAGTTGCTGGA
G 
TAAGGCCTGTTGTTCCTTGC 
Txn AGCTTGTCGTGGTGGACTTC CCCACCTTTTGACCCTTTTT 
Prdx2 CGGAGATCATCGCTTTTAGC TCATTTTTCAACACGCCGTA 
Glrx2 GGAAGGTGGTCGTGTTCAT
C 
CATCCGCCTATGCAGTCTTT 
 
ENaC-α CGGAGTTGCTAAACTCAAC
ATC 
TGGAGACCAGTACCGGCT 
Cftr TCCTGATGTTGATTTTGGGA TGGCTGTCTGCTTCCTGACTATGG 
Cyclophilin TGGAGAGCACCAAGACAGA
CA 
TGCCGGAGTCGACAATGAT 
HbEgf CTTGCGGCTACTTGAACACA GAAAGCAGGATCGAGTGAGC 
Igfbp1 CCAGGGACTCAGCTGCCGT
GCG 
GGCGTTCCACAGGATGGGCTG 
Leftya CGAATTCAGGGCACTTTTAG
GGAC 
ACTCGAGCTCACTGA 
GAATACATCTG 
Timp3 ACACGGAAGCCTCTGAAAG
TC 
ACTTTGTGGAGAGGTGGGAC 
Total-st2 ACGCTCGACTTATCCTGTGG CAGGTCAATTGTTGGACACG 
Tm-st2 GTGATAGTCTTAAAAGTGTT
CTGG 
TCAAAAGTGTTTCAGGTCTAAGCA 
Il-33 TCCTTGCTTGGCAGTATCCA TGCTCAATGTGTCAACAGACG 
Il-1b TCCAGGATGAGGACATG
AGCAC 
GAACGTCACACACCAGCAGGTT
A 
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Table 3.1 Analysis of timed endometrial biopsies – patient characteristics  
 
 Control RPL (n=10) 
 Fertile (n=10) Infertile (n=10) 
Age (years): 34 ± 2.9 32.9 ± 4.1 35.1 ± 2.9 
Live births: 2.5 ± 1.4* 0.2 ± 0.4 0.6 ± 0.7 
Miscarriages: 0.3 ± 0.5 0 7.4 ± 6.1* 
 
The data presented are mean ± standard deviation. * , P<0.001. 
 
Table 3.2 Analysis of fetal versus biochemical RPL - patient characteristics 
 
 Fetal  RPL (n=10) Biochemical RPL (n=10) 
Age (years): 36.6 ± 3.4 30.4 ± 7.4* 
Live births: 0 0 
Miscarriages: 4.4 ± 1.2 4.0 ± 1.0 
 
A ‘fetal’ loss was defined as a pregnancy failure between 6–13 weeks gestation with 
prior ultrasound evidence of fetal development. A ‘biochemical’ loss was defined as a 
miscarriage at 4–6 weeks gestation with ultrasound evidence of either an intrauterine 
pregnancy sac with no fetus or retained products of conception. The data presented 
are mean ± standard deviation. *, P<0.05. 
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Table 3.3: Time-course analysis - patient and culture characteristics 
 
 Control (n=12) RPL (n=9) 
Age (years): 33 ± 4.9 34.1 ± 3.6 
Live births: 0.4 ± 1 0.4 ± 0.7 
Miscarriages: 0.1 ± 0.3 3.9 ± 1.2 * 
Day of biopsy from LMP: 17 ± 5.6 16.2 ± 7.9 
Days in culture 16 ± 5.1 16.3 ± 4.1 
 
LMP= Last menstrual period. The data presented are mean ± standard deviation. *, 
P<0.05. 
 
Table 3.4. hCG analysis - patient characteristics 
 
 Control (n=10) RPL (n=10) 
Age (years): 34.1 ± 3.1 32.3 ± 6.6 
Live births: 0.4 ± 0.9 0.2 ± 0.4 
Miscarriages: 0 7 ± 3.7* 
Day of biopsy from LMP: 17.6 ± 7.1 20.8 ± 5.3 
 
The data presented are mean ± standard deviation. LMP = last menstrual period. *, 
P<0.001. 
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Table 4.1 Gene lists from PCR array  (treated/control regulated genes) 
 
Interleukins & Receptors 
UniGene Description 
 
2D vs. 
Con 
D8 vs. 
Con 
 
Hs.306974 Interleukin 1 family, member 10 (theta) 4.66 -6.81 
Hs.516301 Interleukin 1 family, member 5 (delta) 4.48 -8.75 
Hs.278910 Interleukin 1 family, member 6 (epsilon) 6.16 -8.56 
Hs.166371 Interleukin 1 family, member 7 (zeta) 4.26 -4.69 
Hs.278909 Interleukin 1 family, member 8 (eta) 7.02 -12.53 
Hs.211238 Interleukin 1 family, member 9 3.00 -42.93 
Hs.1722 Interleukin 1, alpha 2.63 -5.33 
Hs.126256 Interleukin 1, beta 2.36 5.02 
Hs.2247 Interleukin 5 (colony-stimulating factor, eosinophil) 3.06 12.33 
Hs.624 Interleukin 8 -1.02 -9.54 
Hs.960 Interleukin 9 10.79 -6.34 
Hs.193717 Interleukin 10 -3.05 7.03 
Hs.845 Interleukin 13 13.25 -7.87 
Hs.278911 Interleukin 17C 8.39 -1.72 
Hs.287369 Interleukin 22 9.06 -2.09 
Hs.81134 Interleukin 1 receptor antagonist 2.43 -8.77 
Hs.701982 Interleukin 1 receptor, type I 1.33 -1.06 
Hs.68876 Interleukin 5 receptor, alpha 10.44 1.38 
Hs.194778 Interleukin 8 receptor, alpha 30.47 2.03 
Hs.846 Interleukin 8 receptor, beta 1.16 -58.15 
Hs.406228 Interleukin 9 receptor 10.73 -2.31 
Hs.504035 Interleukin 10 receptor, alpha 5.99 -1.65 
Hs.654593 Interleukin 10 receptor, beta 2.17 1.59 
Hs.496646 Interleukin 13 receptor, alpha 1 1.74 -1.37 
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Chemokines & Receptors 
 
UniGene Description D2 vs. 
Con 
D8 vs. 
Con 
 
Hs.72918 Chemokine (C-C motif) ligand 1 6.59 -7.38 
Hs.54460 Chemokine (C-C motif) ligand 11 -2.69 8.69 
Hs.414629 Chemokine (C-C motif) ligand 13 6.72 -1.03 
Hs.272493 Chemokine (C-C motif) ligand 15 13.47 -9.50 
Hs.10458 Chemokine (C-C motif) ligand 16 15.76 -3.58 
Hs.546294 Chemokine (C-C motif) ligand 17 13.68 -2.60 
Hs.143961 
Chemokine (C-C motif) ligand 18 (pulmonary and 
activation-regulated) 7.34 -1.37 
Hs.50002 Chemokine (C-C motif) ligand 19 9.87 1.66 
Hs.303649 Chemokine (C-C motif) ligand 2 1.22 -3.21 
Hs.75498 Chemokine (C-C motif) ligand 20 1.86 -8.17 
Hs.57907 Chemokine (C-C motif) ligand 21 13.15 -1.44 
Hs.169191 Chemokine (C-C motif) ligand 23 16.58 2.20 
Hs.247838 Chemokine (C-C motif) ligand 24 3.26 -1.45 
Hs.310511 Chemokine (C-C motif) ligand 25 1.89 2.15 
Hs.131342 Chemokine (C-C motif) ligand 26 4.15 1.24 
Hs.514107 Chemokine (C-C motif) ligand 3 7.97 -1.04 
Hs.75703 Chemokine (C-C motif) ligand 4 5.25 -5.43 
Hs.514821 Chemokine (C-C motif) ligand 5 6.79 -2.38 
Hs.251526 Chemokine (C-C motif) ligand 7 3.90 -1.73 
Hs.271387 Chemokine (C-C motif) ligand 8 2.83 -1.01 
Hs.632586 Chemokine (C-X-C motif) ligand 10 4.97 -5.31 
Hs.632592 Chemokine (C-X-C motif) ligand 11 2.91 -12.83 
Hs.522891 
Chemokine (C-X-C motif) ligand 12 (stromal cell-
derived factor 1) 2.44 2.06 
Hs.100431 Chemokine (C-X-C motif) ligand 13 1.53 -6.48 
Hs.483444 Chemokine (C-X-C motif) ligand 14 3.08 -1.35 
Hs.590921 Chemokine (C-X-C motif) ligand 2 2.72 -7.13 
Hs.89690 Chemokine (C-X-C motif) ligand 3 3.23 -5.57 
Hs.89714 Chemokine (C-X-C motif) ligand 5 2.23 -4.64 
Hs.164021 
Chemokine (C-X-C motif) ligand 6 (granulocyte 
chemotactic protein 2) 3.16 -3.15 
Hs.77367 Chemokine (C-X-C motif) ligand 9 6.21 -14.83 
    
Hs.248116 Chemokine (C motif) receptor 1 10.51 1.17 
Hs.78913 Chemokine (C-X3-C motif) receptor 1 10.36 1.14 
Hs.789 
Chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha) 1.85 -5.99 
Hs.301921 Chemokine (C-C motif) receptor 1 4.04 -2.58 
Hs.511794 Chemokine (C-C motif) receptor 2 10.40 -2.26 
Hs.506190 Chemokine (C-C motif) receptor 3 9.44 -1.52 
Hs.184926 Chemokine (C-C motif) receptor 4 15.83 -1.45 
Hs.450802 Chemokine (C-C motif) receptor 5 18.49 3.16 
Hs.46468 Chemokine (C-C motif) receptor 6 9.62 -1.80 
Hs.370036 Chemokine (C-C motif) receptor 7 4.70 1.48 
Hs.113222 Chemokine (C-C motif) receptor 8 6.07 -1.03 
Hs.225946 Chemokine (C-C motif) receptor 9 6.39 -1.67 
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Miscellaneous  
 
UniGene Description D2 vs. 
Con 
D8 vs. 
Con 
Hs.655285 
 
ATP-binding cassette, sub-family F (GCN20), member 1 2.21 -1.07 
Hs.478588 B-cell CLL/lymphoma 6 2.35 1.48 
Hs.534255 Beta-2-microglobulin -1.49 11.13 
Hs.709456 C-reactive protein, pentraxin-related 21.18 -4.63 
Hs.56279 Caspase recruitment domain family, member 18 32.50 3.49 
Hs.517106 CCAAT/enhancer binding protein (C/EBP), beta 1.90 -1.03 
Hs.592244 CD40 ligand 10.95 1.26 
Hs.529053 Complement component 3 2.11 -4.06 
Hs.534847 Complement component 4A (Rodgers blood group) 6.51 -1.29 
Hs.494997 Complement component 5 4.72 1.17 
Hs.412707 Hypoxanthine phosphoribosyltransferase 1 2.26 3.29 
Hs.211575 Interferon, alpha 2 6.20 2.44 
Hs.655431 Leukotriene B4 receptor 4.08 -1.83 
Hs.36 Lymphotoxin alpha (TNF superfamily, member 1) 5.41 -2.93 
Hs.376208 Lymphotoxin beta (TNF superfamily, member 3) 3.17 -6.90 
Hs.407995 
Macrophage migration inhibitory factor (glycosylation-
inhibiting factor) 1.06 -1.17 
Hs.313 Secreted phosphoprotein 1 2.59 1.57 
Hs.591680 
Small inducible cytokine subfamily E, member 1 
(endothelial monocyte-activating) 2.09 -1.26 
Hs.368527 Toll interacting protein 3.19 1.01 
Hs.241570 Tumor necrosis factor (TNF superfamily, member 2) -6.33 9.84 
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Table 4.2 Analysis of murine implantation sites after exposure to soluble factors 
from HESCs 
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Table 4.3 Gene lists from PCR array  (si-IL-33/control regulated genes) 
 
Interleukins & Receptors 
UniGene Description NT si IL-33  
 
Hs.306974 Interleukin 1 family, member 10 (theta) 6.24 -31.67 
Hs.516301 Interleukin 1 family, member 5 (delta) 16.00 -14.22 
Hs.278910 Interleukin 1 family, member 6 (epsilon) 34.25 -30.37 
Hs.166371 Interleukin 1 family, member 7 (zeta) 4.86 -19.11 
Hs.278909 Interleukin 1 family, member 8 (eta) 1.10 -29.43 
Hs.211238 Interleukin 1 family, member 9 2.02 -35.75 
Hs.1722 Interleukin 1, alpha 3.52 24.62 
Hs.126256 Interleukin 1, beta 4.30 24.37 
Hs.2247 Interleukin 5 (colony-stimulating factor, eosinophil) -4.77 33.68 
Hs.624 Interleukin 8 1.37 25.87 
Hs.193717 Interleukin 10 4.09 -15.39 
Hs.845 Interleukin 13 2.81 -11.53 
Hs.278911 Interleukin 17C 1.12 -11.48 
Hs.287369 Interleukin 22 6.14 -23.78 
Hs.81134 Interleukin 1 receptor antagonist 3.26 -24.71 
Hs.701982 Interleukin 1 receptor, type I 1.78 -23.09 
Hs.68876 Interleukin 5 receptor, alpha 33.98 11.73 
Hs.194778 Interleukin 8 receptor, alpha 40.83 -27.25 
Hs.846 Interleukin 8 receptor, beta 1.55 -27.47 
Hs.406228 Interleukin 9 receptor 9.72 -33.13 
Hs.504035 Interleukin 10 receptor, alpha 1.05 13.03 
Hs.654593 Interleukin 10 receptor, beta 2.25 -21.98 
Hs.496646 Interleukin 13 receptor, alpha 1 3.00 14.42 
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Chemokines & Receptors 
 
UniGene Description NT si IL-33 
Hs.72918 Chemokine (C-C motif) ligand 1 6.50 -35.29 
Hs.54460 Chemokine (C-C motif) ligand 11 -3.60 12.33 
Hs.414629 Chemokine (C-C motif) ligand 13 2.67 11.69 
Hs.272493 Chemokine (C-C motif) ligand 15 8.72 16.70 
Hs.10458 Chemokine (C-C motif) ligand 16 5.45 -27.80 
Hs.546294 Chemokine (C-C motif) ligand 17 5.00 12.75 
Hs.143961 Chemokine (C-C motif) ligand 18 (pulmonary and 
activation-regulated) 2.86 16.81 
Hs.50002 Chemokine (C-C motif) ligand 19 3.12 -21.17 
Hs.303649 Chemokine (C-C motif) ligand 2 1.63 10.05 
Hs.75498 Chemokine (C-C motif) ligand 20 3.83 -21.45 
Hs.57907 Chemokine (C-C motif) ligand 21 5.29 -34.69 
Hs.169191 Chemokine (C-C motif) ligand 23 5.55 -17.77 
Hs.247838 Chemokine (C-C motif) ligand 24 1.71 -26.01 
Hs.310511 Chemokine (C-C motif) ligand 25 -0.48 -21.21 
Hs.131342 Chemokine (C-C motif) ligand 26 1.23 12.81 
Hs.514107 Chemokine (C-C motif) ligand 3 2.68 14.06 
Hs.75703 Chemokine (C-C motif) ligand 4 3.37 -29.26 
Hs.514821 Chemokine (C-C motif) ligand 5 3.09 -26.73 
Hs.251526 Chemokine (C-C motif) ligand 7 1.90 12.43 
Hs.271387 Chemokine (C-C motif) ligand 8 1.13 15.47 
Hs.789 Chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha) 2.48 -18.83 
Hs.632586 Chemokine (C-X-C motif) ligand 10 3.33 -17.01 
Hs.632592 Chemokine (C-X-C motif) ligand 11 4.57 -14.84 
Hs.522891 Chemokine (C-X-C motif) ligand 12 (stromal cell-
derived factor 1) 0.38 10.43 
Hs.100431 Chemokine (C-X-C motif) ligand 13 3.27 9.04 
Hs.483444 Chemokine (C-X-C motif) ligand 14 2.46 8.77 
Hs.590921 Chemokine (C-X-C motif) ligand 2 3.65 -19.15 
Hs.89690 Chemokine (C-X-C motif) ligand 3 2.99 10.62 
Hs.89714 Chemokine (C-X-C motif) ligand 5 2.98 -33.39 
Hs.164021 Chemokine (C-X-C motif) ligand 6 (granulocyte 
chemotactic protein 2) 1.90 -24.39 
Hs.77367 Chemokine (C-X-C motif) ligand 9 5.99 16.60 
Hs.248116 Chemokine (C motif) receptor 1 2.74 -22.37 
Hs.78913 Chemokine (C-X3-C motif) receptor 1 3.55 11.06 
Hs.301921 Chemokine (C-C motif) receptor 1 2.09 11.39 
Hs.511794 Chemokine (C-C motif) receptor 2 3.94 13.78 
Hs.506190 Chemokine (C-C motif) receptor 3 3.98 -21.46 
Hs.184926 Chemokine (C-C motif) receptor 4 4.88 13.72 
Hs.450802 Chemokine (C-C motif) receptor 5 5.44 -29.27 
Hs.46468 Chemokine (C-C motif) receptor 6 3.89 10.43 
Hs.370036 Chemokine (C-C motif) receptor 7 1.30 -24.64 
Hs.113222 Chemokine (C-C motif) receptor 8 2.47 -20.50 
Hs.225946 Chemokine (C-C motif) receptor 9 2.23 12.34 
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Miscellaneous  
 
UniGene Description NT si IL-33  
Hs.655285 ATP-binding cassette, sub-family F (GCN20), member 1 2.96 -19.04 
Hs.478588 B-cell CLL/lymphoma 6 3.15 -17.29 
Hs.534255 Beta-2-microglobulin -2.00 -1.51 
Hs.709456 C-reactive protein, pentraxin-related 3.18 14.05 
Hs.56279 Caspase recruitment domain family, member 18 43.55 3.01 
Hs.517106 CCAAT/enhancer binding protein (C/EBP), beta 2.55 -31.53 
Hs.592244 CD40 ligand 14.67 -23.38 
Hs.529053 Complement component 3 2.16 -31.10 
Hs.534847 Complement component 4A (Rodgers blood group) 1.73 -21.12 
Hs.494997 Complement component 5 6.32 -33.68 
Hs.412707 Hypoxanthine phosphoribosyltransferase 1 3.03 -24.39 
Hs.211575 Interferon, alpha 2 8.30 8.65 
Hs.655431 Leukotriene B4 receptor 1.47 -22.35 
Hs.36 Lymphotoxin alpha (TNF superfamily, member 1) 4.24 20.78 
Hs.376208 Lymphotoxin beta (TNF superfamily, member 3) 2.58 14.55 
Hs.407995 Macrophage migration inhibitory factor (glycosylation-
inhibiting factor) 1.42 -20.00 
Hs.313 Secreted phosphoprotein 1 3.47 -24.40 
Hs.591680 Small inducible cytokine subfamily E, member 1 
(endothelial monocyte-activating) -2.80 13.00 
Hs.368527 Toll interacting protein 4.28 -21.12 
Hs.241570 Tumor necrosis factor (TNF superfamily, member 2) 0.94 -21.23 
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Table 4.4 Patient characteristics 
 
qRT-PCR (Fig ) Control RPL 
Number of patients 12 8 
Age (Years) 33±4.9 32.2 ±3.6 
Live births 0.3±1 0.4±0.7 
Miscarriages 0.1±0.3 5.6±2.2* 
LMP 17±5.6 16.2±4.5 
Days in culture 16±5.1 15.4±2.3 
   
   
ELISA (Fig 4 ) Control RPL 
Number of patients 16 15 
Age (Years) 34±3.1 32.3 ±6.6 
Live births 0.4±0.9 0.2±0.4 
Miscarriages 0 7.0±4.7* 
LMP 17.6±7.1 20.8±5.3 
Days in culture 15±5.3 15.3±4.6 
 
LMP= Last menstrual period. The data presented are mean ± standard deviation. *, 
P<0.05. 
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Table 5.1. Analysis of timed endometrial biopsies – patient characteristics 
 
Samples used in Fig. 5.1.a & c. 
 RPL (n=9) Fertile (FER, n=9) Infertile (INF, n=9) 
Age (years): 35.1 ± 2.9 34 ± 2.9 32.9 ± 4.1 
Live births: 0.6 ± 0.7 2.5 ± 1.4* 0.2 ± 0.4 
Miscarriages: 7.4 ± 6.1* 0.3 ± 0.5 0 
 
The infertile group consisted of patients with unexplained infertility. The data 
presented are mean ± standard deviation. *, P < 0.001. 
 
Table 5.2. Analysis of fetal versus biochemical RPL - patient characteristics 
 
Samples used Fig.5.1.b 
 Biochemical RPL (n=10) Fetal  RPL (n=8) 
Age (years): 30.4 ± 7.4* 36.0 ± 3.5 
Live births: 0 0 
Miscarriages: 4.0 ± 1.0 4.0 ± 0.8 
No. of fetal loss 0.10±0.31 2.55±0.53 
No. of biochemical loss 3.9±0.99 1.5±0.53 
 
The data presented are mean ± standard deviation. *, P < 0.05. A ‘fetal’ loss was 
defined as a pregnancy failure between 6-13 weeks gestation with prior ultrasound 
evidence of fetal development. A ‘biochemical’ loss was defined as a miscarriage at 
4-6 weeks gestation with ultrasound evidence of either an intrauterine pregnancy sac 
with no fetus or retained products of conception. 
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Table 5.3. SGK1 expression and activation in timed endometrial biopsies 
 
Samples used in fig 5.2 A 
 RPL (n=6) INF (n=6) 
Age (years): 33.0 ± 5.9 36.2 ± 2.6 
Parity 0 0 
Miscarriages: 4.3 ± 1.5* 0 
 
Samples used in fig 5.2 B 
 
 RPL (n=5) Control (n=5) 
Age (Years) 32.25±6.6 34 ±3.1 
Parity 0.2±0.4 0.4±0.9 
Miscarriages 7±4.7* 0 
Day of biopsy 20.8±5.3 17.6±7.1 
 
The infertile group consisted of patients with unexplained infertility. The data 
presented are mean ± standard deviation. *, P < 0.001. 
 
 
Table 5.4 Samples used for time-course analysis for Fig 5.8 and Fig 5.10. 
 RPL (n=9) Control (n=11) 
Age (years): 34.1 ± 3.6 33 ± 4.9 
Miscarriages:  3.9 ± 1.2 0.1 ± 0.3* 
Day of biopsy from LMP:  16.2 ± 7.9 17 ± 5.6 
Days in culture  16.3 ± 4.1 16 ± 5.1 
 
The control group consisted of individuals with male factor, peritoneal/tubal or 
unexplained infertility. The data presented are mean ± standard deviation. LMP = last 
menstrual period. *, P < 0.001. 
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